Methods and compositions for screening and treating developmental disorders

ABSTRACT

This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.

CROSS-REFERENCE

This application claims the benefit of U.S. Provisional Application No.61/545,515, filed Oct. 10, 2011, which application is incorporatedherein by reference in its entirety.

REFERENCE TO A SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted in ASCII format via EFS-Web and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Oct. 9, 2012, isnamed 121009_ASD_SK.txt and is 73,619,309 bytes in size. Theaforementioned file was created on Oct. 9, 2012, and is herebyincorporated by reference in their entirety.

BACKGROUND OF THE INVENTION

Genetic risk can be conferred by subtle differences in individualgenomes within a population. Genes can differ between individuals due togenomic variability, the most frequent of which are due to singlenucleotide polymorphisms (SNPs). SNPs can be located, on average, every500-1000 base pairs in the human genome. Additional geneticpolymorphisms in a human genome can be caused by duplication, insertion,deletion, translocation and/or inversion, of short and/or long stretchesof DNA. Thus, in general, genetic variability among individuals occurson many scales, ranging from single nucleotide changes, to gross changesin chromosome structure and function. Recently, many copy numbervariations (CNVs) of DNA segments, including deletions, insertions,duplications, amplifications and complex multi-site variants, ranging inlength from kilobases to megabases in size, have been discovered (Redon,R. et al. Nature 444:444-54 (2006) and Estivill, X. & Armengol, L. PLoSGenetics 3:e190 (2007)). To date, known CNVs account for over 15% of theassembled human genome (Estivill, X. Armengol, L. PLoS Genetics 3:e190(2007)). However, a majority of these variants are extremely rare andcover a small percentage of a human genome of any particular individual.

Today, it is estimated that one in every 110 children is diagnosed withAutism Spectrum Disorder (ASD), making it more common than childhoodcancer, juvenile diabetes and pediatric AIDS combined. An estimated 1.5million individuals in the U.S. and tens of millions worldwide areaffected by autism. Government statistics suggest the prevalence rate ofautism is increasing 10-17 percent annually. There is no establishedexplanation for this increase, although improved screening andenvironmental influences are two reasons often considered. Studiessuggest boys are more likely than girls to develop autism and receivethe screening three to four times more frequently. Current estimates arethat in the United States alone, one out of 70 boys is diagnosed withautism. ASD can be characterized by problems and symptoms in thefollowing areas: communication, both verbal and non-verbal, such aspointing, eye contact, and smiling; social, such as sharing emotions,understanding how others think and feel, and holding a conversation; androutines or repetitive behaviors (also called stereotyped behaviors),such as repeating words or actions, obsessively following routines orschedules, and playing in repetitive ways. As genetic variationsconferring risk to developmental disorders, including ASD, areuncovered, genetic testing can play a role for clinical therapeutics.

Despite these advances towards an understanding of the etiology ofdevelopmental disorders, a large fraction of the genetic contribution tothese disorders remains undetermined Identification of underlyinggenetic variants that can contribute to developmental disorderpathogenesis can aid in the screening and identification of individualsat risk of developing these disorders and can be useful for diseasemanagement. There is a need to identify new treatments for developmentaldisorders, specifically ASD, and the identification of novel geneticrisk factors can assist in the development of potential therapeutics andagents. There is also a need for improved assays for predicting anddetermining potential treatments and their effectiveness.

SUMMARY OF THE INVENTION

An aspect of the invention includes a method of screening one or moresubjects for at least one genetic variation that disrupts or modulatesone or more genes in Table 2, comprising: assaying at least one geneticsample obtained from each of the one or more subjects for the at leastone genetic variation in one or more genes in Table 2.

In some embodiments, at least one genetic variation is associated with aPervasive Developmental Disorders (PDD) or a Pervasive DevelopmentalDisorder—Not Otherwise Specified (PDD-NOS). In some embodiments, the atleast one genetic variation is one encoded by SEQ ID NOs 1 to 76. Insome embodiments, the at least one genetic variation comprises one ormore point mutations, polymorphisms, translocations, insertions,deletions, amplifications, inversions, microsatellites, interstitialdeletions, copy number variations (CNVs), or any combination thereof. Insome embodiments, the at least one genetic variation comprises a loss ofheterozygosity. In some embodiments, the at least one genetic variationdisrupts or modulates one or more genomic sequences of SEQ ID NOs 77 to209. In some embodiments, the at least one genetic variation disrupts ormodulates the expression or function of one or more RNA transcripts, oneor more polypeptides, or a combination thereof, expressed from the oneor more genomic sequences of SEQ ID NOs 77 to 209.

In some embodiments, the assaying comprises detecting nucleic acidinformation from the at least one genetic sample. In some embodiments,the nucleic acid information is detected by one or more methods selectedfrom the group comprising PCR, sequencing, Northern blots, or anycombination thereof. In some embodiments, the sequencing comprises oneor more high-throughput sequencing methods. In some embodiments, the oneor more high throughput sequencing methods comprise Massively ParallelSignature Sequencing (MPSS), polony sequencing, 454 pyrosequencing,Illumina sequencing, SOLiD sequencing, ion semiconductor sequencing, DNAnanoball sequencing, heliscope single molecule sequencing, singlemolecule real time (SMRT) sequencing, RNAP sequencing, Nanopore DNAsequencing, sequencing by hybridization, or microfluidic Sangersequencing. In some embodiments, the at least one genetic sample iscollected from blood, saliva, urine, serum, tears, skin, tissue, or hairfrom the one or more subjects. In some embodiments, the assaying the atleast one genetic sample of the one or more subjects comprises purifyingnucleic acids from the at least one genetic sample. In some embodiments,the assaying the at least one genetic sample of the one or more subjectscomprises amplifying at least one nucleotide sequence in the at leastone genetic sample. In some embodiments, the assaying the at least onegenetic sample for at least one genetic variation comprises a microarrayanalysis of the at least one genetic sample. In some embodiments, themicroarray analysis comprises a CGH array analysis. In some embodiments,the CGH array detects the presence or absence of the at least onegenetic variations.

In some embodiments, the method further comprises determining whetherthe one or more subjects has a Pervasive Developmental Disorders (PDD)or a Pervasive Developmental Disorder—Not Otherwise Specified (PDD-NOS),or an altered susceptibility to a PDD or PDD-NOS. In some embodiments,the one or more subjects were previously diagnosed or are suspected ashaving the PDD or PDD-NOS based on an evaluation by a psychologist, aneurologist, a psychiatrist, a speech therapist, or other professionalswho screen subjects for a PDD or a PDD-NOS. In some embodiments, thedetermining comprises an evaluation of the one or more subject'scommunication, socialization, cognitive abilities, body movements, or acombination thereof. In some embodiments, the evaluation comprisesobservation, a questionnaire, a checklist, a test, or a combinationthereof. In some embodiments, the evaluation comprises a Checklist ofAutism in Toddlers (CHAT), a modified Checklist for Autism in Toddlers(M-CHAT), a Screening Tool for Autism in Two-Year-Olds (STAT), a SocialCommunication Questionnaire (SCQ) for children 4 years of age and older,an Autism Diagnosis Interview-Revised (ADI-R), an Autism DiagnosticObservation Schedule (ADOS), a Childhood Autism Rating Scale (CARS), anAutism Spectrum Screening Questionnaire (ASSQ), an Australian Scale forAsperger's Syndrome, a Childhood Asperger Syndrome Test (CAST), or acombination thereof. In some embodiments, the screening the one or moresubjects further comprises selecting one or more therapies based on thepresence or absence of the one or more genetic variations. In someembodiments, the assaying at least one genetic sample obtained from eachof the one or more subjects comprises analyzing the whole genome orwhole exome from the one or more subjects. In some embodiments, thenucleic acid information has already been obtained for the whole genomeor whole exome from the one or more individuals and the nucleic acidinformation is obtained from in silico analysis.

In some embodiments, the PDD is Autism Spectrum Disorder (ASD). In someembodiments, the PDD-NOS is Asperger Syndrome, Rett Syndrome orChildhood Disintegrative Disorder. In some embodiments, the one or moresubjects has at least one symptom of a PDD. In some embodiments, the PDDis ASD. In some embodiments, the at least one symptom comprisesdifficulty with verbal communication, difficulty using language,difficulty understanding language, difficulty with non-verbalcommunication, difficulty with social interaction, unusual ways ofplaying with toys and other objects, difficulty adjusting to changes inroutine or familiar surroundings, repetitive body movements or patternsof behavior, changing response to sound, temper tantrums, difficultysleeping, aggressive behavior, fearfulness or anxiety, or a combinationthereof. In some embodiments, the at least one symptom comprises notbabbling, pointing, or making meaningful gestures by 1 year of age, notspeaking one word by 16 months of age, not combining two words by 2years of age, not responding to their name, losing language,losingsocial skills, qualitative impairment in social interaction,impairments in the use of multiple nonverbal behaviors to regulatesocial interaction, failure to develop peer relationships appropriate todevelopmental level, not spontaneously seeking to share enjoyment orinterests or achievements with other people, lacking social or emotionalreciprocity, qualitative impairments in verbal communication, repetitiveand stereotyped patterns of behavior and interests and activities,encompassing preoccupation with one or more stereotyped and restrictedpatterns of interest that is abnormal either in intensity or focus,apparently inflexible adherence to specific and nonfunctional routinesor rituals, stereotyped and repetitive motor mannerisms, persistentpreoccupation with parts of objects, abnormal functioning in symbolic orimaginative play, or a combination thereof. In some embodiments, the oneor more subjects has at least one symptom of a PDD-NOS. In someembodiments, the at least one symptom of a PDD-NOS comprises qualitativeimpairment in social interaction, marked impairments in the use ofmultiple nonverbal behaviors to regulate social interaction, failure todevelop peer relationships appropriate to developmental level, a lack ofspontaneous seeking to share enjoyment or interest or achievements withother people lack of social or emotional reciprocity, restrictedrepetitive and stereotyped patterns of behavior or interests andactivities, encompassing preoccupation with one or more stereotyped andrestricted patterns of interest, nonfunctional routines or rituals,stereotyped and repetitive motor mannerisms, persistent preoccupationwith parts of objects, clinically significant impairments in social oroccupational or other important areas of functioning, deceleration ofhead growth between ages 5 and 48 months, loss of previously acquiredpurposeful hand skills between ages 5 and 30 months with the subsequentdevelopment of stereotyped hand movements, loss of social engagementearly in the, appearance of poorly coordinated gait or trunk movements,severely impaired expressive and receptive language development withsevere psychomotor retardation, clinically significant loss ofpreviously acquired skills before age 10 years, impairment in nonverbalbehaviors, failure to develop peer relationships, lack of social oremotional reciprocity, qualitative impairments in communicationrestricted or repetitive or and stereotyped patterns of behavior orinterests and activities, or a combination thereof.

In some embodiments, the one or more subjects is human. In someembodiments, the one or more subjects is less than 12 years old, lessthan 8 years old, less than 6 years old, or less than 3 years.

An aspect of the invention includes a method of diagnosing one or moresubjects for a PDD or a PDD-NOS, comprising: assaying at least onegenetic sample of each of the one or more subjects for the presence orabsence of at least one genetic variation in one or more genes in Table2.

In some embodiments, the at least one genetic variation is one encodedby SEQ ID NOs 1-76. In some embodiments, the one or ore subjects isdiagnosed with the PDD or PDD-NOS if the at least one genetic variationis present. In some embodiments, the one or more subjects is notdiagnosed with PDD or PDD-NOS if the at least one genetic variation isabsent.

In some embodiments, the assaying comprises detecting nucleic acidinformation from the at least one genetic sample. In some embodiments,the nucleic acid information is detected by one or more methods selectedfrom the group comprising PCR, sequencing, Northern blots, or anycombination thereof. In some embodiments, the sequencing comprises oneor more high-throughput sequencing methods. In some embodiments, the oneor more high throughput sequencing methods comprise Massively ParallelSignature Sequencing (MPSS), polony sequencing, 454 pyrosequencing,Illumina sequencing, SOLiD sequencing, ion semiconductor sequencing, DNAnanoball sequencing, heliscope single molecule sequencing, singlemolecule real time (SMRT) sequencing, RNAP sequencing, Nanopore DNAsequencing, sequencing by hybridization, or microfluidic Sangersequencing. In some embodiments, the ethod further comprises determiningwhether the one or more subjects has a PDD or PDD-NOS or an alteredsusceptibility to a PDD or PDD-NOS. In some embodiments, the one or moresubjects were previously diagnosed or are suspected as having the PDD orPDD-NOS based on an evaluation by a psychologist, a neurologist, apsychiatrist, a speech therapist, or other professionals who screensubjects for a PDD or a PDD-NOS.

In some embodiments, the determining comprises an evaluation of the oneor more subject's communication, socialization, cognitive abilities,body movements, or a combination thereof. In some embodiments, theevaluation comprises an evaluation of the one or more subject'scommunication, socialization, cognitive abilities, body movements, or acombination thereof. In some embodiments, the evaluation comprisesobservation, a questionnaire, a checklist, a test, or a combinationthereof. In some embodiments, the evaluation comprises a Checklist ofAutism in Toddlers (CHAT), a modified Checklist for Autism in Toddlers(M-CHAT), a Screening Tool for Autism in Two-Year-Olds (STAT), a SocialCommunication Questionnaire (SCQ) for children 4 years of age and older,an Autism Diagnosis Interview-Revised (ADI-R), an Autism DiagnosticObservation Schedule (ADOS), a Childhood Autism Rating Scale (CARS), anAutism Spectrum Screening Questionnaire (ASSQ), an Australian Scale forAsperger's Syndrome, a Childhood Asperger Syndrome Test (CAST), or acombination thereof. In some embodiments, the determining comprisescomparing the nucleic acid information to those of one or more othersubjects.

In some embodiments, the one more subjects comprise one or more subjectsnot suspected of having the PDD or the PDD-NOS. In some embodiments, theone or more other subjects comprise one or more subjects suspected ofhaving the PDD or the PDD-NOS. In some embodiments, one or more subjectscomprise one or more subjects with the PDD or the PDD-NOS. In someembodiments, the one or more other subjects comprise one or moresubjects without the PDD or the PDD-NOS. In some embodiments, the one ormore subjects comprise one or more subjects who are symptomatic for thePDD or the PDD-NOS. In some embodiments, the one or more other subjectscomprise one or more subjects who are asymptomatic for the PDD or thePDD-NOS. In some embodiments, the one or more subjects comprise one ormore subjects that have an increased susceptibility to the PDD or thePDD-NOS. In some embodiments, the one or more subjects comprise one ormore subjects that have a decreased susceptibility to the PDD or thePDD-NOS. In some embodiments, the one or more subjects comprise one ormore subjects receiving a treatment, therapeutic regimen, or anycombination thereof for a PDD or PDD-NOS.

In some embodiments, determining whether the one or more subjects havethe PDD or the PDD-NOS or an altered susceptibility to the PDD or thePDD-NOS comprises analyzing at least one behavioral analysis of the oneor more subjects and the nucleic acid sequence information of the one ormore subjects, or a combination thereof.

In some embodiments, the at least one genetic sample is collected fromblood, saliva, urine, serum, tears, skin, tissue, or hair from the oneor more subjects. In some embodiments, the assaying the at least onegenetic sample of the one or more subjects comprises purifying nucleicacids from the at least one genetic sample. In some embodiments, theassaying the at least one genetic sample of the one or more subjectscomprises amplifying at least one nucleotide sequence in the at leastone genetic sample. In some embodiments, the assaying the at least onegenetic sample for at least one genetic variation comprises a microarrayanalysis of the at least one genetic sample. In some embodiments, themicroarray analysis comprises a CGH array analysis. In some embodiments,the CGH array detects the presence or absence of the at least onegenetic variations. In some embodiments, the at least one geneticvariation comprises one or more point mutations, polymorphisms,translocations, insertions, deletions, amplifications, inversions,microsatellites, interstitial deletions, copy number variations (CNVs),or any combination thereof. In some embodiments, the at least onegenetic variation comprises a loss of heterozygosity. In someembodiments, the at least one genetic variation disrupts or modulatesone or more genomic sequences of SEQ ID NOs 77 to 209. In someembodiments, the at least one genetic variation disrupts or modulatesthe expression or function of one or more RNA transcripts from the oneor more genomic sequences of SEQ ID NOs 77 to 209.

In some embodiments, the assaying at least one genetic sample obtainedfrom each of the one or more subjects comprises analyzing the wholegenome or whole exome from the one or more subjects. In someembodiments, the nucleic acid information has already been obtained forthe whole genome or whole exome from the one or more individuals and thenucleic acid information is obtained from in silico analysis. In someembodiments, the method further comprises selecting one or moretherapies based on the presence or absence of the one or more geneticvariations.

In some embodiments, the PDD is ASD. In some embodiments, the PDD-NOS isAsperger Syndrome, Rett Syndrome or Childhood Disintegrative Disorder.In some embodiments, the one or more subjects has at least one symptomof a PDD. In some embodiments, the PDD is ASD. In some embodiments, theat least one symptom comprises difficulty with verbal communication,difficulty using language, difficulty understanding language, difficultywith non-verbal communication, difficulty with social interaction,unusual ways of playing with toys and other objects, difficultyadjusting to changes in routine or familiar surroundings, repetitivebody movements or patterns of behavior, changing response to sound,temper tantrums, difficulty sleeping, aggressive behavior, fearfulnessor anxiety, or a combination thereof. In some embodiments, the at leastone symptom comprises not babbling, pointing, or making meaningfulgestures by 1 year of age, not speaking one word by 16 months of age,not combining two words by 2 years of age, not responding to their name,losing language, losingsocial skills, qualitative impairment in socialinteraction, impairments in the use of multiple nonverbal behaviors toregulate social interaction, failure to develop peer relationshipsappropriate to developmental level, not spontaneously seeking to shareenjoyment or interests or achievements with other people, lacking socialor emotional reciprocity, qualitative impairments in verbalcommunication, repetitive and stereotyped patterns of behavior andinterests and activities, encompassing preoccupation with one or morestereotyped and restricted patterns of interest that is abnormal eitherin intensity or focus, apparently inflexible adherence to specific andnonfunctional routines or rituals, stereotyped and repetitive motormannerisms, persistent preoccupation with parts of objects, abnormalfunctioning in symbolic or imaginative play, or a combination thereof.In some embodiments, the one or more subjects has at least one symptomof a PDD-NOS. In some embodiments, the at least one symptom of a PDD-NOScomprises qualitative impairment in social interaction, markedimpairments in the use of multiple nonverbal behaviors to regulatesocial interaction, failure to develop peer relationships appropriate todevelopmental level, a lack of spontaneous seeking to share enjoyment orinterest or achievements with other people lack of social or emotionalreciprocity, restricted repetitive and stereotyped patterns of behavioror interests and activities, encompassing preoccupation with one or morestereotyped and restricted patterns of interest, nonfunctional routinesor rituals, stereotyped and repetitive motor mannerisms, persistentpreoccupation with parts of objects, clinically significant impairmentsin social or occupational or other important areas of functioning,deceleration of head growth between ages 5 and 48 months, loss ofpreviously acquired purposeful hand skills between ages 5 and 30 monthswith the subsequent development of stereotyped hand movements, loss ofsocial engagement early in the, appearance of poorly coordinated gait ortrunk movements, severely impaired expressive and receptive languagedevelopment with severe psychomotor retardation, clinically significantloss of previously acquired skills before age 10 years, impairment innonverbal behaviors, failure to develop peer relationships, lack ofsocial or emotional reciprocity, qualitative impairments incommunication restricted or repetitive or and stereotyped patterns ofbehavior or interests and activities, or a combination thereof.

In some embodiments, the one or more subjects is human. In someembodiments, the one or more subjects is less than 12 years old, lessthan 8 years old, less than 6 years old, or less than 3 years.

One aspect of the invention includes a method of screening for atherapeutic agent for treatment of a PDD or a PDD-NOS, comprisingidentifying an agent that disrupts or modulates one or more genomicsequences of SEQ ID NOs 77 to 209 or one or more expression productsthereof.

In some embodiments, the one or more expression products comprise one ormore RNA transcripts. In some embodiments, the one or more RNAtranscripts comprise one or more RNA transcripts of Table 2. In someembodiments, the one or more expression products comprise one or morepolypeptides. In some embodiments, the one or more polypeptides aretranslated from one or more RNA transcripts of Table 2. In someembodiments, disrupting or modulating the one or more genomic sequencesof SEQ ID NOs 77 to 209 or expression products thereof, comprises anincrease in expression of the one or more expression products. In someembodiments, disrupting or modulating the one or more genomic sequencesof SEQ ID NOs 77 to 209 or expression products thereof, comprises adecrease in expression of the one or more expression products.

An aspect of the invention includes a method of treating a subject for aPDD or a PDD-NOS, comprising administering one or more agents to disruptor modulate one or more genomic sequences of SEQ ID NOs 77 to 209 or oneor more expression products thereof, thereby treating the PDD or thePDD-NOS.

In some embodiments, the one or more expression products comprise one ormore RNA transcripts. In some embodiments, the one or more RNAtranscripts comprise one or more RNA transcripts of Table 2. In someembodiments, the one or more expression products comprise one or morepolypeptides. In some embodiments, the one or more polypeptides aretranslated from one or more RNA transcripts of Table 2. In someembodiments, the one or more agents are selected from the groupcomprising: an antibody, a drug, a combination of drugs, a compound, acombination of compounds, radiation, a genetic sequence, a combinationof genetic sequences, heat, cryogenics, and a combination of two or moreof any combination thereof.

In some embodiments, the PDD is ASD. In some embodiments, the PDD-NOS isAsperger Syndrome, Rett Syndrome or Childhood Disintegrative Disorder.In some embodiments, the one or more subjects has at least one symptomof a PDD. In some embodiments, the PDD is ASD. In some embodiments, theat least one symptom comprises difficulty with verbal communication,difficulty using language, difficulty understanding language, difficultywith non-verbal communication, difficulty with social interaction,unusual ways of playing with toys and other objects, difficultyadjusting to changes in routine or familiar surroundings, repetitivebody movements or patterns of behavior, changing response to sound,temper tantrums, difficulty sleeping, aggressive behavior, fearfulnessor anxiety, or a combination thereof. In some embodiments, the at leastone symptom comprises not babbling, pointing, or making meaningfulgestures by 1 year of age, not speaking one word by 16 months of age,not combining two words by 2 years of age, not responding to their name,losing language, losing social skills, qualitative impairment in socialinteraction, impairments in the use of multiple nonverbal behaviors toregulate social interaction, failure to develop peer relationshipsappropriate to developmental level, not spontaneously seeking to shareenjoyment or interests or achievements with other people, lacking socialor emotional reciprocity, qualitative impairments in verbalcommunication, repetitive and stereotyped patterns of behavior andinterests and activities, encompassing preoccupation with one or morestereotyped and restricted patterns of interest that is abnormal eitherin intensity or focus, apparently inflexible adherence to specific andnonfunctional routines or rituals, stereotyped and repetitive motormannerisms, persistent preoccupation with parts of objects, abnormalfunctioning in symbolic or imaginative play, or a combination thereof.In some embodiments, the one or more subjects has at least one symptomof a PDD-NOS. In some embodiments, the at least one symptom of a PDD-NOScomprises qualitative impairment in social interaction, markedimpairments in the use of multiple nonverbal behaviors to regulatesocial interaction, failure to develop peer relationships appropriate todevelopmental level, a lack of spontaneous seeking to share enjoyment orinterest or achievements with other people lack of social or emotionalreciprocity, restricted repetitive and stereotyped patterns of behavioror interests and activities, encompassing preoccupation with one or morestereotyped and restricted patterns of interest, nonfunctional routinesor rituals, stereotyped and repetitive motor mannerisms, persistentpreoccupation with parts of objects, clinically significant impairmentsin social or occupational or other important areas of functioning,deceleration of head growth between ages 5 and 48 months, loss ofpreviously acquired purposeful hand skills between ages 5 and 30 monthswith the subsequent development of stereotyped hand movements, loss ofsocial engagement early in the, appearance of poorly coordinated gait ortrunk movements, severely impaired expressive and receptive languagedevelopment with severe psychomotor retardation, clinically significantloss of previously acquired skills before age 10 years, impairment innonverbal behaviors, failure to develop peer relationships, lack ofsocial or emotional reciprocity, qualitative impairments incommunication restricted or repetitive or and stereotyped patterns ofbehavior or interests and activities, or a combination thereof.

In some embodiments, the one or more subjects is human. In someembodiments, the one or more subjects is less than 12 years old, lessthan 8 years old, less than 6 years old, or less than 3 years.

An aspect of the invention includes a kit for screening for a PDD orPDD-NOS in one or more subjects, the kit comprising reagents forassaying a genetic sample from the one or more subjects for the presenceof at least one genetic variation encoded by SEQ ID NOs 1-76.

In some embodiments, the at least one genetic variation disrupts ormodulates one or more genomic sequences of SEQ ID NOs 77 to 209, or oneor more expression products thereof. In some embodiments, the one ormore expression products comprise one or more RNA transcripts. In someembodiments, the one or more RNA transcripts comprise one or more RNAtranscripts of Table 2. In some embodiments, the one or more expressionproducts comprise one or more polypeptides. In some embodiments, the oneor more polypeptides are translated from one or more RNA transcripts ofTable 2.

In some embodiments, the reagents comprise nucleic acid probes. In someembodiments, the reagents comprise oligonucleotides. In someembodiments, the reagents comprise primers.

In some embodiments, the PDD is ASD. In some embodiments, the PDD-NOS isAsperger Syndrome, Rett Syndrome or Childhood Disintegrative Disorder.In some embodiments, the one or more subjects has at least one symptomof a PDD. In some embodiments, the PDD is ASD. In some embodiments, theone or more subjects has at least one symptom of a PDD-NOS.

In some embodiments, the one or more subjects is human. In someembodiments, the one or more subjects is less than 12 years old, lessthan 8 years old, less than 6 years old, or less than 3 years.

An aspect of the invention includes an isolated polynucleotide sequenceor fragment thereof, comprising at least 60% identity to any ofpolynucleotide sequence of SEQ ID NOs 1 to 209.

In some embodiments, the isolated polynucleotide sequence comprises atleast 70% identity to any of polynucleotide sequence of SEQ ID NOs 1 to209. In some embodiments, the isolated polynucleotide sequence comprisesat least 80% identity to any of polynucleotide sequence of SEQ ID NOs 1to 209. In some embodiments, the isolated polynucleotide sequencecomprises at least 90% identity to any of polynucleotide sequence of SEQID NOs 1 to 209.

An aspect of the invention includes an isolated polynucleotide sequencecomprising at least 60% identity to a compliment of any ofpolynucleotide sequence of SEQ ID NOs 1 to 209.

In some embodiments, the isolated polynucleotide sequence comprises atleast 70% identity to a compliment of any of polynucleotide sequence ofSEQ ID NOs 1 to 209. In some embodiments, the isolated polynucleotidesequence comprises at least 80% identity to a compliment of any ofpolynucleotide sequence of SEQ ID NOs 1 to 209. In some embodiments, theisolated polynucleotide sequence comprises at least 90% identity to acompliment of any of polynucleotide sequence of SEQ ID NOs 1 to 209. Insome embodiments, the isolated polynucleotide sequence comprises thepolynucleotide sequence comprises any of a CNV of SEQ ID NOs 1-76. Insome embodiments, the isolated polynucleotide sequence comprisescomprises any of a genomic sequence of SEQ ID NOs 77 to 209. In someembodiments, the isolated polynucleotide sequence comprises an RNAsequence transcribed from a genomic sequence of SEQ ID NOs 77 to 209. Insome embodiments, the isolated polynucleotide sequence comprises any ofa genetic variation not present in the human genome.

An aspect of the invention includes an isolated polypeptide encoded byan RNA sequence transcribed from any of genomic sequence of SEQ ID NOs77 to 209.

An aspect of the invention includes ahost cell comprising an expressioncontrol sequence operably linked to a polynucleotide selected from thegroup consisting of any of polynucleotide sequence of SEQ ID Nos 77 to209, or a fragment thereof.

In some embodiments, the expression control sequence is non-native tothe host cell. In some embodiments, the expression control sequence isnative to the host cell.

An aspect of the invention includes a method for identifying an agenthaving a therapeutic benefit for treatment of a PDD or a PDD-NOS,comprising: a) providing cells comprising at least one genetic variationof SEQ ID NOs 1 to 76; b) contacting the cells of step a) with a testagent and c) analyzing whether the agent has a therapeutic benefit fortreatment of the PDD or the PDD-NOS of step a), thereby identifyingagents which have a therapeutic benefit for treatment of the PDD or thePDD-NOS.

In some embodiments, the mothod further comprises: d) providing cellswhich do not comprise at least one genetic variation of SEQ ID NOs 1-76;e) contacting the cells of steps a) and d) with a test agent; and f)analyzing whether the agent has a therapeutic benefit for treatment ofthe PDD or the PDD-NOS of step a) relative to those of step b), therebyidentifying agents which have a therapeutic benefit for treatment of thePDD or the PDD-NOS. In some embodiments, the therapeutic agent hasefficacy for the treatment of a PDD or a PDD-NOS.

An aspect of the invention includes a therapeutic agent identified byany of the methods described herein.

An aspect of the invention includes a panel of biomarkers for a PDD or aPDD-NOS comprising one or more genes contained in the one or morepolynucleotide sequences selected from SEQ ID NOs 77 to 209.

In some embodiments, the panel comprises two or more genes contained inthe one or more polynucleotide sequences selected from SEQ ID NOs 77 to209. In some embodiments, the panel comprises at least 5, 10, 25, 50,100 or 200 genes contained in the one or more polynucleotide sequencesselected from SEQ ID NOs 77-209. In some embodiments, at least one ofthe polynucleotide sequences is a fragment of the one-morepolynucleotide sequences selected from SEQ ID NOs 77-209. In someembodiments, at least one of the polynucleotide sequences is a variantof the one-more polynucleotide sequences selected from SEQ ID NOs77-209. In some embodiments, the panel is selected for analysis ofpolynucleotide expression levels for a PDD-a PDD-NOS. In someembodiments, the polynucleotide expression levels are mRNA expressionlevels. In some embodiments, the panel is used in the management ofpatient care for a PDD or a PDD-NOS, wherein the management of patientcare includes one or more of risk assessment, early diagnosis, prognosisestablishment, patient treatment monitoring, and treatment efficacydetection. In some embodiments, the panel is used in discovery oftherapeutic intervention of a PDD or a PDD-NOS.

An aspect of the invention includes a method for measuring expressionlevels of polynucleotide sequences from biomarkers for a PDD or aPDD-NOS in a subject, comprising: a) selecting a panel of biomarkerscomprising two or more genes contained in one or more polynucleotidesequences selected from SEQ ID Nos 77 to 209; b) isolating cellular RNAfrom a sample obtained from the subject; c) synthesizing cDNA from thecellular RNA for each biomarker in the panel using suitable primers; d)optionally amplifying the cDNA; and e) quantifying levels of the cDNAfrom the sample.

In some embodiments, the step of selecting a panel of biomarkerscomprises at least 5, 10, 25, 50, 100 or 200 genes contained in one ormore polynucleotide sequences selected from SEQ ID NOs 77 to 209. Insome embodiments, the step of quantifying the levels of cDNA furthercomprises labeling cDNA. In some embodiments, labeling cDNA compriseslabeling with at least one chromophore. In some embodiments, the cDNAlevels for the sample are compared to a control cDNA level. In someembodiments, the comparison is used in the management of patient care inPDD or PDD-NOS. In some embodiments, the management of patient careincludes one or more of risk assessment, early diagnosis, establishingprognosis, monitoring patient treatment, and detecting treatmentefficacy. In some embodiments, the comparison is used in discovery oftherapeutic intervention of PDD or PDD-NOS.

An aspect of the invention includes a method for measuring expressionlevels of polypeptides comprising: a) selecting a panel of biomarkerscomprising at least two polypeptides encoded by an RNA sequencetranscribed from a genomic sequence of SEQ ID Nos 77 to 209; b)obtaining a biological sample; c) creating an antibody panel for eachbiomarker in the panel; d) using the antibody panel to bind thepolypeptides from the sample; and e) quantifying levels of thepolypeptides bound from the sample to the antibody panel.

In some embodiments, the polypeptide levels of the biological sample areincreased or decreased compared to the polypeptide levels of a controlbiological sample. In some embodiments, the subject is treated for a PDDor PDD-NOS patient based on the quantified levels of the polypeptidesbound from the sample to the antibody panel. In some embodiments, thetreatment of a subject includes one or more of risk assessment, earlydiagnosis, establishing prognosis, monitoring patient treatment, anddetecting treatment efficacy. In some embodiments, the comparison isused in discovery of a therapeutic intervention of a PDD or PDD-NOS.

An aspect of the invention includes a kit for the determination of PDDor PDD-NOS comprising: at least one reagent that is used in analysis ofone or more polynucleotide expression levels for a panel of biomarkersfor PDD or PDD-NOS, wherein the panel comprises two or more genescontained in one or more polynucleotide sequences selected from SEQ IDNOs 77 to 209, and instructions for using the kit for analyzing theexpression levels.

In some embodiments, the one or more polynucleotide expression levelscomprise one or more RNA transcript expression levels. In someembodiments, the one or more RNA transcript expression levels correspondto one or more RNA transcripts of Table 2. In some embodiments, the atleast one reagent comprises at least two sets of suitable primers. Insome embodiments, the at least one reagent comprises a reagent for thepreparation of cDNA. In some embodiments, the at least one reagentcomprises a reagent that is used for detection and quantization ofpolynucleotides. In some embodiments, the at least one reagent comprisesat least one chromophore.

An aspect of the invention includes a kit for the determination of PDDor PDD-NOS comprising: at least one reagent that is used in analysis ofpolypeptide expression levels for a panel of biomarkers for PDD orPDD-NOS, wherein the panel comprises at least two polypeptides expressedfrom two or more genes contained in one or more polynucleotide sequencesselected from SEQ ID NOs 77 to 209; and instructions for using the kitfor analyzing the expression levels.

In some embodiments, the reagent is an antibody reagent that binds apolypeptide selected in the panel. In some embodiments, the kit furthercomprises a reagent that is used for detection of a bound polypeptide.In some embodiments, the reagent includes a second antibody.

An aspect of the invention includes a method of screening a subject fora PDD or PDD-NOS, the method comprising: a) assaying a nucleic acidsample obtained from the subject by PCR, array ComparativePolynucleotide Hybridization, sequencing, SNP genotyping, orFluorescence in Situ Hybridization to detect sequence information formore than one genetic loci; b) comparing the sequence information to apanel of nucleic acid biomarkers, wherein the panel comprises at leastone nucleic acid biomarker for each of the more than one genetic loci;and wherein the panel comprises at least 2 low frequency nucleic acidbiomarkers, wherein the low frequency nucleic acid biomarkers occur at afrequency of 0.1% or less in a population of subjects without adiagnosis of the PDD or PDD-NOS; and c) screening the subject for thepresence or absence of the PDD or the PDD-NOS if one or more of the lowfrequency biomarkers in the panel are present in the sequenceinformation.

In some embodiments, the panel comprises at least 5, 10, 25, 50, 100 or200 low frequency nucleic acid biomarkers. In some embodiments, thepresence or absence of the PDD or the PDD-NOS in the subject isdetermined with at least 50% confidence. In some embodiments, the lowfrequency biomarkers occur at a frequency of 0.01% or less, 0.001% orless, or 0.0001% or less in a population of subjects without a diagnosisof the PDD or the PDD-NOS. In some embodiments, the panel of nucleicacid biomarkers comprises at least two genes contained in the one ormore polynucleotide sequences selected from SEQ ID NOs 77 to 209. Insome embodiments, the PDD is ASD.

In some embodiments, the PDD-NOS is Asperger Syndrome, Rett Syndrome orChildhood Disintegrative Disorder. In some embodiments, the methodfurther comprises identifying a therapeutic agent useful for treatingthe PDD or the PDD-NOS. In some embodiments, the method furthercomprises administering one or more of the therapeutic agents to thesubject if one or more of the low frequency biomarkers in the panel arepresent in the sequence information.

An aspect of the invention includes a kit for screening a subject for aPDD or a PDD-NOS, the kit comprising at least one reagent for assaying anucleic acid sample from the subject for information on a panel ofnucleic acid biomarkers, wherein the panel comprises at least 2 lowfrequency biomarkers, and wherein the low frequency biomarkers occur ata frequency of 0.1% or less in a population of subjects without adiagnosis of the PDD or the PDD-NOS.

In some embodiments, a presence or absence of the PDD or the PDD-NOS inthe subject is determined with a 50% confidence. In some embodiments,the panel comprises at least 5, 10, 25, 50, 100 or 200 low frequencynucleic acid biomarkers. In some embodiments, the low frequencybiomarkers occur at a frequency of 0.01% or less, 0.001% or less, or0.0001% or less in a population of subjects without a diagnosis of thePDD or PDD-NOS. In some embodiments, the panel of nucleic acidbiomarkers comprises at least two genes contained in the one or morepolynucleotide sequences selected from SEQ ID NOs 77 to 209. In someembodiments, the at least one reagent comprises at least two sets ofsuitable primers. In some embodiments, the at least one reagentcomprises a reagent for the preparation of cDNA. In some embodiments,the at least one reagent comprises a reagent that is used for detectionand quantization of polynucleotides. In some embodiments, the at leastone reagent comprises at least one chromophore.

An aspect of the invention includes a method of generating a panel ofnucleic acid biomarkers comprising: a) assaying a nucleic acid samplefrom a first population of subjects by PCR, array ComparativePolynucleotide Hybridization, sequencing, SNP genotyping, orFluorescence in Situ Hybridization for nucleic acid sequenceinformation, wherein the subjects of the first population have adiagnosis of a PDD or a PDD-NOS. b) assaying a nucleic acid sample froma second population of subjects by PCR, array Comparative PolynucleotideHybridization, sequencing, SNP genotyping, or Fluorescence in SituHybridization for nucleic acid sequence information, wherein thesubjects of the second population are without a diagnosis of a PDD or aPDD-NOS; c) comparing the nucleic acid sequence information from step(a) to that of step (b); d) determining the frequency of one or morebiomarkers from the comparing step; and e) generating the panel of anucleic acid biomarkers, wherein the panel comprises at least 2 lowfrequency biomarkers, and wherein the low frequency biomarkers occur ata frequency of 0.1% or less in a population of subjects without adiagnosis of a PDD or a PDD-NOS.

In some embodiments, the subjects in the second population of subjectswithout a diagnosis of a PDD or a PDD-NOS comprise one or more subjectsnot suspected of having the PDD or the PDD-NOS. In some embodiments, thesubjects in the second population of subjects without a diagnosis of aPDD or a PDD-NOS comprise one or more subjects without the PDD or thePDD-NOS. In some embodiments, the subjects in the second population ofsubjects without a diagnosis of a PDD or a PDD-NOS comprise one or moresubjects who are asymptomatic for the PDD or the PDD-NOS. In someembodiments, the subjects in the second population of subjects without adiagnosis of a PDD or a PDD-NOS comprise one or more subjects who havedecreased susceptibility to the PDD or the PDD—In some embodiments, thesubjects in the second population of subjects without a diagnosis of aPDD or a PDD-NOS comprise one or more subjects who are unassociated witha treatment, therapeutic regimen, or any combination thereof. In someembodiments, the panel comprises at least 5, 10, 25, 50, 100 or 200 lowfrequency nucleic acid biomarkers. In some embodiments, the lowfrequency biomarkers occur at a frequency of 0.01% or less, 0.001% orless, or 0.0001% or less in the second population of subjects without adiagnosis of a PDD or a PDD-NOS. In some embodiments, the panel ofnucleic acid biomarkers comprises at least two genes contained in theone or more polynucleotide sequences selected from SEQ ID NOs 77 to 209.

An aspect of the invention includes an array comprising a plurality ofnucleic acid probes, wherein each probe comprises a sequencecomplimentary to a target sequence of one of the polynucleotidesequences selected from SEQ ID NOs 77 to 209, or a fragment thereof.

In some embodiments, the plurality of nucleic acid probes comprises atleast 5, 10, 25, 50, 100 or 200 of the nucleic acid probes. In someembodiments, the array further comprises a second plurality of nucleicacid probes, wherein each probe in the second plurality of nucleic acidprobes comprises a sequence complimentary to a complimentary targetsequence of one of the polynucleotide sequences selected from SEQ ID NOs1-76, or a fragment thereof. In some embodiments, second plurality ofnucleic acid probes comprises at least 5, 10, 25, 50, 100 or 200 nucleicacid probes. In some embodiments, each different nucleic acid probe isattached to a bead. In some embodiments, each different nucleic acidprobe is labeled with a detectable label. In some embodiments, eachdifferent nucleic acid probe is attached to a solid support in adeterminable location of the array. In some embodiments, the solidsupport comprises plastics, glass, beads, microparticles, microtitredishes, or gels. In some embodiments, the array further comprisescontrol probes.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in thisspecification are herein incorporated by reference to the same extent asif each individual publication, patent, or patent application wasspecifically and individually indicated to be incorporated by reference.In the event of a conflict between a term herein and a term incorporatedby reference, the term herein controls.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the disclosure are set forth with particularity inthe appended claims. A better understanding of the features andadvantages of the present disclosure will be obtained by reference tothe following detailed description that sets forth illustrativeembodiments, in which the principles of the disclosure are utilized, andthe accompanying drawings.

FIG. 1 is an example of a log2ratio plot using an algorithm (DNAAnalytics) to call and classify CNVs.

FIG. 2 is an annotated version of the log2ratio plot from FIG. 1.

FIG. 3 represents an example of intronic CNVs clustered within anintronic region of the gene GPHN located on chromosome 14. There are 7ASD cases in total and 6 of these are depicted. The CNVs include a gain(log2ratio>0.35) and losses (log2ratio<−0.35). The order of ASD patientHospital IDs (top to bottom) are: SS0054, SSO254, SS0100, SS0025,SS0711, SS0175.

FIG. 4 is an annotated version of rare CN-(s) impacting gene CIB2.

FIG. 5 is an annotated version of rare CN-(s) impacting gene SAE1.

FIG. 6 is an annotated version of rare CN-(s) impacting gene PLXNA4.

FIG. 7 is an annotated version of rare CN-(s) impacting gene GPHN.

FIG. 8 is an annotated version of rare CN-(s) impacting gene CECR2.

FIG. 9 is an annotated version of rare CN-(s) impacting gene DAGLA.

DETAILED DESCRIPTION OF THE INVENTION

The details of one or more inventive embodiments are set forth in theaccompanying drawings, the claims, and in the description herein. Otherfeatures, objects, and advantages of inventive embodiments disclosed andcontemplated herein will be apparent from the description and drawings,and from the claims. As used herein, unless otherwise indicated, thearticle “a” means one or more unless explicitly otherwise provided for.As used herein, unless otherwise indicated, terms such as “contain,”“containing,” “include,” “including,” and the like mean “comprising.” Asused herein, unless otherwise indicated, the term “or” can beconjunctive or disjunctive. As used herein, unless otherwise indicated,any embodiment can be combined with any other embodiment. As usedherein, unless otherwise indicated, some inventive embodiments hereincontemplate numerical ranges. When ranges are present, the rangesinclude the range endpoints. Additionally, every subrange and valuewithin the range is present as if explicitly written out.

Described herein are methods of identifying variations in nucleic acidsand genes associated with one or more developmental conditions.Described herein are methods of screening for determining a subject'ssusceptibility to developing or having, one or more developmentaldisorders, for example, ASD, based on identification and detection ofgenetic nucleic acid variations. Also described herein, are methods andcompositions for treating and/or preventing one or more developmentalconditions using a therapeutic modality. The present disclosureencompasses methods of assessing an individual for probability ofresponse to a therapeutic agent for a developmental disorder, methodsfor predicting the effectiveness of a therapeutic agent for adevelopmental disorder, nucleic acids, polypeptides and antibodies andcomputer-implemented functions. Kits for screening a sample from asubject to detect or determine susceptibility to a developmentaldisorder are also encompassed by the disclosure.

Genetic Variations Associated with Developmental Disorders

Genomic sequences within populations exhibit variability betweenindividuals at many locations in the genome. For example, the humangenome exhibits sequence variations that occur on average every 500 basepairs. Such genetic variations in nucleic acid sequences are commonlyreferred to as polymorphisms or polymorphic sites. In some embodiments,these genetic variations can be found to be associated with one or moredisorders and/or diseases using the methods disclosed herein. In someembodiments the one or more disorders and/or diseases comprise one ormore developmental disorders. In some embodiments the one or moredevelopmental disorders comprise one or more Pervasive DevelopmentalDisorders (PDD). In some embodiments, the one or more PDDs comprise ASD.ASD can refer to autism. In another embodiment, the one or moredevelopmental disorders comprise Pervasive Developmental Disorder—NotOtherwise Specified (PDD-NOS). In some embodiments, PDD-NOS can compriseAsperger Syndrome, Rett Syndrome, fragile X syndrome and/or ChildhoodDisintegrative Disorder. In some embodiments genetic variations can beassociated with one or more PDDs. In some embodiments genetic variationscan be associated with one or more PDD-NOSs.

Scientific evidence suggests there is a potential for variouscombinations of factors causing ASD, such as multiple genetic variationsthat may cause autism on their own or when combined with exposure to asyet undetermined environmental factors Timing of exposure during thechild's development, such as before, during, or after birth, may alsoplay a role in the development or final presentation of the disorder. Asmall number of cases can be linked to genetic disorders such as FragileX, Tuberous Sclerosis, and Angelman's Syndrome, as well as exposure toenvironmental agents such as infectious ones (maternal rubella orcytomegalovirus) or chemical ones (thalidomide or valproate) duringpregnancy.

In some embodiments, these genetic variations comprise point mutations,polymorphisms, translocations, insertions, deletions, amplifications,inversions, interstitial deletions, copy number variations (CNVs), lossof heterozygosity, or any combination thereof. In some embodimentspolymorphisms (e.g. polymorphic markers), can comprise any nucleotideposition at which two or more sequences are possible in a subjectpopulation. In some embodiments, each version of a nucleotide sequencewith respect to the polymorphism can represent a specific allele, of thepolymorphism. In some embodiments, genomic DNA from a subject cancontain two alleles for any given polymorphic marker, representative ofeach copy of the marker on each chromosome. In some embodiments, anallele can be a nucleotide sequence of a given location on a chromosome.Polymorphisms can comprise any number of specific alleles. In someembodiments of the disclosure, a polymorphism can be characterized bythe presence of two or more alleles in a population. In someembodiments, the polymorphism can be characterized by the presence ofthree or more alleles. In some embodiments, the polymorphism can becharacterized by four or more alleles, five or more alleles, six or morealleles, seven or more alleles, nine or more alleles, or ten or morealleles. In some embodiments an allele can be associated with one ormore diseases or disorders, for example, a developmental disorder riskallele can be an allele that is associated with increased or decreasedrisk of developing a developmental disorder. In some embodiments,genetic variations and alleles can be used to associate an inheritedphenotype, for example, a developmental disorder, with a responsiblegenotype. In some embodiments, a developmental disorder risk allele canbe a variant allele that is statistically associated with a screening ofone or more developmental disorders. In some embodiments, geneticvariations can be of any measurable frequency in the population, forexample, a frequency higher than 10%, a frequency between 5-10%, afrequency between 1-5%, or frequency below 1%. As used herein, variantalleles can be alleles that differ from a reference allele. As usedherein, a variant can be a segment of DNA that differs from thereference DNA, such as a genetic variation. In some embodiments, geneticvariations can be used to track the inheritance of a gene that has notyet been identified, but whose approximate location is known.

As used herein, a haplotype can be information regarding the presence orabsence of one or more genetic markers in a given chromosomal region ina subject. In some embodiments, a haplotype can be a segment of DNAcharacterized by one or more alleles arranged along the segment, forexample, a haplotype can comprise one member of the pair of alleles foreach genetic variation or locus. In some embodiments, the haplotype cancomprise two or more alleles, three or more alleles, four or morealleles, five or more alleles, or any combination thereof, wherein, eachallele can comprise one or more genetic variations along the segment.

In some embodiments, a genetic variation can be a functional aberrationthat can alter gene function, gene expression, protein expression,protein function, or any combination thereof. In some embodiments, agenetic variation can be a loss-of-function mutation, gain-of-functionmutation, dominant negative mutation, or reversion. In some embodiments,a genetic variation can be part of a gene's coding region or regulatoryregion. Regulatory regions can control gene expression and thus proteinexpression. In some embodiments, a regulatory region can be a segment ofDNA wherein regulatory proteins, for example, transcription factors, canbind. In some embodiments a regulatory region can be positioned near thegene being regulated, for example, positions upstream of the gene beingregulated.

In some embodiments, variants can include changes that affect apolypeptide, such as a change in expression level, sequence, function,localization, binding partners, or any combination thereof. In someembodiments, a genetic variation can be a frameshift mutation, nonsensemutation, missense mutation, neutral mutation, or silent mutation. Forexample, sequence differences, when compared to a reference nucleotidesequence, can include the insertion or deletion of a single nucleotide,or of more than one nucleotide, resulting in a frame shift; the changeof at least one nucleotide, resulting in a change in the encoded aminoacid; the change of at least one nucleotide, resulting in the generationof a premature stop codon; the deletion of several nucleotides,resulting in a deletion of one or more amino acids encoded by thenucleotides; the insertion of one or several nucleotides, such as byunequal recombination or gene conversion, resulting in an interruptionof the coding sequence of a reading frame; duplication of all or a partof a sequence; transposition; or a rearrangement of a nucleotidesequence. Such sequence changes can alter the polypeptide encoded by thenucleic acid, for example, if the change in the nucleic acid sequencecauses a frame shift, the frame shift can result in a change in theencoded amino acids, and/or can result in the generation of a prematurestop codon, causing generation of a truncated polypeptide. In someembodiments, a genetic variation associated with a developmentaldisorder can be a synonymous change in one or more nucleotides, forexample, a change that does not result in a change in the amino acidsequence. Such a polymorphism can, for example, alter splice sites,affect the stability or transport of mRNA, or otherwise affect thetranscription or translation of an encoded polypeptide. In someembodiments, a synonymous mutation can result in the protein producthaving an altered structure due to rare codon usage that impacts proteinfolding during translation, which in some cases may alter its functionand/or drug binding properties if it is a drug target. In someembodiments, the changes that can alter DNA to increase the possibilitythat structural changes, such as amplifications or deletions, occur atthe somatic level. A polypeptide encoded by the reference nucleotidesequence can be a reference polypeptide with a particular referenceamino acid sequence, and polypeptides encoded by variant nucleotidesequences can be variant polypeptides with variant amino acid sequences.

In some embodiments, one or more variant polypeptides or proteins can beassociated with one or more diseases or disorders, such as ASD. In someembodiments, variant polypeptides and changes in expression,localization, and interaction partners thereof, can be used to associatean inherited phenotype, for example, a developmental disorder, with aresponsible genotype. In some embodiments, a developmental disorderassociated variant polypeptide can be statistically associated with adiagnosis, prognosis, or theranosis of one or more developmentaldisorders.

The most common sequence variants comprise base variations at a singlebase position in the genome, and such sequence variants, orpolymorphisms, are commonly called single nucleotide polymorphisms(SNPs) or single nucleotide variants (SNVs). In some embodiments, a SNPrepresents a genetic variant present at greater than or equal to 1%occurrence in a population and in some embodiments a SNP can represent agenetic variant present at any frequency level in a population. A SNPcan be a nucleotide sequence variation occurring when a singlenucleotide at a location in the genome differs between members of aspecies or between paired chromosomes in a subject. SNPs can includevariants of a single nucleotide, for example, at a given nucleotideposition, some subjects can have a ‘G’, while others can have a ‘C’.SNPs can occur in a single mutational event, and therefore there can betwo possible alleles possible at each SNP site; the original allele andthe mutated allele. SNPs that are found to have two different bases in asingle nucleotide position are referred to as biallelic SNPs, those withthree are referred to as triallelic, and those with all four basesrepresented in the population are quadallelic. In some embodiments, SNPscan be considered neutral. In some embodiments SNPs can affectsusceptibility to developmental disorders. SNP polymorphisms can havetwo alleles, for example, a subject can be homozygous for one allele ofthe polymorphism wherein both chromosomal copies of the individual havethe same nucleotide at the SNP location, or a subject can beheterozygous wherein the two sister chromosomes of the subject containdifferent nucleotides. The SNP nomenclature as reported herein is theofficial Reference SNP (rs) ID identification tag as assigned to eachunique SNP by the National Center for Biotechnological Information(NCBI).

Another genetic variation of the disclosure can be copy numbervariations (CNVs). CNVs can be alterations of the DNA of a genome thatresults an abnormal number of copies of one or more sections of DNA.CNVs can be inherited or caused by de novo mutation and can beresponsible for a substantial amount of human phenotypic variability,behavioral traits, and disease susceptibility. In a preferredembodiment, CNVs of the current disclosure can be associated withsusceptibility to one or more developmental disorders, for example, ASD.In some embodiments, CNVs can be a single gene or include a contiguousset of genes. In some embodiments, CNVs can be caused by structuralrearrangements of the genome, for example, translocations, insertions,deletions, amplifications, inversions and interstitial deletions. Insome embodiments, these structural rearrangements occur on one or morechromosomes. Low copy repeats (LCRs), which are region-specific repeatsequences, can be susceptible to these structural rearrangements,resulting in CNVs. Factors such as size, orientation, percentagesimilarity and the distance between the copies can influence thesusceptibility of LCRs to genomic rearrangement. In some embodiments,CNVs are referred to as structural variants. In some embodiments,structural variants can be a broader class of variant that can alsoincludes copy number neutral alterations such as inversions and balancedtranslocations.

CNVs can account for genetic variation affecting a substantialproportion of the human genome, for example, known CNVs can cover over15% of the human genome sequence (Estivill, X Armengol; L., PLoSGenetics 3: 1787-99 (2007)). CNVs can affect gene expression, phenotypicvariation and adaptation by disrupting gene dosage, and can causedisease, for example, microdeletion and microduplication disorders, andcan confer susceptibility to diseases and disorders. Updated informationabout the location, type, and size of known CNVs can be found in one ormore databases, for example, the Database of Genomic Variants(http://projects.tcag.ca/variation/), which currently contains data forover 66,000 CNVs (as of Nov. 2, 2010).

Other types of sequence variants can be found in the human genome andcan be associated with a disease or disorder, including but not limitedto, microsatellites. Microsatellite markers are stable, polymorphic,easily analyzed, and can occur regularly throughout the genome, makingthem especially suitable for genetic analysis. A polymorphicmicrosatellite can comprise multiple small repeats of bases, forexample, CA repeats, at a particular site wherein the number of repeatlengths varies in a population. In some embodiments, microsatellites,for example, variable number of tandem repeats (VNTRs), can be shortsegments of DNA that have one or more repeated sequences, for example,about 2 to 5 nucleotides long, that can occur in non-coding DNA. In someembodiments, changes in microsatellites can occur during geneticrecombination of sexual reproduction, increasing or decreasing thenumber of repeats found at an allele, or changing allele length.

Developmental Disorders

Developmental disorders are disorders that occur at some stage in achild's development, often retarding the development, includingpsychological or physical disorders. In some embodiments, they can bedistinguished into specific developmental disorders including PervasiveDevelopmental Disorders (PDDs) and Pervasive Developmental Disorder—NotOtherwise Specified (PDD-NOS). A PDD can comprise ASD. Generally,symptoms that may be present to some degree in a subject of the presentdisclosure with a PDD can include difficulty with verbal communication,including problems using and understanding language, difficulty withnon-verbal communication, such as gestures and facial expressions suchas smiling, difficulty with social interaction, including relating topeople and to his or her surroundings, unusual ways of playing with toysand other objects, difficulty adjusting to changes in routine orfamiliar surroundings, repetitive body movements or patterns ofbehavior, such as hand flapping, spinning, and head banging, changingresponse to sound, temper tantrums, difficulty sleeping, aggressivebehavior, and/or fearfulness or anxiety. ASD can be defined by a certainset of behaviors that can range from the very mild to the severe.Possible indicators of ASDs include a subject whom does not babble,point, or make meaningful gestures by 1 year of age; does not speak oneword by 16 months, does not combine two words by 2 years, does notrespond to their name, and/or loses language or social skills. Othersymptoms include qualitative impairment in social interaction, asmanifested by marked impairments in the use of multiple nonverbalbehaviors such as eye-to-eye gaze, facial expression, body posture, andgestures to regulate social interaction, failure to develop peerrelationships appropriate to developmental level, a lack of spontaneousseeking to share enjoyment, interests, or achievements with otherpeople, (e.g., by a lack of showing, bringing, or pointing out objectsof interest to other people), or lack of social or emotional reciprocity(note: in the description, it gives the following as examples: notactively participating in simple social play or games, preferringsolitary activities, or involving others in activities only as tools or“mechanical” aids). Symptoms of Autism can also include qualitativeimpairments in communication as manifested by delay in, or total lackof, the development of spoken language (not accompanied by an attempt tocompensate through alternative modes of communication such as gesture ormime), in individuals with adequate speech, marked impairment in theability to initiate or sustain a conversation with others, stereotypedand repetitive use of language or idiosyncratic language, or lack ofvaried, spontaneous make-believe play or social imitative playappropriate to developmental level. Other symptoms of Autism includerestricted repetitive and stereotyped patterns of behavior, interestsand activities, as manifested by encompassing preoccupation with one ormore stereotyped and restricted patterns of interest that is abnormaleither in intensity or focus, apparently inflexible adherence tospecific, nonfunctional routines or rituals, stereotyped and repetitivemotor mannerisms (e.g hand or finger flapping or twisting, or complexwhole-body movements), or persistent preoccupation with parts ofobjects. Other symptoms of Autism include delays or abnormal functioningin at areas, with onset prior to age 3 years including socialinteraction, language as used in social communication and symbolic orimaginative play As described herein, Pervasive DevelopmentalDisorders—Not Otherwise Specified (PDD-NOS) can comprise AspergerSyndrome, Rett Syndrome, fragile X syndrome, and/or ChildhoodDisintegrative Disorder. In some embodiments a screening of PDD-NOS canbe a screening of being on the autism spectrum, but not falling withinany of the existing specific categories of autism. PDD-NOS is apervasive developmental disorder (PDD)/autism spectrum disorder (ASD)and is often referred to as atypical autism.

Symptoms of Asperger Sydrome can include qualitative impairment insocial interaction, marked impairments in the use of multiple nonverbalbehaviors such as eye-to-eye gaze, facial expression, body posture, andgestures to regulate social interaction, failure to develop peerrelationships appropriate to developmental level a lack of spontaneousseeking to share enjoyment, interest or achievements with other people,(e.g. by a lack of showing, bringing, or pointing out objects ofinterest to other people) and lack of social or emotional reciprocity.Other symptoms can include restricted repetitive & stereotyped patternsof behavior, interests and activities, encompassing preoccupation withone or more stereotyped and restricted patterns of interest that isabnormal either in intensity or focus apparently inflexible adherence tospecific, nonfunctional routines or rituals stereotyped and repetitivemotor mannerisms (e.g. hand or finger flapping or twisting, or complexwhole-body movements) and persistent preoccupation with parts of objectsand clinically significant impairments in social, occupational, or otherimportant areas of functioning. There may be no clinically significantgeneral delay in language (for example, single words used by age 2years, communicative phrases used by age 3 years). There may be noclinically significant delay in cognitive development or in thedevelopment of age-appropriate self help skills, adaptive behavior(other than in social interaction) and curiosity about the environmentin childhood.

Although apparently normal prenatal and perinatal development,apparently normal psychomotor development through the first 5 monthsafter birth, normal head circumference at birth are observed, symptomsof Rett Syndrome begin after the period of normal development andinclude deceleration of head growth between ages 5 and 48 months, lossof previously acquired purposeful hand skills between ages 5 and 30months with the subsequent development of stereotyped hand movements(i.e., hand-wringing or hand washing), loss of social engagement earlyin the course (although often social interaction develops later),appearance of poorly coordinated gait or trunk movements, and severelyimpaired expressive and receptive language development with severepsychomotor retardation.

Although apparently normal development occurs for at least the first 2years after birth, Childhood Disintegrative Disorder symptoms manifestby the presence of age-appropriate verbal and nonverbal communication,social relationships, play, and adaptive behavior. Symptoms includeclinically significant loss of previously acquired skills (before age 10years) including expressive or receptive language, social skills oradaptive behavior, bowel or bladder control, play, and motor skills.Oher symtoms include abnormalities of functioning in areas includingqualitative impairment in social interaction (e.g., impairment innonverbal behaviors, failure to develop peer relationships, lack ofsocial or emotional reciprocity), qualitative impairments incommunication (e.g., delay or lack of spoken language, inability toinitiate or sustain a conversation, stereotyped and repetitive use oflanguage, lack of varied make-believe play), and restricted, repetitive,and stereotyped patterns of behavior, interests, and activities,including motor stereotypies and mannerisms.

Subjects

A subject, as used herein, can be an individual of any age or sex fromwhom a sample containing nucleotides is obtained for analysis by one ormore methods described herein so as to obtain genetic data, for example,a male or female adult, child, newborn, or fetus. In some embodiments, asubject can be any target of therapeutic administration. In someembodiments, a subject can be a test subject or a reference subject. Insome embodiments, a subject can be associated with a condition ordisease or disorder, asymptomatic or symptomatic, have increased ordecreased susceptibility to a disease or disorder, be associated orunassociated with a treatment or treatment regimen, or any combinationthereof. As used in the present disclosure a cohort can represent anethnic group, a patient group, a particular age group, a group notassociated with a particular disease or disorder, a group associatedwith a particular disease or disorder, a group of asymptomatic subjects,a group of symptomatic subjects, or a group or subgroup of subjectsassociated with a particular response to a treatment regimen or clinicaltrial. In some embodiments, a patient can be a subject afflicted with adisease or disorder. In some embodiments, a patient can be a subject notafflicted with a disease or disorder. In some embodiments, a subject canbe a test subject, a patient or a candidate for a therapeutic, whereingenomic DNA from said subject, patient, or candidate is obtained foranalysis by one or more methods of the present disclosure herein, so asto obtain genetic variation information of said subject, patient orcandidate.

In some embodiments, the sample can be obtained prenatally from a fetusor embryo or from the mother, for example, from fetal or embryonic cellsin the maternal circulation. In some embodiments, the sample can beobtained with the assistance of a health care provider, for example, todraw blood. In some embodiments, the sample can be obtained without theassistance of a health care provider, for example, where the sample isobtained non-invasively, such as a sample comprising buccal cells thatis obtained using a buccal swab or brush, or a mouthwash sample.

The present disclosure also provides methods for assessing geneticvariations in subjects who are members of a target population. Such atarget population is in some embodiments a population or group ofsubjects at risk of developing the disease, based on, for example, othergenetic factors, biomarkers, biophysical parameters, family history of adevelopmental disorder, previous screening or medical history, or anycombination thereof.

Although ASD is known to affect children to a higher extent than adults,subjects of all ages are contemplated in the present disclosure. In someembodiments subjects can be from specific age subgroups, such as thoseover the age of 1, over the age of 2, over the age of 3, over the age of4, over the age of 5, over the age of 6, over the age of 7, over the ageof 8, over the age of 9, over the age of 10, over the age of 15, overthe age of 20, over the age of 25, over the age of 30, over the age of35, over the age of 40, over the age of 45, over the age of 50, over theage of 55, over the age of 60, over the age of 65, over the age of 70,over the age of 75, over the age of 80, or over the age of 85. Otherembodiments of the disclosure pertain to other age groups, such assubjects aged less than 85, such as less than age 80, less than age 75,less than age 70, less than age 65, less than age 60, less than age 55,less than age 50, less than age 45, less than age 40, less than age 35,less than age 30, less than age 25, less than age 20, less than age 15,less than age 10, less than age 9, less than age 8, less than age 6,less than age 5, less than age 4, less than age 3, less than age 2, orless than age 1. Other embodiments relate to subjects with age at onsetof the disease in any of particular age or age ranges defined by thenumerical values described in the above or other numerical valuesbridging these numbers. It is also contemplated that a range of ages canbe relevant in certain embodiments, such as age at onset at more thanage 15 but less than age 20. Other age ranges are however alsocontemplated, including all age ranges bracketed by the age valueslisted in the above.

The genetic variations of the present disclosure found to be associatedwith a developmental disorder can show similar association in otherhuman populations. Particular embodiments comprising subject humanpopulations are thus also contemplated and within the scope of thedisclosure. Such embodiments relate to human subjects that are from oneor more human populations including, but not limited to, Caucasian,European, American, Eurasian, Asian, Central/South Asian, East Asian,Middle Eastern, African, Hispanic, and Oceanic populations. Europeanpopulations include, but are not limited to, Swedish, Norwegian,Finnish, Russian, Danish, Icelandic, Irish, Kelt, English, Scottish,Dutch, Belgian, French, German, Spanish, Portuguese, Italian, Polish,Bulgarian, Slavic, Serbian, Bosnian, Czech, Greek and Turkishpopulations. The racial contribution in subject subjects can also bedetermined by genetic analysis, for example, genetic analysis ofancestry can be carried out using unlinked microsatellite markers suchas those set out in Smith et al. (Am J Hum Genet. 74, 1001-13 (2004))

It is also well known to the person skilled in the art that certaingenetic variations have different population frequencies in differentpopulations, or are polymorphic in one population but not in another. Aperson skilled in the art can however apply the methods available and asthought herein to practice the present disclosure in any given humanpopulation. This can include assessment of genetic variations of thepresent disclosure, so as to identify those markers that give strongestassociation within the specific population. Thus, the at-risk variantsof the present disclosure can reside on different haplotype backgroundand in different frequencies in various human populations.

Samples

Samples that are suitable for use in the methods described herein can befrom a subject and can contain genetic or proteinaceous material, forexample, genomic DNA (gDNA). Genetic material can be extracted from oneor more biological samples including but not limited to, blood, saliva,urine, mucosal scrapings of the lining of the mouth, expectorant, serum,tears, skin, tissue, or hair.

In some embodiments, the sample can comprise cells or tissue, forexample, cell lines. Exemplary cell types from which genetic materialcan be obtained using the methods described herein and include but arenot limited to, a blood cell; such as a B lymphocyte, T lymphocyte,leukocyte, erythrocyte, macrophage, or neutrophil; a muscle cell such asa skeletal cell, smooth muscle cell or cardiac muscle cell; a germ cell,such as a sperm or egg; an epithelial cell; a connective tissue cell,such as an adipocyte, chondrocyte; fibroblast or osteoblast; a neuron;an astrocyte; a stromal cell; an organ specific cell, such as a kidneycell, pancreatic cell, liver cell, or a keratinocyte; a stem cell; orany cell that develops there from. A cell from which gDNA is obtainedcan be at a particular developmental level including, for example, ahematopoietic stem cell or a cell that arises from a hematopoietic stemcell such as a red blood cell, B lymphocyte, T lymphocyte, naturalkiller cell, neutrophil, basophil, eosinophil, monocyte, macrophage, orplatelet. Generally any type of stem cell can be used including, withoutlimitation, an embryonic stem cell, adult stem cell, or pluripotent stemcell.

In some embodiments, a sample can be processed for DNA isolation, forexample, DNA in a cell or tissue sample can be separated from othercomponents of the sample. Cells can be harvested from a biologicalsample using standard techniques known in the art, for example, bycentrifuging a cell sample and resuspending the pelleted cells, forexample, in a buffered solution, for example, phosphate-buffered saline(PBS). In some embodiments, after centrifuging the cell suspension toobtain a cell pellet, the cells can be lysed to extract DNA. In someembodiments, the sample can be concentrated and/or purified to isolateDNA. All samples obtained from a subject, including those subjected toany sort of further processing, are considered to be obtained from thesubject. In some embodiments, standard techniques and kits known in theart can be used to extract genomic DNA from a biological sample,including, for example, phenol extraction, a QIAamp® Tissue Kit (Qiagen,Chatsworth, Calif.), a Wizard® Genomic DNA purification kit (Promega),or a Qiagen Autopure method using Puregene chemistry, which can enablepurification of highly stable DNA well-suited for archiving.

In some embodiments, determining the identity of an allele ordetermining copy number can, but need not, include obtaining a samplecomprising DNA from a subject, and/or assessing the identity, copynumber, presence or absence of one or more genetic variations and theirchromosomal locations in the sample. The individual or organization thatperforms the determination need not actually carry out the physicalanalysis of a sample from a subject. In some embodiments, the methodscan include using information obtained by analysis of the sample by athird party. In some embodiments, the methods can include steps thatoccur at more than one site. For example, a sample can be obtained froma subject at a first site, such as at a health care provider or at thesubject's home in the case of a self-testing kit. The sample can beanalyzed at the same or a second site, for example, at a laboratory orother testing facility.

Methods of Screening

As used herein, screening a subject comprises diagnosing or determining,theranosing, or determining the susceptibility to developing(prognosing) a developmental disorder, for example, ASD. In particularembodiments, the disclosure is a method of determining a presence of, ora susceptibility to, a developmental disorder, by detecting at least onegenetic variation in a sample from a subject as described herein. Insome embodiments, detection of particular alleles, markers, variations,or haplotypes is indicative of a presence or susceptibility to adevelopmental disorder. Although there can be many concerns aboutscreening a subject with an ASD, the earlier the screening of ASD ismade, the earlier needed interventions can begin. Evidence over the last15 years indicates that intensive early intervention in optimaleducational settings for at least 2 years during the preschool yearsresults in improved outcomes in most young children with ASD. Inevaluating a child, clinicians rely on behavioral characteristics tomake a diagnosis, prognosis, or theranosis. Some of the characteristicbehaviors of ASD may be apparent in the first few months of a child'slife, or they may appear at any time during the early years. For thescreening problems in at least one of the areas of communication,socialization, or restricted behavior must be present before the age of3. The screening requires a two-stage process. The first stage involvesdevelopmental screening during “well-child” check-ups; the second stageentails a comprehensive evaluation by a multidisciplinary team. A “wellchild” check-up should include a developmental screening test. Severalscreening instruments have been developed to quickly gather informationabout a child's social and communicative development within medicalsettings. Among them are the Checklist of Autism in Toddlers (CHAT), themodified Checklist for Autism in Toddlers (M-CHAT), the Screening Toolfor Autism in Two-Year-Olds (STAT), and the Social CommunicationQuestionnaire (SCQ) for children 4 years of age and older. Somescreening instruments rely solely on parent responses to aquestionnaire, and some rely on a combination of parent report andobservation. Key items on these instruments that appear to differentiatechildren with autism from other groups before the age of 2 includepointing and pretend play. Screening instruments do not provideindividual diagnosis, prognosis, or theranosis, but serve to assess theneed for referral for possible screening of ASD. These screening methodsmay not identify children with mild ASD, such as those withhigh-functioning autism or Asperger syndrome. The second stage ofscreening must be comprehensive in order to accurately rule in or ruleout an ASD or other developmental problem. This evaluation may be doneby a multidisciplinary team that includes a psychologist, a neurologist,a psychiatrist, a speech therapist, or other professionals who screenchildren with ASD. Because ASDs are complex disorders and may involveother developmental or genetic problems, a comprehensive evaluationshould entail developmental and genetic assessment, along with in-depthcognitive and language testing. In addition, measures developedspecifically for screening autism are often used. These include theAutism Diagnosis Interview-Revised (ADI-R) and the Autism DiagnosticObservation Schedule (ADOS-G). The ADI-R is a structured interview thatcontains over 100 items and is conducted with a caregiver. It consistsof four main factors including the child's communication, socialinteraction, repetitive behaviors, and age-of-onset symptoms. The ADOS-Gis an observational measure used to “press” for socio-communicativebehaviors that are often delayed, abnormal, or absent in children withASD. Still another instrument often used by professionals is theChildhood Autism Rating Scale (CARS). It can aid in evaluating thechild's body movements, adaptation to change, listening response, verbalcommunication, and relationship to people. It is suitable for use withchildren over 2 years of age. The examiner observes the child and alsoobtains relevant information from the parents. The child's behavior israted on a scale based on deviation from the typical behavior ofchildren of the same age. Two other tests that can be used to assess anychild with a developmental delay are a formal audiologic hearingevaluation and a lead screening. Although some hearing loss can co-occurwith ASD, some children with ASD may be incorrectly thought to have sucha loss. In addition, if the child has suffered from an ear infection,transient hearing loss can occur. Lead screening is essential forchildren who remain for a long period of time in the oral-motor stage inwhich they put any and everything into their mouths. Children with anautistic disorder usually have elevated blood lead levels. Customarily,an expert screening team has the responsibility of thoroughly evaluatingthe child, assessing the child's unique strengths and weaknesses, anddetermining a formal screen. The team will then meet with the parents toexplain the results of the evaluation.

PDD-NOS is typically screened by psychologists and PediatricNeurologists. No singular specific test can be administered to determinewhether or not a child is on the spectrum. Screening can be made throughobservations, questionnaires, and tests. A parent will usually initiatethe quest into the screening with questions for their child'spediatrician about their child's development after noticingabnormalities. From there, doctors will ask questions to gauge thechild's development in comparison to age-appropriate milestones. Onetest that measures this is the Modified Checklist of Autism in Toddlers(MCHAT). This is a list of questions whose answers will determinewhether or not the child should be referred to a specialist such as adevelopmental pediatrician, a neurologist, a psychiatrist, or apsychologist. Another checklist, the DSM-IV is a series ofcharacteristics and criteria to qualify for an autism diagnosis. BecausePDD-NOS is a spectrum disorder, not every child shows the same signs.The two main characteristics of the disorder are difficulties withsocial interaction skills and communication. Signs are often visible inbabies but a diagnosis is usually not made until around age 4. Eventhough PDD-NOS is considered milder than typical autism, this is notalways true. While some characteristics may be milder, others may bemore severe. Once a child with PDD-NOS enters school, he or she willoften be very eager to interact with classmates, but may act sociallydifferent to peers and be unable to make genuine connections. As theyage, the closest connections they make are typically with their parents.Children with PDD-NOS have difficulty reading facial expressions andrelating to feelings of others. They may not know how to respond whensomeone is laughing or crying. Literal thinking is also characteristicof PDD-NOS. They will most likely have difficulty understandingfigurative speech and sarcasm. Inhibited communication skills are a signof PDD-NOS that begins immediately after birth. As an infant, they willnot babble, and as they age, they do not speak when age appropriate.Once verbal communication begins, their vocabulary is often limited.Some characteristics of language-based patterns are: repetitive or rigidlanguage, narrow interests, uneven language development, and poornonverbal communication. A very common characteristic of PDD-NOS issevere difficulty grasping the difference between pronouns, particularlybetween “you” and “me” when conversing. During the last few years,screening instruments have been devised to screen for Asperger syndromeand higher functioning autism. The Autism Spectrum ScreeningQuestionnaire (ASSQ), the Australian Scale for Asperger's Syndrome, andthe most recent, the Childhood Asperger Syndrome Test (CAST), are someof the instruments that are reliable for identification of school-agechildren with Asperger syndrome or higher functioning autism. Thesetools concentrate on social and behavioral impairments in childrenwithout significant language delay. If, following the screening processor during a routine “well child” check-up, a subject's doctor sees anyof the possible indicators of ASD, further evaluation is indicated.

While means for screening ASDs exist, many times symptoms go unnoticeduntil late in childhood or symptoms are so minor they are leftunnoticed. Thus there exists a need for an improved ASD screening test.Described herein are methods of screening an individual for one or moredevelopmental disorders, including but not limited to, determining theidentity and location of genetic variations, such as variations innucleotide sequence and copy number, and the presence or absence ofalleles or genotypes in one or more samples from one or more subjectsusing any of the methods described herein. In some embodiments,determining an association to having or developing a developmentaldisorder can be performed by detecting particular variations that appearmore frequently in test subjects compared to reference subjects andanalyzing the molecular and physiological pathways these variations canaffect.

Within any given population, there can be an absolute susceptibility ofdeveloping a disease or trait, defined as the chance of a persondeveloping the specific disease or trait over a specified time-period.Susceptibility (e.g. being at-risk) is typically measured by looking atvery large numbers of people, rather than at a particular individual. Asdescribed herein, certain copy number variations (genetic variations)are found to be useful for susceptibility assessment of a developmentaldisorder. Susceptibility assessment can involve detecting particulargenetic variations in the genome of individuals undergoing assessment.Particular genetic variations are found more frequently in individualswith a developmental disorder, than in individuals without screening ofa developmental disorder. Therefore, these genetic variations havepredictive value for detecting a developmental disorder, or asusceptibility to a developmental disorder, in an individual. Withoutintending to be limited by theory, it is believed that the geneticvariations described herein to be associated with susceptibility of adevelopmental disorder represent functional variants predisposing to thedisease. In some embodiments, a genetic variation can confer asusceptibility of the condition, for example, carriers of the geneticvariation are at a different risk of the condition than non-carriers. Ina preferred embodiment, the presence of a genetic variation isindicative of increased susceptibility to a developmental disorder, suchas ASD.

In some embodiments, screening can be performed using any of the methodsdisclosed, alone or in combination. In some embodiments, screening canbe performed using Polymerase Chain Reaction (PCR). In a preferredembodiment screening can be performed using Array Comparative GenomicHybridization (aCGH). In some embodiments, the genetic variationinformation as it relates to the current disclosure can be used inconjunction with any of the above mentioned symptomatic screening teststo screen a subject for ASD, for example, using a combination of aCGHand a childhood screening test, such as the Checklist of Autism inToddlers (CHAT).

In some embodiments, information from any of the above screening methods(e.g. specific symptoms, scoring matrix, or genetic variation data) canbe used to define a subject as a test subject or reference subject. Insome embodiments, information from any of the above screening methodscan be used to associate a subject with a test or reference population,for example, a subject in a population. In the present study, forexample, all the probands in Table 1 met the criteria for autism on oneor both of the screening measures including the Autism DiagnosticInterview-Revised (ADI-R) training and the Autism Diagnostic ObservationSchedule (ADOS) training.

In one embodiment, an association with a developmental disorder candetermined by the statistical likelihood of the presence of a geneticvariation in a subject with a developmental disorder, for example, anunrelated individual or a first or second-degree relation of thesubject. In some embodiments, an association with a developmentaldisorder can be determined by determining the statistical likelihood ofthe absence of a genetic variation in an unaffected reference subject,for example, an unrelated individual or a first or second-degreerelation of the subject. The methods described herein can includeobtaining and analyzing a sample from one or more suitable referencesubjects.

In the present context, the term screening comprises diagnosis,prognosis, and theranosis. Screening can refer to any availablescreening method, including those mentioned herein. As used herein,susceptibility can be proneness of a subject towards the development ofa developmental condition, or towards being less able to resist aparticular developmental condition than one or more control subjects. Insome embodiments, susceptibility can encompass increased susceptibility.For example, particular nucleic acid variations of the disclosure asdescribed herein can be characteristic of increased susceptibility todevelopment of a developmental disorder. In some embodiments,susceptibility can encompass decreased susceptibility, for example,particular nucleic variations of the disclosure as described herein canbe characteristic of decreased susceptibility to development of adevelopmental disorder.

As described herein, a genetic variation predictive of susceptibility toor presence of a developmental disorder can be one where the particulargenetic variation is more frequently present in a subject with thecondition (affected), compared to the frequency of its presence in areference group (control), such that the presence of the geneticvariation is indicative of susceptibility to or presence of thedevelopmental disorder. In some embodiments, the reference group can bea population sample, for example, a random sample from the generalpopulation or a mixture of two or more samples from a population. Insome embodiments, disease-free controls can be characterized by theabsence of one or more specific disease-associated symptoms, forexample, individuals who have not experienced symptoms associated with adevelopmental disorder. In another embodiment, the disease-free controlgroup is characterized by the absence of one or more disease-specificrisk factors, for example, at least one genetic and/or environmentalrisk factor. In some embodiments, a reference sequence can be referredto for a particular site of genetic variation. In some embodiments, areference allele can be a wild-type allele and can be chosen as eitherthe first sequenced allele or as the allele from a control individual.In some embodiments, one or more reference subjects can becharacteristically matched with one or more affected subjects, forexample, with matched aged, gender or ethnicity.

A person skilled in the art will appreciate that for genetic variationswith two alleles present in the population being studied, and whereinone allele can found in increased frequency in a group of individualswith a developmental disorder in the population, compared with controls,the other allele of the marker can be found in decreased frequency inthe group of individuals with the trait or disease, compared withcontrols. In such a case, one allele of the marker, for example, theallele found in increased frequency in individuals with a developmentaldisorder, can be the at-risk allele, while the other allele can be aneutral or protective allele.

A genetic variant associated with a developmental disorder can be usedto predict the susceptibility of the disease for a given genotype. Forany genetic variation, there can be one or more possible genotypes, forexample, homozygote for the at-risk variant (e.g., in autosomalrecessive disorders), heterozygote, and non-carrier of the at-riskvariant. In some embodiments, susceptibility associated with variants atmultiple loci can be used to estimate overall susceptibility. Formultiple genetic variants, there can be k (k=3̂n*2̂P) possible genotypes;wherein n can be the number of autosomal loci and p can be the number ofgonosomal (sex chromosomal) loci. Overall susceptibility assessmentcalculations can assume that the relative susceptibilities of differentgenetic variants multiply, for example, the overall susceptibilityassociated with a particular genotype combination can be the product ofthe susceptibility values for the genotype at each locus. If thesusceptibility presented is the relative susceptibility for a person, ora specific genotype for a person, compared to a reference population,then the combined susceptibility can be the product of the locusspecific susceptibility values and can correspond to an overallsusceptibility estimate compared with a population. If thesusceptibility for a person is based on a comparison to non-carriers ofthe at-risk allele, then the combined susceptibility can correspond toan estimate that compares the person with a given combination ofgenotypes at all loci to a group of individuals who do not carry at-riskvariants at any of those loci. The group of non-carriers of any at-riskvariant can have the lowest estimated susceptibility and can have acombined susceptibility, compared with itself, for example,non-carriers, of 1.0, but can have an overall susceptibility, comparedwith the population, of less than 1.0.

Overall risk for multiple risk variants can be performed using standardmethodology. Genetic variations described herein can form the basis ofrisk analysis that combines other genetic variations known to increaserisk of a developmental disorder, or other genetic risk variants for adevelopmental disorder. In certain embodiments of the disclosure, aplurality of variants (genetic variations, variant alleles, and/orhaplotypes) can be used for overall risk assessment. These variants arein some embodiments selected from the genetic variations as disclosedherein. Other embodiments include the use of the variants of the presentdisclosure in combination with other variants known to be useful forscreening a susceptibility to a developmental disorder. In suchembodiments, the genotype status of a plurality of genetic variations,markers and/or haplotypes is determined in an individual, and the statusof the individual compared with the population frequency of theassociated variants, or the frequency of the variants in clinicallyhealthy subjects, such as age-matched and sex-matched subjects.

Methods known in the art, such as the use of available algorithms andsoftware can be used to identify, or call, significant geneticvariations, including but not limited to, algorithms of DNA Analytics orDNAcopy, iPattern and/or QuantiSNP. For example, an Aberration DetectionModule 2 (ADM2) algorithm, such as that of DNA Analytics 4.0.85 can beused to identify, or call, significant genetic variations. In someembodiments, two or more algorithms can be used to identify, or call,significant genetic variations. For example, 2, 3, 4, 5, 6, 7, 8, 9, or10 or more algorithms can be used to identify, or call, significantgenetic variations. In some embodiments, significant genetic variationscan be CNVs.

CNVs detected by 2 or more algorithms can be defined as stringent andcan be utilized for further analyses. In some embodiments, theinformation and calls from two or more of the methods described hereincan be compared to each other to identify significant genetic variationsmore or less stringently. For example, CNV calls generated by bothAberration Detection Module 2 (ADM2) algorithms and DNAcopy algorithmscan be defined as stringent CNVs. In some embodiments, significant orstringent genetic variations can be tagged as identified or called if itcan be found to have a minimal reciprocal overlap to a genetic variationdetected by one or more platforms and/or methods described herein. Forexample, significant or stringent genetic variations can be tagged asidentified or called if it can be found to have a reciprocal overlap ofmore than about 50%, 55% 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, 99%,or equal to 100%, to a genetic variation detected by one or moreplatforms and/or methods described herein. For example, significant orstringent genetic variations can be tagged as identified or called if itcan be found to have a reciprocal overlap of more than about 50%reciprocal overlap to a genetic variation detected by one or moreplatforms and/or methods described herein.

In some embodiments, a threshold log ratio value can be used todetermine losses and gains. A log ratio value can be any log ratiovalue; for example, a log ratio value can be a log2 ratio or a log10ratio. In some embodiments, a CNV segment whose median log2 ratio isless than or equal to a log2 ratio threshold value can be classified asa loss. For example, any segment whose median log2 ratio is less than orequal to −0.1, −0.11, −0.12, −0.13, −0.14, −0.15, −0.16, −0.17, −0.18,−0.19, −0.2, −0.21, −0.22, −0.23, −0.24, −0.25, −0.26, −0.27, −0.28,−0.29, −0.3, −0.31, −0.32, −0.33, −0.34, −0.35, −0.36, −0.37, −0.38,−0.39, −0.4, −0.41, −0.42, −0.43, −0.44, −0.45, −0.46, −0.47, −0.48,−0.49, −0.5, −0.55, −0.6, −0.65, −0.7, −0.75, −0.8, −0.85, −0.9, −0.95,−1, −1.1, −1.2, −1.3, −1.4, −1.5, −1.6, −1.7, −1.8, −1.9, −2, −2.1,−2.2, −2.3, −2.4, −2.5, −2.6, −2.7, −2.8, −2.9, −3, −3.1, −3.2, −3.3,−3.4, −3.5, −3.6, −3.7, −3.8, −3.9, −4, −4.1, −4.2, −4.3, −4.4, −4.5,−4.6, −4.7, −4.8, −4.9, −5, −5.5, −6, −6.5, −7, −7.5, −8, −8.5, −9,−9.5, −10, −11, −12, −13, −14, −15, −16, −17, −18, −19, −20 or less, canbe classified as a loss.

In some embodiments, one algorithm can be used to call or identifysignificant genetic variations, wherein any segment whose median log2ratio was less than or equal to −0.1, −0.11, −0.12, −0.13, −0.14, −0.15,−0.16, −0.17, −0.18, −0.19, −0.2, −0.21, −0.22, −0.23, −0.24, −0.25,−0.26, −0.27, −0.28, −0.29, −0.3, −0.31, −0.32, −0.33, −0.34, −0.35,−0.36, −0.37, −0.38, −0.39, −0.4, −0.41, −0.42, −0.43, −0.44, −0.45,−0.46, −0.47, −0.48, −0.49, −0.5, −0.55, −0.6, −0.65, −0.7, −0.75, −0.8,−0.85, −0.9, −0.95, −1, −1.1, −1.2, −1.3, −1.4, −1.5, −1.6, −1.7, −1.8,−1.9, −2, −2.1, −2.2, −2.3, −2.4, −2.5, −2.6, −2.7, −2.8, −2.9, −3,−3.1, −3.2, −3.3, −3.4, −3.5, −3.6, −3.7, −3.8, −3.9, −4, −4.1, −4.2,−4.3, −4.4, −4.5, −4.6, −4.7, −4.8, −4.9, −5, −5.5, −6, −6.5, −7, −7.5,−8, −8.5, −9, −9.5, −10, −11, −12, −13, −14, −15, −16, −17, −18, −19,−20 or less, can be classified as a loss. For example, any CNV segmentwhose median log2 ratio is less than −0.35 as determined by DNAcopy canbe classified as a loss. For example, losses can be determined accordingto a threshold log2 ratio, which can be set at −0.35.

In some embodiments, two algorithms can be used to call or identifysignificant genetic variations, wherein any segment whose median log2ratio is less than or equal to −0.1, −0.11, −0.12, −0.13, −0.14, −0.15,−0.16, −0.17, −0.18, −0.19, −0.2, −0.21, −0.22, −0.23, −0.24, −0.25,−0.26, −0.27, −0.28, −0.29, −0.3, −0.31, −0.32, −0.33, −0.34, −0.35,−0.36, −0.37, −0.38, −0.39, −0.4, −0.41, −0.42, −0.43, −0.44, −0.45,−0.46, −0.47, −0.48, −0.49, −0.5, −0.55, −0.6, −0.65, −0.7, −0.75, −0.8,−0.85, −0.9, −0.95, −1, −1.1, −1.2, −1.3, −1.4, −1.5, −1.6, −1.7, −1.8,−1.9, −2, −2.1, −2.2, −2.3, −2.4, −2.5, −2.6, −2.7, −2.8, −2.9, −3,−3.1, −3.2, −3.3, −3.4, −3.5, −3.6, −3.7, −3.8, −3.9, −4, −4.1, −4.2,−4.3, −4.4, −4.5, −4.6, −4.7, −4.8, −4.9, −5, −5.5, −6, −6.5, −7, −7.5,−8, −8.5, −9, −9.5, −10, −11, −12, −13, −14, −15, −16, −17, −18, −19,−20 or less, as determined by one algorithm, and wherein any segmentwhose median log2 ratio is less than or equal to −0.1, −0.11, −0.12,−0.13, −0.14, −0.15, −0.16, −0.17, −0.18, −0.19, −0.2, −0.21, −0.22,−0.23, −0.24, −0.25, −0.26, −0.27, −0.28, −0.29, −0.3, −0.31, −0.32,−0.33, −0.34, −0.35, −0.36, −0.37, −0.38, −0.39, −0.4, −0.41, −0.42,−0.43, −0.44, −0.45, −0.46, −0.47, −0.48, −0.49, −0.5, −0.55, −0.6,−0.65, −0.7, −0.75, −0.8, −0.85, −0.9, −0.95, −1, −1.1, −1.2, −1.3,−1.4, −1.5, −1.6, −1.7, −1.8, −1.9, −2, −2.1, −2.2, −2.3, −2.4, −2.5,−2.6, −2.7, −2.8, −2.9, −3, −3.1, −3.2, −3.3, −3.4, −3.5, −3.6, −3.7,−3.8, −3.9, −4, −4.1, −4.2, −4.3, −4.4, −4.5, −4.6, −4.7, −4.8, −4.9,−5, −5.5, −6, −6.5, −7, −7.5, −8, −8.5, −9, −9.5, −10, −11, −12, −13,−14, −15, −16, −17, −18, −19, −20, or less, as determined by the otheralgorithm can be classified as a loss. For example, CNV calling cancomprise using the Aberration Detection Module 2 (ADM2) algorithm andthe DNAcopy algorithm, wherein losses can be determined according to atwo threshold log2 ratios, wherein the Aberration Detection Module 2(ADM2) algorithm log2 ratio can be −0.25 and the DNAcopy algorithm log2ratio can be −0.41.

In some embodiments, the use of two algorithms to call or identifysignificant genetic variations can be a stringent method. In someembodiments, the use of two algorithms to call or identify significantgenetic variations can be a more stringent method compared to the use ofone algorithm to call or identify significant genetic variations.

In some embodiments, any CNV segment whose median log2 ratio is greaterthan a log2 ratio threshold value can be classified as a gain. Forexample, any segment whose median log2 ratio is greater than 0.1, 0.11,0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23,0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35,0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47,0.48, 0.49, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1,1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5,2.6, 2.7, 2.8, 2.9, 3, or more can be classified as a gain.

In some embodiments, one algorithm can be used to call or identifysignificant genetic variations, wherein any segment whose median log2ratio is greater than or equal to 0.1, 0.11, 0.12, 0.13, 0.14, 0.15,0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27,0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39,0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, 0.5, 0.55,0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.1, 1.2, 1.3, 1.4, 1.5,1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3,or more can be classified as a gain. For example, any CNV segment whosemedian log2 ratio is greater than 0.35 as determined by DNAcopy can beclassified as a gain. For example, gains can be determined according toa threshold log2 ratio, which can be set at 0.35.

In some embodiments, two algorithms can be used to call or identifysignificant genetic variations, wherein any segment whose median log2ratio is greater than or equal to 0.1, 0.11, 0.12, 0.13, 0.14, 0.15,0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27,0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39,0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, or 0.5, 0.55,0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.1, 1.2, 1.3, 1.4, 1.5,1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3 ormore, as determined by one algorithm, and wherein any segment whosemedian log2 ratio is greater than or equal to 0.1, 0.11, 0.12, 0.13,0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25,0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37,0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49,or 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.1, 1.2,1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7,2.8, 2.9, 3, or more, as determined by the other algorithm the can beclassified as a gain. For example, CNV calling can comprise using theAberration Detection Module 2 (ADM2) algorithm and the DNAcopyalgorithm, wherein gains can be determined according to a two thresholdlog2 ratios, wherein the Aberration Detection Module 2 (ADM2) algorithmlog2 ratio can be 0.25 and the DNAcopy algorithm log2 ratio can be 0.32.

Any CNV segment whose absolute (median log-ratio/mad) value is less than2 can be excluded (not identified as a significant genetic variation).For example, any CNV segment whose absolute (median log-ratio/mad) valueis less than 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1, 0.9,0.8, 0.7, 0.6, or 0.5 or less can be excluded.

In some embodiments, multivariate analyses or joint risk analyses,including the use of multiplicative model for overall risk assessment,and can subsequently be used to determine the overall risk conferredbased on the genotype status at the multiple loci. Use of amultiplicative model, for example, assuming that the risk of individualrisk variants multiply to establish the overall effect, allows for astraight-forward calculation of the overall risk for multiple markers.The multiplicative model is a parsimonious model that usually fits thedata of complex traits reasonably well. Deviations from multiplicityhave been rarely described in the context of common variants for commondiseases, and if reported are usually only suggestive since very largesample sizes are usually required to be able to demonstrate statisticalinteractions between loci. Assessment of risk based on such analysis cansubsequently be used in the methods, uses and kits of the disclosure, asdescribed herein.

In some embodiments, the significance of increased or decreasedsusceptibility can be measured by a percentage. In some embodiments, asignificant increased susceptibility can be measured as a relativesusceptibility of at least 1.2, including but not limited to: at least1.5, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least1.7, 1.8, at least 1.9, at least 2.0, at least 2.5, at least 3.0, atleast 4.0, at least 5.0, at least 6.0, at least 7.0, at least 8.0, atleast 9.0, at least 10.0, and at least 15.0. In some embodiments, arelative susceptibility of at least 2.0, at least 3.0, at least 4.0, atleast, 5.0, at least 6.0, or at least 10.0 is significant. Other valuesfor significant susceptibility are also contemplated, for example, atleast 2.5, 3.5, 4.5, 5.5, or any suitable other numerical values,wherein said values are also within scope of the present disclosure. Insome embodiments, a significant increase in susceptibility is at leastabout 20%, including but not limited to about 25%, 30%, 35%, 40%, 45%,50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%,300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, and 1500%. In oneparticular embodiment, a significant increase in susceptibility is atleast 100%. In other embodiments, a significant increase insusceptibility is at least 200%, at least 300%, at least 400%, at least500%, at least 700%, at least 800%, at least 900% and at least 1000%.Other cutoffs or ranges as deemed suitable by the person skilled in theart to characterize the disclosure are also contemplated, and those arealso within scope of the present disclosure. In certain embodiments, asignificant increase in susceptibility is characterized by a p-value,such as a p-value of less than 0.5, less than 0.4, less than 0.3, lessthan 0.2, less than 0.1, less than 0.05, less than 0.01, less than0.001, less than 0.0001, less than 0.00001, less than 0.000001, lessthan 0.0000001, less than 0.00000001, or less than 0.000000001.

In some embodiments, an individual who is at a decreased susceptibilityfor or the lack of presence of a developmental condition can be anindividual in whom at least one genetic variation, conferring decreasedsusceptibility for or the lack of presence of the developmental disorderis identified. In some embodiments, the genetic variations conferringdecreased susceptibility are also said to be protective. In one aspect,the genetic variations can confer a significant decreased susceptibilityof or lack of presence of the developmental disorder.

In some embodiments, significant decreased susceptibility can bemeasured as a relative susceptibility of less than 0.9, including butnot limited to less than 0.9, less than 0.8, less than 0.7, less than0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2 and lessthan 0.1. In another embodiment, the decrease in susceptibility is atleast 20%, including but not limited to at least 25%, at least 30%, atleast 35%, at least 40%, at least 45%, at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95% and at least 98%. Other cutoffs orranges as deemed suitable by the person, skilled in the art tocharacterize the disclosure are however also contemplated, and those arealso within scope of the present disclosure. In certain embodiments, asignificant decrease in susceptibility is characterized by a p-value,such as a p-value of less than 0.05, less than 0.01, less than 0.001,less than 0.0001, less than 0.00001, less than 0.000001, less than0.0000001, less than 0.00000001, or less than 0.000000001. Other testsfor significance can be used, for example, a Fisher-exact test. Otherstatistical tests of significance known to the skilled person are alsocontemplated and are also within scope of the disclosure.

In some preferred embodiments, the significance of increased ordecreased susceptibility can be determined according to the ratio ofmeasurements from a test subject to a reference subject. In a preferredembodiment, losses or gains of one or more CNVs can be determinedaccording to a threshold log₂ ratio determined by these measurements. Insome embodiments, a log₂ ratio value greater than 0.35 is indicative ofa gain of one or more CNVs. In some embodiments, a log₂ ratio value lessthan −0.35 is indicative of a loss of one or more CNVs. In someembodiments, the ratio of measurements from a test subject to areference subject may be inverted such that the log2 ratios of copynumber gains are negative and the log2 ratios of copy number losses arepositive.

In some embodiments, the combined or overall susceptibility associatedwith a plurality of variants associated with a developmental disordercan also be assessed; for example, the genetic variations describedherein to be associated with susceptibility to a developmental disordercan be combined with other common genetic risk factors. Combined riskfor such genetic variants can be estimated in an analogous fashion tothe methods described herein.

Calculating risk conferred by a particular genotype for the individualcan be based on comparing the genotype of the individual to previouslydetermined risk expressed, for example, as a relative risk (RR) or anodds ratio (OR), for the genotype, for example, for a heterozygouscarrier of an at-risk variant for a developmental disorder. An oddsratio can be a statistical measure used as a metric of causality. Forexample, in genetic disease research it can be used to convey thesignificance of a variant in a disease cohort relative to anunaffected/normal cohort. The calculated risk for the individual can bethe relative risk for a subject, or for a specific genotype of asubject, compared to the average population. The average population riskcan be expressed as a weighted average of the risks of differentgenotypes, using results from a reference population, and theappropriate calculations to calculate the risk of a genotype grouprelative to the population can then be performed. Alternatively, therisk for an individual can be based on a comparison of particulargenotypes, for example, heterozygous carriers of an at-risk allele of amarker compared with non-carriers of the at-risk allele. Using thepopulation average can, in certain embodiments, be more convenient,since it provides a measure which can be easy to interpret for the user,such as a measure that gives the risk for the individual, based onhis/her genotype, compared with the average in the population.

In certain embodiments of the disclosure, a genetic variation iscorrelated to a developmental disorder by referencing genetic variationdata to a look-up table that comprises correlations between the geneticvariation and a developmental disorder. The genetic variation in certainembodiments comprises at least one indication of the genetic variation.In some embodiments, the table comprises a correlation for one geneticvariation. In other embodiments, the table comprises a correlation for aplurality of genetic variations. In both scenarios, by referencing to alook-up table that gives an indication of a correlation between agenetic variation and a developmental disorder, a risk for adevelopmental disorder, or a susceptibility to a developmental disorder,can be identified in the individual from whom the sample is derived.

The present disclosure also pertains to methods of clinical screening,for example, diagnosis, prognosis, or theranosis of a subject performedby a medical professional using the methods disclosed herein. In otherembodiments, the disclosure pertains to methods of screening performedby a layman. The layman can be a customer of a genotyping service. Thelayman can also be a genotype service provider, who performs genotypeanalysis on a DNA sample from an individual, in order to provide servicerelated to genetic risk factors for particular traits or diseases, basedon the genotype status of the subject obtained from use of the methodsdescribed herein. The resulting genotype information can be madeavailable to the individual and can be compared to information aboutdevelopmental disorder or risk of developing a developmental disorderassociated with various genetic variations, including but not limitedto, information from public literature and scientific publications. Thescreening applications of developmental disorder-associated geneticvariations, as described herein, can, for example, be performed by anindividual, a health professional, or a third party, for example, aservice provider who interprets genotype information from the subject.

The information derived from analyzing sequence data can be communicatedto any particular body, including the individual from which the sampleor sequence data is derived, a guardian or representative of theindividual, clinician, research professional, medical professional,service provider, and medical insurer or insurance company. Medicalprofessionals can be, for example, doctors, nurses, medical laboratorytechnologists, and pharmacists. Research professionals can be, forexample, principle investigators, research technicians, postdoctoraltrainees, and graduate students.

In some embodiments, a professional can be assisted by determiningwhether specific genetic variants are present in a biological samplefrom a subject, and communicating information about genetic variants toa professional. After information about specific genetic variants isreported, a medical professional can take one or more actions that canaffect subject care. For example, a medical professional can recordinformation in the subject's medical record regarding the subject's riskof developing a developmental disorder. In some embodiments, a medicalprofessional can record information regarding risk assessment, orotherwise transform the subject's medical record, to reflect thesubject's current medical condition. In some embodiments, a medicalprofessional can review and evaluate a subject's entire medical recordand assess multiple treatment strategies for clinical intervention of asubject's condition.

A medical professional can initiate or modify treatment after receivinginformation regarding a subject's screening of a developmental disorder,for example. In some embodiments, a medical professional can recommend achange in therapy. In some embodiments, a medical professional canenroll a subject in a clinical trial for, by way of example, detectingcorrelations between a haplotype as described herein and any measurableor quantifiable parameter relating to the outcome of the treatment asdescribed above.

In some embodiments, a medical professional can communicate informationregarding a subject's screening of developing a developmental disorderto a subject or a subject's family. In some embodiments, a medicalprofessional can provide a subject and/or a subject's family withinformation regarding a developmental disorder and risk assessmentinformation, including treatment options, and referrals to specialists.In some embodiments, a medical professional can provide a copy of asubject's medical records to a specialist. In some embodiments, aresearch professional can apply information regarding a subject's riskof developing a developmental disorder to advance scientific research.In some embodiments, a research professional can obtain a subject'shaplotype as described herein to evaluate a subject's enrollment, orcontinued participation, in a research study or clinical trial. In someembodiments, a research professional can communicate informationregarding a subject's screening of a developmental disorder to a medicalprofessional. In some embodiments, a research professional can refer asubject to a medical professional.

Any appropriate method can be used to communicate information to anotherperson. For example, information can be given directly or indirectly toa professional and laboratory technician can input a subject's geneticvariation as described herein into a computer-based record. In someembodiments, information is communicated by making a physical alterationto medical or research records. For example, a medical professional canmake a permanent notation or flag a medical record for communicating therisk assessment to other medical professionals reviewing the record. Inaddition, any type of communication can be used to communicate the riskassessment information. For example, mail, e-mail, telephone, andface-to-face interactions can be used. The information also can becommunicated to a professional by making that information electronicallyavailable to the professional. For example, the information can becommunicated to a professional by placing the information on a computerdatabase such that the professional can access the information. Inaddition, the information can be communicated to a hospital, clinic, orresearch facility serving as an agent for the professional.

Results of these tests, and optionally interpretive information, can bereturned to the subject, the health care provider or to a third party.The results can be communicated to the tested subject, for example, witha prognosis and optionally interpretive materials that can help thesubject understand the test results and prognosis; used by a health careprovider, for example, to determine whether to administer a specificdrug, or whether a subject should be assigned to a specific category,for example, a category associated with a specific diseaseendophenotype, or with drug response or non-response; used by a thirdparty such as a healthcare payer, for example, an insurance company orHMO, or other agency, to determine whether or not to reimburse a healthcare provider for services to the subject, or whether to approve theprovision of services to the subject. For example, the healthcare payercan decide to reimburse a health care provider for treatments for adevelopmental disorder if the subject has a developmental disorder orhas an increased risk of developing a developmental disorder.

Also provided herein are databases that include a list of geneticvariations as described herein, and wherein the list can be largely orentirely limited to genetic variations identified as useful forscreening a developmental disorder as described herein. The list can bestored, for example, on a flat file or computer-readable medium. Thedatabases can further include information regarding one or moresubjects, for example, whether a subject is affected or unaffected,clinical information such as endophenotype, age of onset of symptoms,any treatments administered and outcomes, for example, data relevant topharmacogenomics, diagnostics, prognostics or theranostics, and otherdetails, for example, data about the disorder in the subject, orenvironmental or other genetic factors. The databases can be used todetect correlations between a particular haplotype and the informationregarding the subject.

The methods described herein can also include the generation of reportsfor use, for example, by a subject, care giver, or researcher, thatinclude information regarding a subject's genetic variations, andoptionally further information such as treatments administered,treatment history, medical history, predicted response, and actualresponse. The reports can be recorded in a tangible medium, e.g., acomputer-readable disk, a solid state memory device, or an opticalstorage device.

Methods of Screening using Variations in Polypeptides

In another embodiment of the disclosure, screening of a developmentaldisorder can be made by examining or comparing changes in expression,localization, binding partners, and composition of a polypeptide encodedby a nucleic acid associated with a developmental disorder, for example,in those instances where the genetic variations of the presentdisclosure results in a change in the composition or expression of thepolypeptide. Thus, screening of a developmental disorder can be made byexamining expression and/or composition of one of these polypeptides, oranother polypeptide encoded by a nucleic acid associated with adevelopmental disorder, in those instances where the genetic variationof the present disclosure results in a change in the expression,localization, binding partners, and/or composition of the polypeptide.In some embodiments, screening can comprise diagnosing a subject. Insome embodiments, screening can comprise determining a prognosis of asubject, for example, determining the susceptibility of developing adevelopmental disorder. In some embodiments, screening can comprisetheranosing a subject.

The genetic variations described herein that show association to adevelopmental disorder can play a role through their effect on one ormore of these nearby genes. For example, while not intending to belimited by theory, it is generally expected that a deletion of achromosomal segment comprising a particular gene, or a fragment of agene, can either result in an altered composition or expression, orboth, of the encoded protein. Likewise, duplications, or high numbercopy number variations, are in general expected to result in increasedexpression of encoded polypeptide. Other possible mechanisms affectinggenes within a genetic variation region include, for example, effects ontranscription, effects on RNA splicing, alterations in relative amountsof alternative splice forms of mRNA, effects on RNA stability, effectson transport from the nucleus to cytoplasm, and effects on theefficiency and accuracy of translation. Thus, DNA variations can bedetected directly, using the subjects unamplified or amplied genomicDNA, or indirectly, using RNA or DNA obtained from the subject'stissue(s) that are present in an aberrant form or expression level as aresult of the genetic variations of the disclosure showing associationto ASD.

In some embodiments, the genetic variations of the disclosure showingassociation to a developmental disorder can affect the expression of agene within the genetic variation region. In some embodiments, a geneticvariation affecting an exonic region of a gene can affect, disrupt, ormodulate the expression of the gene. In some embodiments, a geneticvariation affecting an intergenic region of a gene can affect, disrupt,or modulate the expression of the gene. Certain genetic variationregions can have flanking duplicated segments, and genes within suchsegments can have altered expression and/or composition as a result ofsuch genomic alterations. Regulatory elements affecting gene expressioncan be located far away, even as far as tens or hundreds of kilobasesaway, from the promoter region of a gene. Thus, in some embodiments,regulatory elements for genes that are located outside the geneticvariation region can be located within the genetic variation, and can beaffected by the genetic variation. It is thus contemplated that thedetection of the genetic variations described herein, can be used forassessing expression for one or more of associated genes not directlyimpacted by the genetic variations. In some embodiments, a geneticvariation affecting an intergenic region of a gene can affect, disrupt,or modulate the expression of a gene located elsewhere in the genome,such as described above. For example, a genetic variation affecting anintergenic region of a gene can affect, disrupt, or modulate theexpression of a transcription factor, located elsewhere in the genome,which regulates the gene.

In some embodiments, genetic variations of the disclosure showingassociation to ASD can affect protein expression at the translationallevel. It can be appreciated by those skilled in the art that this canoccur by increased or decreased expression of one or more microRNAs(miRNAs) that regulates expression of a protein known to be important,or implicated, in the cause, onset, or progression of ASD. Increased ordecreased expression of the one or more miRNAs can result from gain orloss of the whole miRNA gene, disruption of a portion of the gene (e.g.,by an indel or CNV), or even a single base change (SNP or SNV) thatproduces an altered, non-functional or aberrant functioning miRNAsequence. It can also be appreciated by those skilled in the art thatthe expression of protein, for example, one known to cause ASD byincreased or decreased expression, can result due to a genetic variationthat results in alteration of an existing miRNA binding site within theprotein's mRNA transcript, or even creates a new miRNA binding site thatleads to aberrant protein expression.

A variety of methods can be used for detecting protein compositionand/or expression levels, including but not limited to enzyme linkedimmunosorbent assays (ELISA), Western blots, spectroscopy, massspectrometry, peptide arrays, colorimetry, electrophoresis, isoelectricfocusing, immunoprecipitations, immunoassays, and immunofluorescence andother methods well-known in the art. A test sample from a subject can beassessed for the presence of an alteration in the expression and/or analteration in composition of the polypeptide encoded by a nucleic acidassociated with a developmental disorder. An “alteration” in thepolypeptide expression or composition, as used herein, refers to analteration in expression or composition in a test sample, as compared tothe expression or composition of the polypeptide in a control sample.Such alteration can, for example, be an alteration in the quantitativepolypeptide expression or can be an alteration in the qualitativepolypeptide expression, for example, expression of a mutant polypeptideor of a different splicing variant, or a combination thereof. In someembodiments, screening of a developmental disorder can be made bydetecting a particular splicing variant encoded by a nucleic acidassociated with a developmental disorder, or a particular pattern ofsplicing variants.

Antibodies can be polyclonal or monoclonal and can be labeled orunlabeled. An intact antibody, or a fragment thereof can be used. Theterm “labeled”, with regard to the probe or antibody, is intended toencompass direct labeling of the probe or antibody by coupling adetecTable substance to the probe or antibody, as well as indirectlabeling of the probe or antibody by reactivity with another reagentthat is directly labeled as previously described herein. Othernon-limiting examples of indirect labeling include detection of aprimary antibody using a labeled secondary antibody, for example, afluorescently-labeled secondary antibody and end-labeling of a DNA probewith biotin such that it can be detected with fluorescently-labeledstreptavidin.

Detecting Genetic Variations Associated with Autism Spectrum Disorder

Described herein, are methods that can be used to detect geneticvariations. Detecting specific genetic variations, for example,polymorphic markers and/or haplotypes, copy number, absence or presenceof an allele, or genotype associated with a developmental disorder asdescribed herein, can be accomplished by methods known in the art foranalyzing nucleic acids and/or detecting sequences at polymorphic orgenetically variable sites, for example, amplification techniques,hybridization techniques, sequencing, arrays, or any combinationthereof. Thus, by use of these methods disclosed herein or other methodsavailable to the person skilled in the art, one or more alleles atpolymorphic markers, including microsatellites, SNPs, CNVs, or othertypes of genetic variations, can be identified in a sample obtained froma subject.

Nucleic Acids

The nucleic acids and polypeptides described herein can be used inmethods and kits of the present disclosure. In some embodiments,aptamers that specifically bind the nucleic acids and polypeptidesdescribed herein can be used in methods and kits of the presentdisclosure. As used herein, a nucleic acid can comprise adeoxyribonucleotide (DNA) or ribonucleotide (RNA), whether singular orin polymers, naturally occurring or non-naturally occurring,double-stranded or single-stranded, coding, for example, a translatedgene, or non-coding, for example, a regulatory region, or any fragments,derivatives, mimetics or complements thereof. In some embodiments,nucleic acids can comprise oligonucleotides, nucleotides,polynucleotides, nucleic acid sequences, genomic sequences, antisensenucleic acids, DNA regions, probes, primers, genes, regulatory regions,introns, exons, open-reading frames, binding sites, target nucleic acidsand allele-specific nucleic acids.

“Isolated” nucleic acids, as used herein, are separated from nucleicacids that normally flank the gene or nucleotide sequence (as in genomicsequences) and/or has been completely or partially purified from othertranscribed sequences (e.g., as in an RNA library). For example,isolated nucleic acids of the disclosure can be substantially isolatedwith respect to the complex cellular milieu in which it naturallyoccurs, or culture medium when produced by recombinant techniques, orchemical precursors or other chemicals when chemically synthesized. Insome instances, the isolated material can form part of a composition,for example, a crude extract containing other substances, buffer systemor reagent mix. In some embodiments, the material can be purified toessential homogeneity using methods known in the art, for example, bypolyacrylamide gel electrophoresis (PAGE) or column chromatography(e.g., HPLC). With regard to genomic DNA (gDNA), the term “isolated”also can refer to nucleic acids that are separated from the chromosomewith which the genomic DNA is naturally associated. For example, theisolated nucleic acid molecule can contain less than about 250 kb, 200kb, 150 kb, 100 kb, 75 kb, 50 kb, 25 kb, 10 kb, 5 kb, 4 kb, 3 kb, 2 kb,1 kb, 0.5 kb or 0.1 kb of the nucleotides that flank the nucleic acidmolecule in the gDNA of the cell from which the nucleic acid molecule isderived.

Nucleic acids can be fused to other coding or regulatory sequences canbe considered isolated. For example, recombinant DNA contained in avector is included in the definition of “isolated” as used herein. Insome embodiments, isolated nucleic acids can include recombinant DNAmolecules in heterologous host cells or heterologous organisms, as wellas partially or substantially purified DNA molecules in solution.Isolated nucleic acids also encompass in vivo and in vitro RNAtranscripts of the DNA molecules of the present disclosure. An isolatednucleic acid molecule or nucleotide sequence can be synthesizedchemically or by recombinant means. Such isolated nucleotide sequencescan be useful, for example, in the manufacture of the encodedpolypeptide, as probes for isolating homologous sequences (e.g., fromother mammalian species), for gene mapping (e.g., by in situhybridization with chromosomes), or for detecting expression of thegene, in tissue (e.g., human tissue), such as by Northern blot analysisor other hybridization techniques disclosed herein. The disclosure alsopertains to nucleic acid sequences that hybridize under high stringencyhybridization conditions, such as for selective hybridization, to anucleotide sequence described herein. Such nucleic acid sequences can bedetected and/or isolated by allele- or sequence-specific hybridization(e.g., under high stringency conditions). Stringency conditions andmethods for nucleic acid hybridizations are well known to the skilledperson (see, e.g., Current Protocols in Molecular Biology, Ausubel, F.et al., John Wiley & Sons, (1998), and Kraus, M. and Aaronson, S.,Methods Enzymol., 200:546-556 (1991), the entire teachings of which areincorporated by reference herein.

Calculations of “identity” or “percent identity” between two or morenucleotide or amino acid sequences can be determined by aligning thesequences for optimal comparison purposes (e.g., gaps can be introducedin the sequence of a first sequence). The nucleotides at correspondingpositions are then compared, and the percent identity between the twosequences is a function of the number of identical positions shared bythe sequences (i.e., % identity=# of identical positions/total # ofpositions×100). For example, a position in the first sequence isoccupied by the same nucleotide as the corresponding position in thesecond sequence, then the molecules are identical at that position. Thepercent identity between the two sequences is a function of the numberof identical positions shared by the sequences, taking into account thenumber of gaps, and the length of each gap, which need to be introducedfor optimal alignment of the two sequences. In some embodiments, thelength of a sequence aligned for comparison purposes is at least 30%, atleast 40%, at least 50%, at least 60%, at least 70%, at least 80%, atleast 90%, or at least 95%, of the length of the reference sequence. Theactual comparison of the two sequences can be accomplished by well-knownmethods, for example, using a mathematical algorithm. A non-limitingexample of such a mathematical algorithm is described in Karlin, S, andAltschul, S., Proc. Natl. Acad. Sci. USA, 90-5873-5877 (1993). Such analgorithm is incorporated into the NBLAST and XBLAST programs (version2.0), as described in Altschul, S. et al., Nucleic Acids Res.,25:3389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, anyrelevant parameters of the respective programs (e.g., NBLAST) can beused. For example, parameters for sequence comparison can be set atscore=100, word length=12, or can be varied (e.g., W=5 or W=20). Otherexamples include the algorithm of Myers and Miller, CABIOS (1989),ADVANCE, ADAM, BLAT, and FASTA. In another embodiment, the percentidentity between two amino acid sequences can be accomplished using, forexample, the GAP program in the GCG software package (Accelrys,Cambridge, UK).

“Probes” or “primers” can be oligonucleotides that hybridize in abase-specific manner to a complementary strand of a nucleic acidmolecule. Probes can include primers, which can be a single-strandedoligonucleotide probe that can act as a point of initiation oftemplate-directed DNA synthesis using methods including but not limitedto, polymerase chain reaction (PCR) and ligase chain reaction (LCR) foramplification of a target sequence. Oligonucleotides, as describedherein, can include segments or fragments of nucleic acid sequences, ortheir complements. In some embodiments, DNA segments can be between 5and 10,000 contiguous bases, and can range from 5, 10, 12, 15, 20, or 25nucleotides to 10, 15, 20, 25, 30, 40, 50, 100, 200, 500, 1000 or 10,000nucleotides. In addition to DNA and RNA, probes and primers can includepolypeptide nucleic acids (PNA), as described in Nielsen, P. et al.,Science 254: 1497-1500 (1991). A probe or primer can comprise a regionof nucleotide sequence that hybridizes to at least about 15, typicallyabout 20-25, and in certain embodiments about 40, 50 or 75, consecutivenucleotides of a nucleic acid molecule.

The present disclosure also provides isolated nucleic acids, forexample, probes or primers, that contain a fragment or portion that canselectively hybridize to a nucleic acid that comprises, or consists of,a nucleotide sequence, wherein the nucleotide sequence can comprise atleast one polymorphism or polymorphic allele contained in the geneticvariations described herein or the wild-type nucleotide that is locatedat the same position, or the compliments thereof. In some embodiments,the probe or primer can be at least 70% identical, at least 80%identical, at least 85% identical, at least 90% identical, or at least95% identical, to the contiguous nucleotide sequence or to thecomplement of the contiguous nucleotide sequence.

In a preferred embodiment, a nucleic acid probe can be anoligonucleotide capable of hybridizing with a complementary regions of agene associated with a developmental disorder containing a geneticvariation described herein. The nucleic acid fragments of the disclosurecan be used as probes or primers in assays such as those describedherein.

The nucleic acids of the disclosure, such as those described above, canbe identified and isolated using standard molecular biology techniqueswell known to the skilled person. In some embodiments, DNA can beamplified and/or can be labeled (e.g., radiolabeled, fluorescentlylabeled) and used as a probe for screening, for example, a cDNA libraryderived from an organism. cDNA can be derived from mRNA and can becontained in a suitable vector. For example, corresponding clones can beisolated, DNA obtained fallowing in vivo excision, and the cloned insertcan be sequenced in either or both orientations by art-recognizedmethods to identify the correct reading frame encoding a polypeptide ofthe appropriate molecular weight. Using these or similar methods, thepolypeptide and the DNA encoding the polypeptide can be isolated,sequenced and further characterized.

In some embodiments, nucleic acid can comprise one or morepolymorphisms, variations, or mutations, for example, single nucleotidepolymorphisms (SNPs), copy number variations (CNVs), for example,insertions, deletions, inversions, and translocations. In someembodiments, nucleic acids can comprise analogs, for example,phosphorothioates, phosphoramidates, methyl phosphonate, chiralmethylphosphonates, 2-O-methyl ribonucleotides, or modified nucleic acids, forexample, modified backbone residues or linkages, or nucleic acidscombined with carbohydrates, lipids, protein or other materials, orpeptide nucleic acids (PNAs), for example, chromatin, ribosomes, andtranscriptosomes. In some embodiments nucleic acids can comprise nucleicacids in various structures, for example, A DNA, B DNA, Z-form DNA,siRNA, tRNA, and ribozymes. In some embodiments, the nucleic acid may benaturally or non-naturally polymorphic, for example, having one or moresequence differences, for example, additions, deletions and/orsubstitutions, as compared to a reference sequence. In some embodiments,a reference sequence can be based on publicly available information, forexample, the U.C. Santa Cruz Human Genome Browser Gateway(genome.ucsc.edu/cgi-bin/hgGateway) or the NCBI website (www.ncbi.nlmnih gov). In another embodiment, a reference sequence can be determinedby a practitioner of the present invention using methods well known inthe art, for example, by sequencing a reference nucleic acid.

In some embodiment a probe can hybridize to an allele, SNP, or CNV asdescribed herein. In some embodiments, the probe can bind to anothermarker sequence associated with a developmental disorder as describedherein.

One of skill in the art would know how to design a probe so thatsequence specific hybridization will occur only if a particular alleleis present in a genomic sequence from a test sample. The disclosure canalso be reduced to practice using any convenient genotyping method,including commercially available technologies and methods for genotypingparticular genetic variations

Control probes can also be used, for example, a probe that binds a lessvariable sequence, for example, a repetitive DNA associated with acentromere of a chromosome, can be used as a control. In someembodiments, probes can be obtained from commercial sources. In someembodiments, probes can be synthesized, for example, chemically or invitro, or made from chromosomal or genomic DNA through standardtechniques. In some embodiments sources of DNA that can be used includegenomic DNA, cloned DNA sequences, somatic cell hybrids that containone, or a part of one, human chromosome along with the normal chromosomecomplement of the host, and chromosomes purified by flow cytometry ormicrodissection. The region of interest can be isolated through cloning,or by site-specific amplification using PCR.

One or more nucleic acids for example, a probe or primer, can also belabeled, for example, by direct labeling, to comprise a detecTablelabel. A detecTable label can comprise any label capable of detection bya physical, chemical, or a biological process for example, a radioactivelabel, such as ³²P or ³H, a fluorescent label, such as FITC, achromophore label, an affinity-ligand label, an enzyme label, such asalkaline phosphatase, horseradish peroxidase, or 12 galactosidase, anenzyme cofactor label, a hapten conjugate label, such as digoxigenin ordinitrophenyl, a Raman signal generating label, a magnetic label, a spinlabel, an epitope label, such as the FLAG or HA epitope, a luminescentlabel, a heavy atom label, a nanoparticle label, electrochemical label,a light scattering label, a spherical shell label, semiconductornanocrystal label, such as quantum dots (described in U.S. Pat. No.6,207,392), and probes labeled with any other signal generating labelknown to those of skill in the art, wherein a label can allow the probeto be visualized with or without a secondary detection molecule. Anucleotide can be directly incorporated into a probe with standardtechniques, for example, nick translation, random priming, and PCRlabeling.

Non-limiting examples of label moieties useful for detection in theinvention include, without limitation, suitable enzymes such ashorseradish peroxidase, alkaline phosphatase, beta-galactosidase, oracetylcholinesterase; members of a binding pair that are capable offorming complexes such as streptavidin/biotin, avidin/biotin or anantigen/antibody complex including, for example, rabbit IgG andanti-rabbit IgG; fluorophores such as umbelliferone, fluorescein,fluorescein isothiocyanate, rhodamine, tetramethyl rhodamine, eosin,green fluorescent protein, erythrosin, coumarin, methyl coumarin,pyrene, malachite green, stilbene, lucifer yellow, Cascade Blue, TexasRed, dichlorotriazinylamine fluorescein, dansyl chloride, phycoerythrin,fluorescent lanthanide complexes such as those including Europium andTerbium, cyanine dye family members, such as Cy3 and Cy5, molecularbeacons and fluorescent derivatives thereof, as well as others known inthe art as described, for example, in Principles of FluorescenceSpectroscopy, Joseph R. Lakowicz (Editor), Plenum Pub Corp, 2nd edition(July 1999) and the 6th Edition of the Molecular Probes Handbook byRichard P. Hoagland; a luminescent material such as luminol; lightscattering or plasmon resonant materials such as gold or silverparticles or quantum dots; or radioactive material include ¹⁴C, ¹²³I,¹²⁴I, ¹²⁵I, Tc⁹⁹m, ³²P, ³³P, ³⁵S or ³H.

Other labels can also be used in the methods of the present disclosure,for example, backbone labels. Backbone labels comprise nucleic acidstains that bind nucleic acids in a sequence independent mannerNon-limiting examples include intercalating dyes such as phenanthridinesand acridines (e.g., ethidium bromide, propidium iodide, hexidiumiodide, dihydroethidium, ethidium homodimer-1 and -2, ethidiummonoazide, and ACMA); some minor grove binders such as indoles andimidazoles (e.g., Hoechst 33258, Hoechst 33342, Hoechst 34580 and DAPI);and miscellaneous nucleic acid stains such as acridine orange (alsocapable of intercalating), 7-AAD, actinomycin D, LDS751, andhydroxystilbamidine. All of the aforementioned nucleic acid stains arecommercially available from suppliers such as Molecular Probes, Inc.Still other examples of nucleic acid stains include the following dyesfrom Molecular Probes: cyanine dyes such as SYTOX Blue, SYTOX Green,SYTOX Orange, POPO-1, POPO-3, YOYO-1, YOYO-3, TOTO-1, TOTO-3, JOJO-1,LOLO-1, BOBO-1, BOBO-3, PO-PRO-1, PO-PRO-3, BO-PRO-1, BO-PRO-3,TO-PRO-1, TO-PRO-3, TO-PRO-5, JO-PRO-1, LO-PRO-1, YO-PRO-1, YO-PRO-3,PicoGreen, OliGreen, RiboGreen, SYBR Gold, SYBR Green I, SYBR Green II,SYBR DX, SYTO-40, -41, -42, -43, -44, -45 (blue), SYTO-13, -16, -24,-21, -23, -12, -11, -20, -22, -15, -14, -25 (green), SYTO-81, -80, -82,-83, -84, -85 (orange), SYTO-64, -17, -59, -61, -62, -60, -63 (red).

In some embodiments, fluorophores of different colors can be chosen, forexample, 7-amino-4-methylcoumarin-3-acetic acid (AMCA),5-(and-6)-carboxy-X-rhodamine, lissamine rhodamine B,5-(and-6)-carboxyfluorescein, fluorescein-5-isothiocyanate (FITC),7-diethylaminocoumarin-3-carboxylic acid,tetramethylrhodamine-5-(and-6)-isothiocyanate,5-(and-6)-carboxytetramethylrhodamine, 7-hydroxycoumarin-3-carboxylicacid, 6-[fluorescein 5-(and-6)-carboxamido]hexanoic acid,N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a diaza-3-indacenepropionicacid, eosin-5-isothiocyanate, erythrosin-5-isothiocyanate, TRITC,rhodamine, tetramethylrhodamine, R-phycoerythrin, Cy-3, Cy-5, Cy-7,Texas Red, Phar-Red, allophycocyanin (APC), and CASCADE™ blueacetylazide, such that each probe in or not in a set can be distinctlyvisualized. In some embodiments, fluorescently labeled probes can beviewed with a fluorescence microscope and an appropriate filter for eachfluorophore, or by using dual or triple band-pass filter sets to observemultiple fluorophores. In some embodiments, techniques such as flowcytometry can be used to examine the hybridization pattern of theprobes.

In other embodiments, the probes can be indirectly labeled, for example,with biotin or digoxygenin, or labeled with radioactive isotopes such as³²P and/or ³H. As a non-limiting example, a probe indirectly labeledwith biotin can be detected by avidin conjugated to a detecTable marker.For example, avidin can be conjugated to an enzymatic marker such asalkaline phosphatase or horseradish peroxidase. In some embodiments,enzymatic markers can be detected using colorimetric reactions using asubstrate and/or a catalyst for the enzyme. In some embodiments,catalysts for alkaline phosphatase can be used, for example,5-bromo-4-chloro-3-indolylphosphate and nitro blue tetrazolium. In someembodiments, a catalyst can be used for horseradish peroxidase, forexample, diaminobenzoate.

Methods of Detecting Genetic Variations

In some embodiments, standard techniques for genotyping for the presencegenetic variations, for example, amplification, can be used.Amplification of nucleic acids can be accomplished using methods knownin the art. Generally, sequence information from the region of interestcan be used to design oligonucleotide primers that can be identical orsimilar in sequence to opposite strands of a template to be amplified.In some embodiments, amplification methods can include but are notlimited to, fluorescence-based techniques utilizing PCR, for example,ligase chain reaction (LCR), Nested PCR, transcription amplification,self-sustained sequence replication, and nucleic acid based sequenceamplification (NASBA), and multiplex ligation-dependent probeamplification (MLPA). Guidelines for selecting primers for PCRamplification are well known in the art. In some embodiments, a computerprogram can be used to design primers, for example, Oligo (NationalBiosciences, Inc, Plymouth Minn.), MacVector (Kodak/IBI), and GCG suiteof sequence analysis programs.

In some embodiments, commercial methodologies available for genotyping,for example, SNP genotyping, can be used, but are not limited to, TaqMangenotyping assays (Applied Biosystems), SNPlex platforms (AppliedBiosystems), gel electrophoresis, capillary electrophoresis, sizeexclusion chromatography, mass spectrometry, for example, MassARRAYsystem (Sequenom), minisequencing methods, real-time Polymerase ChainReaction (PCR), Bio-Plex system (BioRad), CEQ and SNPstream systems(Beckman), array hybridization technology, for example, AffymetrixGeneChip (Perlegen), BeadArray Technologies, for example, IlluminaGoldenGate and Infinium assays, array tag technology, MultiplexLigation-dependent Probe Amplification (MLPA), and endonuclease-basedfluorescence hybridization technology (Invader; Third Wave). PCR can bea procedure in which target nucleic acid is amplified in a mannersimilar to that described in U.S. Pat. No. 4,683,195 and subsequentmodifications of the procedure described therein. In some embodiments,real-time quantitative PCR can be used to determine genetic variations,wherein quantitative PCR can permit both detection and quantification ofa DNA sequence in a sample, for example, as an absolute number of copiesor as a relative amount when normalized to DNA input or othernormalizing genes. In some embodiments, methods of quantification caninclude the use of fluorescent dyes that can intercalate withdouble-stranded DNA, and modified DNA oligonucleotide probes that canfluoresce when hybridized with a complementary DNA.

In some embodiments of the disclosure, a sample containing genomic DNAobtained from the subject can be collected and PCR can used to amplify afragment of nucleic acid that comprises one or more genetic variationsthat can be indicative of a susceptibility to a developmental disorder.In another embodiment, detection of genetic variations can beaccomplished by expression analysis, for example, by using quantitativePCR. In some embodiments, this technique can assess the presence of analteration in the expression or composition of one or more polypeptidesor splicing variants encoded by a nucleic acid associated with adevelopmental disorder.

In a preferred embodiment, the DNA template of a sample from a subjectcontaining a SNP can be amplified by PCR prior to detection with aprobe. In such an embodiment, the amplified DNA serves as the templatefor a detection probe and, in some embodiments, an enhancer probe.Certain embodiments of the detection probe, the enhancer probe, and/orthe primers used for amplification of the template by PCR can comprisethe use of modified bases, for example, modified A, T, C, G, and U,wherein the use of modified bases can be useful for adjusting themelting temperature of the nucleotide probe and/or primer to thetemplate DNA. In a preferred embodiment, modified bases are used in thedesign of the detection nucleotide probe. Any modified base known to theskilled person can be selected in these methods, and the selection ofsuitable bases is well within the scope of the skilled person based onthe teachings herein and known bases available from commercial sourcesas known to the skilled person.

In some embodiments, identification of genetic variations can beaccomplished using hybridization methods. The presence of a specificmarker allele or a particular genomic segment comprising a geneticvariation, or representative of a genetic variation, can be indicated bysequence-specific hybridization of a nucleic acid probe specific for theparticular allele or the genetic variation in a nucleic acid containingsample that has or has not been amplified but methods described herein.The presence of more than one specific marker allele or several geneticvariations can be indicated by using two or more sequence-specificnucleic acid probes, wherein each is specific for a particular alleleand/or genetic variation.

Hybridization can be performed by methods well known to the personskilled in the art, for example, hybridization techniques such asfluorescent in situ hybridization (FISH), Southern analysis, Northernanalysis, or in situ hybridization. In some embodiments, hybridizationrefers to specific hybridization, wherein hybridization can be performedwith no mismatches. Specific hybridization, if present, can be usingstandard methods. In some embodiments, if specific hybridization occursbetween a nucleic acid probe and the nucleic acid in the sample, thesample can contain a sequence that can be complementary to a nucleotidepresent in the nucleic acid probe. In some embodiments, if a nucleicacid probe can contain a particular allele of a polymorphic marker, orparticular alleles for a plurality of markers, specific hybridization isindicative of the nucleic acid being completely complementary to thenucleic acid probe, including the particular alleles at polymorphicmarkers within the probe. In some embodiments a probe can contain morethan one marker alleles of a particular haplotype, for example, a probecan contain alleles complementary to 2, 3, 4, 5 or all of the markersthat make up a particular haplotype. In some embodiments detection ofone or more particular markers of the haplotype in the sample isindicative that the source of the sample has the particular haplotype.

In some embodiments, PCR conditions and primers can be developed thatamplify a product only when the variant allele is present or only whenthe wild type allele is present, for example, allele-specific PCR. Insome embodiments of allele-specific PCR, a method utilizing a detectionoligonucleotide probe comprising a fluorescent moiety or group at its 3′terminus and a quencher at its 5′ terminus, and an enhanceroligonucleotide, can be employed, as described by Kutyavin et al.(Nucleic Acid Res. 34:e128 (2006)).

An allele-specific primer/probe can be an oligonucleotide that isspecific for particular a polymorphism can be prepared using standardmethods. In some embodiments, allele-specific oligonucleotide probes canspecifically hybridize to a nucleic acid region that contains a geneticvariation. In some embodiments, hybridization conditions can be selectedsuch that a nucleic acid probe can specifically bind to the sequence ofinterest, for example, the variant nucleic acid sequence.

In some embodiments, allele-specific restriction digest analysis can beused to detect the existence of a polymorphic variant of a polymorphism,if alternate polymorphic variants of the polymorphism can result in thecreation or elimination of a restriction site. Allele-specificrestriction digests can be performed, for example, with the particularrestriction enzyme that can differentiate the alleles. In someembodiments, PCR can be used to amplify a region comprising thepolymorphic site, and restriction fragment length polymorphism analysiscan be conducted. In some embodiments, for sequence variants that do notalter a common restriction site, mutagenic primers can be designed thatcan introduce one or more restriction sites when the variant allele ispresent or when the wild type allele is present.

In some embodiments, fluorescence polarization template-directeddye-terminator incorporation (FP-TDI) can be used to determine which ofmultiple polymorphic variants of a polymorphism can be present in asubject. Unlike the use of allele-specific probes or primers, thismethod can employ primers that can terminate adjacent to a polymorphicsite, so that extension of the primer by a single nucleotide can resultin incorporation of a nucleotide complementary to the polymorphicvariant at the polymorphic site.

In some embodiments, DNA containing an amplified portion can bedot-blotted, using standard methods and the blot contacted with theoligonucleotide probe. The presence of specific hybridization of theprobe to the DNA can then be detected. The methods can includedetermining the genotype of a subject with respect to both copies of thepolymorphic site present in the genome, wherein if multiple polymorphicvariants exist at a site, this can be appropriately indicated byspecifying which variants are present in a subject. Any of the detectionmeans described herein can be used to determine the genotype of asubject with respect to one or both copies of the polymorphism presentin the subject's genome.

In some embodiments, a peptide nucleic acid (PNA) probe can be used inaddition to, or instead of, a nucleic acid probe in the methodsdescribed herein. A PNA can be a DNA mimic having a peptide-like,inorganic backbone, for example, N-(2-aminoethyl) glycine units with anorganic base (A, G, C, T or U) attached to the glycine nitrogen via amethylene carbonyl linker.

Nucleic acid sequence analysis can also be used to detect geneticvariations, for example, genetic variations can be detected bysequencing exons, introns, 5′ untranslated sequences, or 3′ untranslatedsequences. One or more methods of nucleic acid analysis that areavailable to those skilled in the art can be used to detect geneticvariations, including but not limited to, direct manual sequencing,automated fluorescent sequencing, single-stranded conformationpolymorphism assays (SSCP); clamped denaturing gel electrophoresis(CDGE); denaturing gradient gel electrophoresis (DGGE), two-dimensionalgel electrophoresis (2DGE or TDGE); conformational sensitive gelelectrophoresis (CSGE); denaturing high performance liquidchromatography (DHPLC), infrared matrix-assisted laserdesorption/ionization (IR-MALDI) mass spectrometry, mobility shiftanalysis, quantitative real-time PCR, restriction enzyme analysis,heteroduplex analysis; chemical mismatch cleavage (CMC), RNaseprotection assays, use of polypeptides that recognize nucleotidemismatches, allele-specific PCR, real-time pyrophosphate DNA sequencing,PCR amplification in combination with denaturing high performance liquidchromatography (dHPLC), and combinations of such methods.

Sequencing can be accomplished through classic Sanger sequencingmethods, which are known in the art. In a preferred embodimentsequencing can be performed using high-throughput sequencing methodssome of which allow detection of a sequenced nucleotide immediatelyafter or upon its incorporation into a growing strand, for example,detection of sequence in substantially real time or real time. In somecases, high throughput sequencing generates at least 1,000, at least5,000, at least 10,000, at least 20,000, at least 30,000, at least40,000, at least 50,000, at least 100,000 or at least 500,000 sequencereads per hour; with each read being at least 50, at least 60, at least70, at least 80, at least 90, at least 100, at least 120 or at least 150bases per read (or 500-1,000 bases per read for 454).

High-throughput sequencing methods can include but are not limited to,Massively Parallel Signature Sequencing (MPSS, Lynx Therapeutics),Polony sequencing, 454 pyrosequencing, Illumina (Solexa) sequencing,SOLiD sequencing, on semiconductor sequencing, DNA nanoball sequencing,Helioscope™ single molecule sequencing, Single Molecule SMRT™sequencing, Single Molecule real time (RNAP) sequencing, Nanopore DNAsequencing, and/or sequencing by hybridization, for example, anon-enzymatic method that uses a DNA microarray, or microfluidic Sangersequencing.

In some embodiments, high-throughput sequencing can involve the use oftechnology available by Helicos BioSciences Corporation (Cambridge,Mass.) such as the Single Molecule Sequencing by Synthesis (SMSS)method. SMSS is unique because it allows for sequencing the entire humangenome in up to 24 hours. This fast sequencing method also allows fordetection of a SNP/nucleotide in a sequence in substantially real timeor real time. Finally, SMSS is powerful because, like the MIPtechnology, it does not use a pre-amplification step prior tohybridization. SMSS does not use any amplification. SMSS is described inUS Publication Application Nos. 20060024711; 20060024678; 20060012793;20060012784; and 20050100932. In some embodiments, high-throughputsequencing involves the use of technology available by 454 LifeSciences, Inc. (a Roche company, Branford, Conn.) such as thePicoTiterPlate device which includes a fiber optic plate that transmitschemiluminescent signal generated by the sequencing reaction to berecorded by a CCD camera in the instrument. This use of fiber opticsallows for the detection of a minimum of 20 million base pairs in 4.5hours.

In some embodiments, PCR-amplified single-strand nucleic acid can behybridized to a primer and incubated with a polymerase, ATP sulfurylase,luciferase, apyrase, and the substrates luciferin and adenosine 5′phosphosulfate. Next, deoxynucleotide triphosphates corresponding to thebases A, C, G, and T (U) can be added sequentially. A base incorporationcan be accompanied by release of pyrophosphate, which can be convertedto ATP by sulfurylase, which can drive synthesis of oxyluciferin and therelease of visible light. Since pyrophosphate release can be equimolarwith the number of incorporated bases, the light given off can beproportional to the number of nucleotides adding in any one step. Theprocess can repeat until the entire sequence can be determined. In someembodiments, pyrosequencing can be utilized to analyze amplicons todetermine whether breakpoints are present. In another embodiment,pyrosequencing can map surrounding sequences as an internal qualitycontrol.

Pyrosequencing analysis methods are known in the art. Sequence analysiscan include a four-color sequencing by ligation scheme (degenerateligation), which involves hybridizing an anchor primer to one of fourpositions. Then an enzymatic ligation reaction of the anchor primer to apopulation of degenerate nonamers that are labeled with fluorescent dyescan be performed. At any given cycle, the population of nonamers that isused can be structured such that the identity of one of its positionscan be correlated with the identity of the fluorophore attached to thatnonamer. To the extent that the ligase discriminates for complementarilyat that queried position, the fluorescent signal can allow the inferenceof the identity of the base. After performing the ligation andfour-color imaging, the anchor primer: nonamer complexes can be strippedand a new cycle begins. Methods to image sequence information afterperforming ligation are known in the art.

In some embodiments, analysis by restriction enzyme digestion can beused to detect a particular genetic variation if the genetic variationresults in creation or elimination of one or more restriction sitesrelative to a reference sequence. In some embodiments, restrictionfragment length polymorphism (RFLP) analysis can be conducted, whereinthe digestion pattern of the relevant DNA fragment indicates thepresence or absence of the particular genetic variation in the sample.

In some embodiments, arrays of oligonucleotide probes that can becomplementary to target nucleic acid sequence segments from a subjectcan be used to identify genetic variations. In some embodiments, anarray of oligonucleotide probes comprises an oligonucleotide array, forexample, a microarray. In some embodiments, the present disclosurefeatures arrays that include a substrate having a plurality ofaddressable areas, and methods of using them. At least one area of theplurality includes a nucleic acid probe that binds specifically to asequence comprising a genetic variation, and can be used to detect theabsence or presence of said genetic variation, for example, one or moreSNPs, microsatellites, or CNVs, as described herein, to determine oridentify an allele or genotype. For example, the array can include oneor more nucleic acid probes that can be used to detect a geneticvariation such as those listed in Table 1. In some embodiments, thearray can further comprise at least one area that includes a nucleicacid probe that can be used to specifically detect another markerassociated with a developmental disorder, for example, ASD, as describedherein.

Microarray hybridization can be performed by hybridizing a nucleic acidof interest; for example, a nucleic acid encompassing a geneticvariation, with the array and detecting hybridization using nucleic acidprobes. In some embodiments, the nucleic acid of interest is amplifiedprior to hybridization. Hybridization and detecting can be carried outaccording to standard methods described in Published PCT Applications:WO 92/10092 and WO 95/11995, and U.S. Pat. No. 5,424,186. For example,an array can be scanned to determine the position on the array to whichthe nucleic acid hybridizes. The hybridization data obtained from thescan can be, for example, in the form of fluorescence intensities as afunction of location on the array.

Arrays can be formed on substrates fabricated with materials such aspaper; glass; plastic, for example, polypropylene, nylon, orpolystyrene; polyacrylamide; nitrocellulose; silicon; optical fiber; orany other suitable solid or semisolid support; and can be configured ina planar, for example, glass plates or silicon chips); or threedimensional, for example, pins, fibers, beads, particles, microtiterwells, and capillaries, configuration.

Methods for generating arrays are known in the art and can include forexample; photolithographic methods (U.S. Pat. Nos. 5,143,854, 5,510,270and 5,527,681); mechanical methods, for example, directed-flow methods(U.S. Pat. No. 5,384,261); pin-based methods (U.S. Pat. No. 5,288,514);bead-based techniques (PCT US/93/04145); solid phase oligonucleotidesynthesis methods; or by other methods known to a person skilled in theart (see, e.g., Bier, F. F., et al. Adv Biochem Eng Biotechnol109:433-53 (2008); Hoheisel, J. D., Nat Rev Genet. 7: 200-10 (2006);Fan, J. B., et al. Methods Enzymol 410:57-73 (2006); Raqoussis, J. &Elvidge, G., Expert Rev Mol Design 6: 145-52 (2006); Mockler, T. C., etal. Genomics 85: 1-15 (2005), and references cited therein, the entireteachings of each of which are incorporated by reference herein). Manyadditional descriptions of the preparation and use of oligonucleotidearrays for detection of polymorphisms can be found, for example, in U.S.Pat. No. 6,858,394, U.S. Pat. No. 6,429,027, U.S. Pat. No. 5,445,934,U.S. Pat. No. 5,700,637, U.S. Pat. No. 5,744,305, U.S. Pat. No.5,945,334, U.S. Pat. No. 6,054,270, U.S. Pat. No. 6,300,063, U.S. Pat.No. 6,733,977, U.S. Pat. No. 7,364,858, EP 619 321, and EP 373 203, theentire teachings of which are incorporated by reference herein. Methodsfor array production, hybridization, and analysis are also described inSnijders et al., Nat. Genetics 29:263-264 (2001); Klein et al., Proc.Natl. Acad. Sci. USA 96:4494-4499 (1999); Albertson et al., BreastCancer Research and Treatment 78:289-298 (2003); and Snijders et al.,“BAC microarray based comparative genomic hybridization,” in: Zhao etal. (eds), Bacterial Artificial Chromosomes: Methods and Protocols,Methods in Molecular Biology, Humana Press, 2002.

In some embodiments, oligonucleotide probes forming an array can beattached to a substrate by any number of techniques, including, but notlimited to, in situ synthesis, for example, high-density oligonucleotidearrays, using photolithographic techniques; spotting/printing a mediumto low density on glass, nylon, or nitrocellulose; by masking; and bydot-blotting on a nylon or nitrocellulose hybridization membrane. Insome embodiments, oligonucleotides can be immobilized via a linker,including but not limited to, by covalent, ionic, or physical linkage.Linkers for immobilizing nucleic acids and polypeptides, includingreversible or cleavable linkers, are known in the art (U.S. Pat. No.5,451,683 and WO98/20019). In some embodiments, oligonucleotides can benon-covalently immobilized on a substrate by hybridization to anchors,by means of magnetic beads, or in a fluid phase, for example, in wellsor capillaries.

An array can comprise oligonucleotide hybridization probes capable ofspecifically hybridizing to different genetic variations. In someembodiments, oligonucleotide arrays can comprise a plurality ofdifferent oligonucleotide probes coupled to a surface of a substrate indifferent known locations. In some embodiments, oligonucleotide probescan exhibit differential or selective binding to polymorphic sites, andcan be readily designed by one of ordinary skill in the art, forexample, an oligonucleotide that is perfectly complementary to asequence that encompasses a polymorphic site, for example, a sequencethat includes the polymorphic site, within it, or at one end, canhybridize preferentially to a nucleic acid comprising that sequence, asopposed to a nucleic acid comprising an alternate polymorphic variant.

In some embodiments, arrays can include multiple detection blocks, forexample, multiple groups of probes designed for detection of particularpolymorphisms. In some embodiments, these arrays can be used to analyzemultiple different polymorphisms. In some embodiments, detection blockscan be grouped within a single array or in multiple, separate arrays,wherein varying conditions, for example, conditions optimized forparticular polymorphisms, can be used during hybridization. Generaldescriptions of using oligonucleotide arrays for detection ofpolymorphisms can be found, for example, in U.S. Pat. Nos. 5,858,659 and5,837,832. In addition to oligonucleotide arrays, cDNA arrays can beused similarly in certain embodiments.

The methods described herein can include but are not limited toproviding an array as described herein; contacting the array with asample, and detecting binding of a nucleic acid from the sample to thearray. In some embodiments, the method can comprise amplifying nucleicacid from the sample, for example, a region associated with adevelopmental disorder or a region that includes another regionassociated with a developmental disorder. In some embodiments, themethods described herein can include using an array that can identifydifferential expression patterns or copy numbers of one or more genes insamples from control and affected individuals. For example, arrays ofprobes to a marker described herein can be used to identify geneticvariations between DNA from an affected subject, and control DNAobtained from an individual that does not have a developmental disorder.Since the nucleotides on the array can contain sequence tags, theirpositions on the array can be accurately known relative to the genomicsequence.

In some embodiments, it can be desirable to employ methods that candetect the presence of multiple genetic variations, for example,polymorphic variants at a plurality of polymorphic sites, in parallel orsubstantially simultaneously. In some embodiments, these methods cancomprise oligonucleotide arrays and other methods, including methods inwhich reactions, for example, amplification and hybridization, can beperformed in individual vessels, for example, within individual wells ofa multi-well plate or other vessel.

Determining the identity of a genetic variation can also include orconsist of reviewing a subject's medical history, where the medicalhistory includes information regarding the identity, copy number,presence or absence of one or more alleles or SNPs in the subject, e.g.,results of a genetic test.

In some embodiments extended runs of homozygosity (ROH) may be useful tomap recessive disease genes in outbred populations. Furthermore, even incomplex disorders, a high number of affected individuals may have thesame haplotype in the region surrounding a disease mutation. Therefore,a rare pathogenic variant and surrounding haplotype can be enriched infrequency in a group of affected individuals compared with the haplotypefrequency in a cohort of unaffected controls. Homozygous haplotypes (HH)that are shared by multiple affected individuals can be important forthe discovery of recessive disease genes in complex disorders such asASD. In some embodiments, the traditional homozygosity mapping methodcan be extended by analysing the haplotype within shared ROH regions toidentify homozygous segments of identical haplotype that are presentuniquely or at a higher frequency in ASD probands compared to parentalcontrols. Such regions are termed risk homozygous haplotypes (rHH),which may contain low-frequency recessive variants that contribute toASD risk in a subset of ASD patients.

Genetic variations can also be identified using any of a number ofmethods well known in the art. For example, genetic variations availablein public databases, which can be searched using methods and customalgorithms or algorithms known in the art, can be used. In someembodiments, a reference sequence can be from, for example, the humandraft genome sequence, publicly available in various databases, or asequence deposited in a database such as GenBank.

Methods of Detecting CNVs

Detection of genetic variations, specifically CNVs, can be accomplishedby one or more suitable techniques described herein. Generally,techniques that can selectively determine whether a particularchromosomal segment is present or absent in an individual can be usedfor genotyping CNVs. Identification of novel copy number variations canbe done by methods for assessing genomic copy number changes.

In some embodiments, methods include but are not limited to, methodsthat can quantitatively estimate the number of copies of a particulargenomic segment, but can also include methods that indicate whether aparticular segment is present in a sample or not. In some embodiments,the technique to be used can quantify the amount of segment present, forexample, determining whether a DNA segment is deleted, duplicated, ortriplicated in subject, for example, Fluorescent In Situ Hybridization(FISH) techniques, and other methods described herein. In someembodiments, methods include detection of copy number variation fromarray intensity and sequencing read depth using a stepwise Bayesianmodel (Zhang Z. D., et al. BMC Bioinformatics. 2010 Oct. 31; 11:539). Insome embodiments, methods include detecting copy number variations usingshotgun sequencing, CNV-seq (Xie C., et al. BMC Bioinformatics. 2009Mar. 6; 10:80). In some embodiments, methods include analyzingnext-generation sequencing (NGS) data for CNV detection using any one ofseveral algorithms developed for each of the four broad methods for CNVdetection using NGS, namely the depth of coverage (DOC), read-pair (RP),split-read (SR) and assembly-based (AS) methods. (Teo S. M., et al.Bioinformatics. 2012 Aug. 31). In some embodiments, methods includecombining coverage with map information for the identification ofdeletions and duplications in targeted sequence data (Nord A. S., et al.BMC Genomics. 2011 Apr. 12; 12:184).

In some embodiments, other genotyping technologies can be used fordetection of CNVs, including but not limited to, karyotype analysis,Molecular Inversion Probe array technology, for example, Affymetrix SNPArray 6.0, and BeadArray Technologies, for example, Illumina GoldenGateand Infinium assays, as can other platforms such as NimbleGen HD2.1 orHD4.2, High-Definition Comparative Genomic Hybridization (CGH) arrays(Agilent Technologies), tiling array technology (Affymetrix), multiplexligation-dependent probe amplification (MLPA), Invader assay,fluorescence in situ hybridization, and, in one preferred embodiment,Array Comparative Genomic Hybridization (aCGH) methods. As describedherein, karyotype analysis can be a method to determine the content andstructure of chromosomes in a sample. In some embodiments, karyotypingcan be used, in lieu of aCGH, to detect translocations, which can becopy number neutral, and, therefore, not detecTable by aCGH. Informationabout amplitude of particular probes, which can be representative ofparticular alleles, can provide quantitative dosage information for theparticular allele, and by consequence, dosage information about the CNVin question, since the marker can be selected as a marker representativeof the CNV and can be located within the CNV. In some embodiments, ifthe CNV is a deletion, the absence of particular marker allele isrepresentative of the deletion. In some embodiments, if the CNV is aduplication or a higher order copy number variation, the signalintensity representative of the allele correlating with the CNV canrepresent the copy number. A summary of methodologies commonly used isprovided in Perkel (Perkel J Nature Methods 5:447-453 (2008)).

PCR assays can be utilized to detect CNVs and can provide an alternativeto array analysis. In particular, PCR assays can enable detection ofprecise boundaries of gene/chromosome variants, at the molecular level,and which boundaries are identical in different individuals. PCR assayscan be based on the amplification of a junction fragment present only inindividuals that carry a deletion. This assay can convert the detectionof a loss by array CGH to one of a gain by PCR.

Examples of PCR techniques that can be used in the present inventioninclude, but are not limited to quantitative PCR, real-time quantitativePCR (qPCR), quantitative fluorescent PCR (QF-PCR), multiplex fluorescentPCR (MF-PCR), real time PCR(RT-PCR), single cell PCR,PCR-RFLP/RT-PCR-RFLP, hot start PCR and Nested PCR. Other suitableamplification methods include the ligase chain reaction (LCR), ligationmediated PCR (LM-PCR), degenerate oligonucleotide probe PCR (DOP-PCR),transcription amplification, self-sustained sequence replication,selective amplification of target polynucleotide sequences, consensussequence primed polymerase chain reaction (CP-PCR), arbitrarily primedpolymerase chain reaction (AP-PCR) and nucleic acid based sequenceamplification (NABSA).

Alternative methods for the simultaneous interrogation of multipleregions include quantitative multiplex PCR of short fluorescentfragments (QMPSF), multiplex amplifiable probe hybridization (MAPH) andmultiplex ligation-dependent probe amplification (MLPA), in whichcopy-number differences for up to 40 regions can be scored in oneexperiment. Another approach can be to specifically target regions thatharbor known segmental duplications, which are often sites ofcopy-number variation. By targeting the variable nucleotides between twocopies of a segmental duplication (called paralogous sequence variants)using a SNP-genotyping method that provides independent fluorescenceintensities for the two alleles, it is possible to detect an increase inintensity of one allele compared with the other.

In another embodiment, the amplified piece of DNA can be bound to beadsusing the sequencing element of the nucleic acid tag under conditionsthat favor a single amplified piece of DNA molecule to bind a differentbead and amplification occurs on each bead. In some embodiments, suchamplification can occur by PCR. Each bead can be placed in a separatewell, which can be a picoliter-sized well. In some embodiments, eachbead is captured within a droplet of aPCR-reaction-mixture-in-oil-emulsion and PCR amplification occurs withineach droplet. The amplification on the bead results in each beadcarrying at least one million, at least 5 million, or at least 10million copies of the single amplified piece of DNA molecule.

In embodiments where PCR occurs in oil-emulsion mixtures, the emulsiondroplets are broken, the DNA is denatured and the beads carryingsingle-stranded nucleic acids clones are deposited into a well, such asa picoliter-sized well, for further analysis according to the methodsdescribed herein. These amplification methods allow for the analysis ofgenomic DNA regions. Methods for using bead amplification followed byfiber optics detection are described in Margulies et al. 2005, Nature.15; 437(7057):376-80, and as well as in US Publication Application Nos.20020012930; 20030068629; 20030100102; 20030148344; 20040248161;20050079510, 20050124022; and 20060078909.

Another variation on the array-based approach can be to use thehybridization signal intensities that are obtained from theoligonucleotides employed on Affymetrix SNP arrays or in Illumina BeadArrays. Here hybridization intensities are compared with average valuesthat are derived from controls, such that deviations from these averagesindicate a change in copy number. As well as providing information aboutcopy number, SNP arrays have the added advantage of providing genotypeinformation. For example, they can reveal loss of heterozygosity, whichcould provide supporting evidence for the presence of a deletion, ormight indicate segmental uniparental disomy (which can recapitulate theeffects of structural variation in some genomic regions—Prader-Willi andAngelman syndromes, for example).

Many of the basic procedures followed in microarray-based genomeprofiling are similar, if not identical, to those followed in expressionprofiling and SNP analysis, including the use of specialized microarrayequipment and data-analysis tools. Since microarray-based expressionprofiling has been well established in the last decade, much can belearned from the technical advances made in this area. Examples of theuse of microarrays in nucleic acid analysis that can be used aredescribed in U.S. Pat. No. 6,300,063, U.S. Pat. No. 5,837,832, U.S. Pat.No. 6,969,589, U.S. Pat. No. 6,040,138, U.S. Pat. No. 6,858,412, U.S.application Ser. No. 08/529,115, U.S. application Ser. No. 10/272,384,U.S. application Ser. No. 10/045,575, U.S. application Ser. No.10/264,571 and U.S. application Ser. No. 10/264,574. It should be notedthat there are also distinct differences such as target and probecomplexity, stability of DNA over RNA, the presence of repetitive DNAand the need to identify single copy number alterations in genomeprofiling.

In a preferred embodiment, the genetic variations detected comprise CNVsand can be detected using array CGH. In some embodiments, array CGH canbe been implemented using a wide variety of techniques. The initialapproaches used arrays produced from large-insert genomic clones such asbacterial artificial chromosomes (BACs). Producing sufficient BAC DNA ofadequate purity to make arrays is arduous, so several techniques toamplify small amounts of starting material have been employed. Thesetechniques include ligation-mediated PCR (Snijders et al, Nat. Genet.29:263-64), degenerate primer PCR using one or several sets of primers,and rolling circle amplification. BAC arrays that provide completegenome tiling paths are also available. Arrays made from less complexnucleic acids such as cDNAs, selected PCR products, and oligonucleotidescan also be used. Although most CGH procedures employ hybridization withtotal genomic DNA, it is possible to use reduced complexityrepresentations of the genome produced by PCR techniques. Computationalanalysis of the genome sequence can be used to design array elementscomplementary to the sequences contained in the representation. VariousSNP genotyping platforms, some of which use reduced complexity genomicrepresentations, can be useful for their ability to determine both DNAcopy number and allelic content across the genome. In some embodiments,small amounts of genomic DNA can be amplified with a variety of wholegenome amplification methods prior to CGH analysis of the sample.

The different basic approaches to array CGH provide different levels ofperformance, so some are more suitable for particular applications thanothers. The factors that determine performance include the magnitudes ofthe copy number changes, their genomic extents, the state andcomposition of the specimen, how much material is available foranalysis, and how the results of the analysis can be used. Manyapplications use reliable detection of copy number changes of much lessthan 50%, a more stringent requirement than for other microarraytechnologies. Note that technical details are extremely important anddifferent implementations of methods using the same array CGH approachcan yield different levels of performance. Various CGH methods are knownin the art and are equally applicable to one or more methods of thepresent invention. For example, CGH methods are disclosed in U.S. Pat.Nos. 7,034,144; 7,030,231; 7,011,949; 7,014,997; 6,977,148; 6,951,761;and 6,916,621, the disclosure from each of which is incorporated byreference herein in its entirety.

The data provided by array CGH are quantitative measures of DNA sequencedosage. Array CGH provides high-resolution estimates of copy numberaberrations, and can be performed efficiently on many samples. Theadvent of array CGH technology makes it possible to monitor DNA copynumber changes on a genomic scale and many projects have been launchedfor studying the genome in specific diseases.

In a preferred embodiment, whole genome array-based comparative genomehybridization (array CGH) analysis, or array CGH on a subset of genomicregions, can be used to efficiently interrogate human genomes forgenomic imbalances at multiple loci within a single assay. Thedevelopment of comparative genomic hybridization (CGH) (Kallioniemi etal, 1992, Science 258: 818-21) provided the first efficient approach toscanning entire genomes for variations in DNA copy number. Theimportance of normal copy number variation involving large segments ofDNA has been unappreciated. Array CGH is a breakthrough technique inhuman genetics, which is attracting interest from clinicians working infields as diverse as cancer and IVF (In Vitro Fertilization). The use ofCGH microarrays in the clinic holds great promise for identifyingregions of genomic imbalance associated with disease. Advances fromidentifying chromosomal critical regions associated with specificphenotypes to identifying the specific dosage sensitive genes can leadto therapeutic opportunities of benefit to patients. Array CGH is aspecific, sensitive and rapid technique that can enable the screening ofthe whole genome in a single test. It can facilitate and accelerate thescreening process in human genetics and is expected to have a profoundimpact on the screening and counseling of patients with geneticdisorders. It is now possible to identify the exact location on thechromosome where an aberration has occurred and it is possible to mapthese changes directly onto the genomic sequence.

An array CGH approach provides a robust method for carrying out agenome-wide scan to find novel copy number variants (CNVs). The arrayCGH methods can use labeled fragments from a genome of interest, whichcan be competitively hybridized with a second differentially labeledgenome to arrays that are spotted with cloned DNA fragments, revealingcopy-number differences between the two genomes. Genomic clones (forexample, BACs), cDNAs, PCR products and oligonucleotides, can all beused as array targets. The use of array CGH with BACs was one of theearliest employed methods and is popular, owing to the extensivecoverage of the genome it provides, the availability of reliable mappingdata and ready access to clones. The last of these factors is importantboth for the array experiments themselves, and for confirmatory FISHexperiments.

In a typical CGH measurement, total genomic DNA is isolated from controland reference subjects, differentially labeled, and hybridized to arepresentation of the genome that allows the binding of sequences atdifferent genomic locations to be distinguished. More than two genomescan be compared simultaneously with suitable labels. Hybridization ofhighly repetitive sequences is typically suppressed by the inclusion ofunlabeled Cot-1 DNA in the reaction. In some embodiments of array CGH,it is beneficial to mechanically shear the genomic DNA sample, forexample, with sonication, prior to its labeling and hybridization step.In another embodiment, array CGH may be performed without use of Cot-1DNA or a sonication step in the preparation of the genomic DNA sample.The relative hybridization intensity of the test and reference signalsat a given location can be proportional to the relative copy number ofthose sequences in the test and reference genomes. If the referencegenome is normal then increases and decreases in signal intensity ratiosdirectly indicate DNA copy number variation within the genome of thetest cells. Data are typically normalized so that the modal ratio forthe genome is set to some standard value, typically 1.0 on a linearscale or 0.0 on a logarithmic scale. Additional measurements such asFISH or flow cytometry can be used to determine the actual copy numberassociated with a ratio level.

In some embodiments, an array CGH procedure can include the followingsteps. First, large-insert clones, for example, BACs can be obtainedfrom a supplier of clone libraries. Then, small amounts of clone DNA canbe amplified, for example, by degenerate oligonucleotide-primed (DOP)PCR or ligation-mediated PCR in order to obtain sufficient quantitiesneeded for spotting. Next, PCR products can be spotted onto glass slidesusing, for example, microarray robots equipped with high-precisionprinting pins. Depending on the number of clones to be spotted and thespace available on the microarray slide, clones can either be spottedonce per array or in replicate. Repeated spotting of the same clone onan array can increase precision of the measurements if the spotintensities are averaged, and allows for a detailed statistical analysisof the quality of the experiments. Subject and control DNAs can belabeled, for example, with either Cy3 or Cy5-dUTP using random primingand can be subsequently hybridized onto the microarray in a solutioncontaining an excess of Cot1-DNA to block repetitive sequences.Hybridizations can either be performed manually under a coverslip, in agasket with gentle rocking or, automatically using commerciallyavailable hybridization stations. These automated hybridization stationscan allow for an active hybridization process, thereby improving thereproducibility as well as reducing the actual hybridization time, whichincreases throughput. The hybridized DNAs can detected through the twodifferent fluorochromes using standard microarray scanning equipmentwith either a scanning confocal laser or a charge coupled device (CCD)camera-based reader, followed by spot identification using commerciallyor freely available software packages.

The use of CGH with arrays that comprise long oligonucleotides (60-100bp) can improve the detection resolution (in some embodiments, as smallas ˜3-5 kb sized CNVs on arrays designed for interrogation of humanwhole genomes) over that achieved using BACs (limited to 50-100 kb orlarger sized CNVs due to the large size of BAC clones). In someembodiments, the resolution of oligonucleotide CGH arrays is achievedvia in situ synthesis of 1-2 million unique features/probes permicroarray, which can include microarrays available from Roche NimbleGenand Agilent Technologies. In addition to array CGH methods for copynumber detecton, other embodiments for partial or whole genome analysisof CNVs within a genome include, but are not limited to, use of SNPgenotyping microarrays and sequencing methods.

Another method for copy number detection that uses oligonucleotides canbe representational oligonucleotide microarray analysis (ROMA). It issimilar to that applied in the use of BAC and CGH arrays, but toincrease the signal-to-noise ratio, the ‘complexity’ of the input DNA isreduced by a method called representation or whole-genome sampling.Here, the DNA that is to be hybridized to the array can be treated byrestriction digestion and then ligated to adapters, which results in thePCR-based amplification of fragments in a specific size-range. As aresult, the amplified DNA can make up a fraction of the entire genomicsequence—that is, it is a representation of the input DNA that hassignificantly reduced complexity, which can lead to a reduction inbackground noise. Other suitable methods available to the skilled personcan also be used, and are within scope of the present disclosure.

A comparison of one or more genomes relative to one or more othergenomes with array CGH, or a variety of other CNV detection methods, canreveal the set of CNVs between two genomes, between one genome incomparison to multiple genomes, or between one set of genomes incomparison to another set of genomes. In some embodiments, an array CGHexperiment can be performed by hybrizing a single test genome against apooled sample of two or more genomes, which can result in minimizing thedetection of higher frequency variants in the experiment. In someembodiments, a test genome can be hybridized alone (i.e., one-colordetetion) to a microarray, for example, using array CGH or SNPgenotyping methods, and the comparison step to one or more referencegenomes can be performed in silico to reveal the set of CNVs in the testgenome relative to the one or more reference genomes. In one preferredembodiment, a single test genome is compared to a single referencegenome in a 2-color experiment wherein both genomes are cohybridized tothe microarray.

Array CGH can be used to identify genes that are causative or associatedwith a particular phenotype, condition, or disease by comparing the setof CNVs found in the affected cohort to the set of CNVs found in anunaffected cohort. An unaffected cohort may consist of any individualunaffected by the phenotype, condition, or disease of interest, but inone preferred embodiment is comprised of individuals or subjects thatare apparently healthy (normal). Methods employed for such analyses aredescribed in U.S. Pat. Nos. 7,702,468 and 7,957,913. In some embodimentsof CNV comparison methods, candidate genes that are causative orassociated (i.e., potentially serving as a biomarker) with a phenotype,condition, or disease will be identified by CNVs that occur in theaffected cohort but not in the unaffected cohort. In some embodiments ofCNV comparison methods, candidate genes that are causative or associated(i.e., potentially serving as a biomarker) with a phenotype, condition,or disease will be identified by CNVs that occur at a statisticallysignificant higher frequency in the affected cohort as compared theirfrequency in the unaffected cohort. Thus, CNVs preferentially detectedin the affected cohort as compared to the unaffected cohort can serve asbeacons of genes that are causative or associated with a particularphenotype, condition, or disease. In some embodiments, CNV detection andcomparison methods can result in direct identification of the gene thatis causative or associated with phenotype, condition, or disease if theCNVs are found to overlap with or encompass the gene(s). In someembodiments, CNV detection and comparison methods can result inidentification of regulatory regions of the genome (e.g., promoters,enhancers, transcription factor binding sites) that regulate theexpression of one or more genes that are causative or associated withthe phenotype, condition, or disease of interest.

Due to the large amount of genetic variation between any two genomes, ortwo sets (cohorts) of genomes, being compared, one preferred embodimentis to reduce the genetic variation search space by interrogating onlyCNVs, as opposed to the full set of genetic variants that can beidentified in an individual's genome or exome. The set of CNVs thatoccur only, or at a statistically higher frequency, in the affectedcohort as compared to the unaffected cohort can then be furtherinvestigated in targeted sequencing experiments to reveal the full setof genetic variants (of any size or type) that are causative orassociated (i.e., potentially serving as a biomarker) with a phenotype,condition, or disease. It can be appreciated to those skilled in the artthat the targeted sequencing experiments are performed in both theaffected and unaffected cohorts in order to identify the geneticvariants (e.g., SNVs and indels) that occur only, or at a statisticallysignificant higher frequency, in the affected individual or cohort ascompared to the unaffected cohort.

When investigating a particular phenotype, condition, or disease, suchas ASD, it can be appreciated by those skilled in the art that thenumber of ASD candidate genes (or regulatory sequences) identified viaCNV (or other variant types) detection methods may increase or decreasewhen additional ASD cohorts are analyzed. Similarly, the number of ASDcandidate genes (or regulatory sequences), for example, identified viaCNV (or other variant types) detection methods may increase or decreasewhen additional unaffected cohorts are used to interpret the affectedcohort CNVs (or other variat types). For very rare CNVs (e.g., <0.1%frequency in the general population), only a single case may be observedin a given ASD cohort (e.g., 100 cases) but further statisticalsignificance or evidence for the gene (or regulatory sequence/locus inthe genome) can be established by: 1) CNV analysis of additional ASDcohorts, 2) CNV analysis of additional Normal cohorts, 3) targeted genesequencing of both ASD and Normal cohorts, and/or 4) functionalcharacterization of the ASD candidate gene (e.g., in silico analysis ofthe predicted impact of the candidate mutation on the gene product, RNAiknockdown experiments, biochemical assays on ASD patient tissue, geneexpression analysis of disease-relevant tissues or of inducedpluripotent stem cells (iPSCs) created from the ASD patient(s) harboringthe candidate ASD-causing genetic variant).

It can be appreciated by those skilled in the art that a candidate genemay validate as causative of the phenotype, condition, or disease (e.g.,ASD), which may, for example, be confirmed via mechansism of actionexperiments, or it may serve as a biomarker of the phenotype, condition,or disease. Thus, in the example of ASD, in some embodiments, theASD-specific gene (or regulatory sequence/locus) may be a biomarker ofage-of-onset for ASD and disease severity, and thus have diagnosticutility for monitoring patients known to be at risk for ASD or as ageneral screening test in the population for early diagnosis of thedisease. In some embodiments, the ASD-specific gene/biomarker may be anindicator of drug response (e.g., a particular subtype of ASD mayrespond best to a therapeutic targeting a particular phenotype,causative gene, or other gene in the same pathway as the causative gene)and thus have utility during drug development in clinical trials. Forexample, clinical trials for a therapeutic that targets a ASD geneticsubtype comprising only 10% of all patients exhibiting symptoms of ASD,can be designed to comprise only those 10% of patients with a specificgenotype(s) in order to reduce the time and cost of such clinical trials(e.g., smaller number of patients in the clinical trial). It can beappreciated by those skilled in the art that such patient stratificationmethods (i.e., specific genotypes correlated with the disease or drugresponse) can be employed not only for targeted therapeutics, but ingeneral for any drug that is approved or in development (i.e., themechanism of action may or may not be known). For example, drugs indevelopment or approved to treat, for example, cancer, may have utilityin being repurposed to treat ASD. Such patient stratification methodscan also be utilized to develop a companion diagnostic test (e.g.,comprising the specific genes/genotypes found in patients that areindicative of drug response) for a particular drug, either concurrentlyduring the clinical trials for the drug or after drug approval (e.g., asa new indication or for the physician to use in guiding medicaldecisions for the patient).

Further neurodevelopmental and/or links to ASD pathology can beestablished via pathway analysis of the genes, which may take intoconsideration binding interactions (e.g., via yeast 2-hybrid screen) andmolecular events (e.g., kinase activity or other enzymatic processes) ifsuch information is available for the gene(s) of interest (i.e.,specified in the analysis). Both commercial (e.g., Ingenuity's IPAsoftware and Thomson Reuter's GeneGo software) and open source software(e.g., String: string-db.org/) are available for such analyses. Toassess connections to established ASD biology, analyses can be performedfor the set of candidate ASD genes independently or against knowncausative ASD genes singly or as a group. In some embodiments, ASDcandidate genes can be distributed into categories such as: 1) geneswith neuroprotective function, 2) neuropsychiatric genes, some of whichmay be known drug targets 3) genes linked to a known causative ASD gene(e.g., binding partner) or a novel gene family member of a known ASDgene, 4) genes linked to neurodevelopmental regulation, neurogenesis,and G-protein signaling pathways, and 5) other (e.g., established rolein other diseases with no obvious neurodevelopmental biology, such ascancer) or unknown gene function (e.g., limited or no gene informationpresently annotated for the ASD-specific gene).

A method of screening a subject for a disease or disorder can compriseassaying a nucleic acid sample from the subject to detect sequenceinformation for more than one genetic locus and comparing the sequenceinformation to a panel of nucleic acid biomarkers and screening thesubject for the presence or absence of the disease or disorder if one ormore of low frequency biomarkers in the panel are present in thesequence information.

The panel can comprise at least one nucleic acid biomarker for each ofthe more than one genetic loci. For example, the panel can comprise 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 3, 14, 15, 15, 17, 18, 19, 20, 25, 30,35, 40, 45, 50, 75, 100, 150, 200 or more nucleic acid biomarkers foreach of the more than one genetic loci. In some embodiments, the panelcan comprise from about 2-1000 nucleic acid biomarkers. For example, thepanel can comprise from about 2-900, 2-800, 2-700, 2-600, 2-500, 2-400,2-300, 2-200, 2-100, 25-900, 25-800, 25-700, 25-600, 25-500, 25-400,25-300, 25-200, 25-100, 100-1000, 100-900, 100-800, 100-700, 100-600,100-500, 100-400, 100-300, 100-200, 200-1000, 200-900, 200-800, 200-700,200-600, 200-500, 200-400, 200-300, 300-1000, 300-900, 300-800, 300-700,300-600, 300-500, 300-400, 400-1000, 400-900, 400-800, 400-700, 400-600,400-500, 500-1000, 500-900, 500-800, 500-700, 500-600, 600-1000,600-900, 600-800, 600-700, 700-1000, 700-900, 700-800, 800-1000,800-900, or 900-1000 nucleic acid biomarkers.

The panel can comprise at least 2 low frequency biomarkers. For example,the panel can comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 3,14, 15, 15, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150, 200,250, 500, or 1000 or more low frequency biomarkers. In some embodiments,the panel can comprise from about 2-1000 low frequency biomarkers. Forexample, the panel can comprise from about 2-900, 2-800, 2-700, 2-600,2-500, 2-400, 2-300, 2-200, 2-100, 25-900, 25-800, 25-700, 25-600,25-500, 25-400, 25-300, 25-200, 25-100, 100-1000, 100-900, 100-800,100-700, 100-600, 100-500, 100-400, 100-300, 100-200, 200-1000, 200-900,200-800, 200-700, 200-600, 200-500, 200-400, 200-300, 300-1000, 300-900,300-800, 300-700, 300-600, 300-500, 300-400, 400-1000, 400-900, 400-800,400-700, 400-600, 400-500, 500-1000, 500-900, 500-800, 500-700, 500-600,600-1000, 600-900, 600-800, 600-700, 700-1000, 700-900, 700-800,800-1000, 800-900, or 900-1000 1000 low frequency biomarkers. In someembodiments, a low frequency biomarker can occur at a frequency of 0.1%or less in a population of subjects without a diagnosis of the diseaseor disorder. For example, a low frequency biomarker can occur at afrequency of 0.05%, 0.01%, 0.005%, 0.001%, 0.0005%, 0.0001%, 0.00005%,or 0.00001% or less in a population of subjects without a diagnosis ofthe disease or disorder. In some embodiments, a low frequency biomarkercan occur at a frequency from about 0.00001%-0.1% in a population ofsubjects without a diagnosis of the disease or disorder. For example, alow frequency biomarker can occur at a frequency of from about0.00001%-0.00005%, 0.00001%-0.0001%, 0.00001%-0.0005%, 0.00001%-0.001%,0.00001%-0.005%, 0.00001%-0.01%, 0.00001%-0.05%, 0.00005%-0.0001%,0.00005%-0.0005%, 0.00005%-0.001%, 0.00005%-0.005%, 0.00005%-0.01%,0.00005%-0.05%, 0.00005%-0.1%, 0.0001%-0.0005%, 0.0001%-0.001%,0.0001%-0.005%, 0.0001%-0.01%, 0.0001%-0.05%, 0.0001%-0.1%,0.0005%-0.001%, 0.0005%-0.005%, 0.0005%-0.01%, 0.0005%-0.05%,0.0005%-0.1%, 0.001%-0.005%, 0.001%-0.01%, 0.001%-0.05%, 0.001%-0.1%,0.005%-0.01%, 0.005%-0.05%, 0.005%-0.1%, 0.01%-0.05%, 0.01%-0.1%, or0.05%-0.1% in a population of subjects without a diagnosis of thedisease or disorder

In some embodiments, the presence or absence of the disease or disorderin the subject can be determined with at least 50% confidence. Forexample, the presence or absence of the disease or disorder in thesubject can be determined with at least 50%, 55%, 60%, 65%, 70%, 75%,80%, 85%, 90%, 95%, 98%, 99%, or 100% confidence. In some embodiments,the presence or absence of the disease or disorder in the subject can bedetermined with a 50%-100% confidence. For example, the presence orabsence of the disease or disorder in the subject can be determined witha 60%-100%, 70%-100%, 80%-100%, 90%-100%, 50%-90%, 50%-80%, 50%-70%,50%-60%, 60%-90%, 60%-80%, 60%-70%, 70%-90%, 70%-80%, or 80%-90%. In oneembodiement, ASD candidate CNVs and genes or regulatory loci associatedwith these CNVs can be determined or identified by comparing geneticdata from a cohort of normal individuals to that of an individual or acohort of individuals known to have, or be susceptible to adevelopmental disorder such as ASD.

In some embodiments, a genomic DNA sample from one individual or genomicsamples from a pool of two or more individuals without ASD can serve asas the reference genome(s) and the genomic DNA sample from an individualknown to have ASD or being tested to determine if they have ASD canserve as the test DNA. In one preferred embodiment, the reference andtest samples are sex-matched and co-hybridized on the CGH array. Forexample, reference DNA samples can be labeled with a fluorophore such asCy5, using methods described herein, and test subject DNA samples can belabeled with a different fluorophore, such as Cy3. After labeling,samples can be combined and can be co-hybridized to a microarray andanalyzed using any of the methods described herein, such as aCGH. Arrayscan then be scanned and the data can be analyzed with software. Geneticalterations, such as CNVs, can be called using any of the methodsdescribed herein. A list of the genetic alterations, such as CNVs, canbe generated for one or more test subjects and/or for one or morereference subjects. Such lists of CNVs can be used to generate a masterlist of non-redundant CNVs for each type of cohort. In one embodiment, acohort of test samples, such as individuals known to have or suspectedto have ASD, can be cohybridized with an identical sex-matched referenceindividual or sex-matched pool of reference individuals to generate alist of redundant or non-redudant CNVs. Such lists can be based on thepresence or absence of one or more CNVs present in individuals withinthe cohort. In this manner, a master list can contain a number ofdistinct CNVs, some of which are uniquely present in a single individualand some of which are present in multiple individuals.

In some embodiments, CNVs of interest can be obtained by annotation ofeach CNV with relevant information, such as overlap with known genesand/or exons or intergenic regulatory regions such as transcriptionfactor binding sites. In some embodiments, CNVs of interest can beobtained by calculating the OR for a CNV according to the followingformula: OR=(ASD/((# individuals in ASD cohort)−ASD))/(Normal/((#individuals in Normal cohort)−Normal)), where: ASD=number of ASDindividuals with a CNV of interest and Normal=number of Normalindividuals with the CNV of interest. If Normal=0, it can be set to 1 toavoid dealing with infinities in cases where no CNVs are seen in theNormal cohort. In some embodiments, a set of publicly available CNVs(e.g., the Database of Genomic Variants,http://projects.tcag.ca/variation/) can be used as the Normal cohort forcomparison to the affected cohort CNVs. In another embodiment, the setof Normal cohort CNVs may comprise a private database generated by thesame CNV detection method, such as array CGH, or by a plurality of CNVdetection methods that include, but are not limited to, array CGH, SNPgenotyping arrays, custom CGH arrays, custom genotyping arrays, exomesequencing, whole genome sequencing, targeted sequencing, FISH, q-PCR,or MLPA.

The number of individuals in any given cohort can be at least about 10,50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2500, 5000, 7500,10,000, 100,000, or more. In some embodiments, the number of individualsin any given cohort can be from 25-900, 25-800, 25-700, 25-600, 25-500,25-400, 25-300, 25-200, 25-100, 100-1000, 100-900, 100-800, 100-700,100-600, 100-500, 100-400, 100-300, 100-200, 200-1000, 200-900, 200-800,200-700, 200-600, 200-500, 200-400, 200-300, 300-1000, 300-900, 300-800,300-700, 300-600, 300-500, 300-400, 400-1000, 400-900, 400-800, 400-700,400-600, 400-500, 500-1000, 500-900, 500-800, 500-700, 500-600,600-1000, 600-900, 600-800, 600-700, 700-1000, 700-900, 700-800,800-1000, 800-900, or 900-1000.

Different categories for CNVs of interest can be defined. In someembodiments, CNVs can be of interest if the CNVs are rare in the generalpopulation or in a cohort of individuals without the disease orcondition of interest. In another embodiment, CNVs can be of interest ifthey are found only in those affected by a disease or condition and notin those without the disease or condition. In another embodiment, CNVscan be of interest if they are found at much greater frequency in thoseaffected by the disease or condition as compared to those without thedisease or condition.

The data presented in Tables 1 and 2 was generated on the basis of acomparison of copy number variants (CNVs) identified in an ASD cohort.CNV genome locations are provided using the Human March 2006(NCBI36/hg18) assembly. It can be appreciated by those skilled in theart that a CNV found in an affected individual may have one or more CNVsthat are preferentially found in the affected cohort as compared to theunaffected cohort and, similarly, other CNVs that are found atcomparable frequencies, or not statistically significant differentfrequencies, in the affected and unaffected cohorts. In a preferredembodiment, CNV detection and analysis methods are employed that enablecomparison of CNVs to facilitate identification of genes (or regulatoryloci) that are causative or associated with the phenotype, condition, ordisease being investigated (or detected for diagnostic purposes). InTable 1, SEQ IDs 1-76 refer to the CNV sequences (full sequence obtainedfor the whole CNV). In Table 2, SEQ IDs 77-209 refer to the genomicsequences over which the relevant transcripts extend (full genomicextent of the transcripts, not just the short sequence associated withthe mRNA).

Table 1 shows a list of the novel, rare identified CNVs affecting genesthat could play a role in neurodevelopment. Table 1 shows a list of allCNVs of interest (76 total), obtained as described in Example 1. Column1 refers to the SEQ ID in the sequence file 121009_ASD_SK.txt. Column 2refers to the Hospital ID of the patient in whom the CNV was discovered.Column 3 refers to the chromosome location of the CNV. Column 4 refersto the nucleotide position in the respective chromosome (column 3) wherethe corresponding CNV begins and column 5 refers to the nucleotideposition in the respective chromosome where the corresponding CNV ends.Column 6 refers to the length/size of the CNV in bps. Column 7 refers tothe chromosomal cytoband location. The CNV classifications (column 8) ofgain or loss indicate whether each CNV region found in the subjects wasduplicated/amplified (gain) or deleted (loss) in the genome. Column 9refers to whether or not the CNV has been validated by qPCR. Column 10refers to the CNV priority number.

Nucleotide positions were determined using the database Hg18 Mar. 2006(NCBI Build 36.1). The CNVs in Table 1 were detected using Agilent 1Marray on the ASD cohort but were assessed as not being present in anynormal subjects analyzed on SNP genotyping platforms or not overlappingwith CNVs present in the Database of Genomic Variants(http://projects.tcag.ca/variation/). Most of these CNVs have beenexperimentally validated by quantitative PCR (qPCR) and theirsegregation in the families was tested. All of the probands met thecriteria for autism on one or both screening measures-Autism DiagnosticInterview-Revised (ADI-R) training and Autism Diagnostic ObservationSchedule (ADOS) training. For the control cohorts analyzed for CNVsusing SNP genotyping arrays, the control population from the Study onAddiction: Genetics and Environment (SAGE) had no psychiatric historyand the other two control sets from an Ottawa Heart Institute (OHI)study and a PopGen study had no information on psychiatric history. Thetotal number of controls from these cohorts (SAGE, OHI, PopGen), whichwere used as one assessment to determine if a CNV found in one or moreindividuals with ASD is rare or not present in the general population,was 4,139 individuals.

Table 2 shows a list of the gene biomarkers associated with therespective CNVs identified in Table 1. Column 1 refers to the number ofdistinct genes overlapped by the CNV. Column 2 refers to the names ofgenes affected by, impacted by, or within the CNV. Column 3 refers tothe SEQ ID of the genomic sequence, including intragenic and exonicregions, in the sequence file 121009_ASD_SK.txt. Column 4 refers toaccession information for transcripts found within the CNV. Coulmn 4refers to the version number of the accession information. Column 5refers to the genomic start of the transcript. Column 7 refers to thegenomic end of the transcript. Column 8 refers to the length of thegenomic sequence over which transcript extends (from start to end).Column 9 refers to a brief description of gene function. More than oneRNA product (e.g., alternatively spliced mRNA transcripts and non-codingRNAs) can be produced from a single gene. Table 2 lists presently knowntranscript variants (and their RNA accession numbers) but it can beappreciated by those skilled in the art that new variants may be foundwhen further studies are completed and that generation of theseadditional transcript variants (and ultimately protein and/or regulatoryRNA products) may also be impacted by one or more CNVs listed inTable 1. Table 2 contains 170 entries. This number exceeds that in Table1, both because some CNVs overlap multiple genes and because, for somegenes, there are multiple transcripts described. The priority numbercorresponds to column 10 of Table 1.

In one embodiment, the transcripts listed in Table 2 can be expressionproducts of the same gene. In another embodiment, the gene biomarker isthe DNA encoding gene, including exons, introns, and/or regulatorybinding regions such as enhancers, promoters, silencers, and responseelements. In one embodiment, point mutations, polymorphisms,translocations, insertions, deletions, amplifications, inversions,microsatellites, interstitial deletions, copy number variations (CNVs),loss of heterozygosity, or any other aberrations which affect thestructure or function of one or more gene biomarkers and/or expressionproducts thereof, are associated with a developmental disorder asdescribed herein.

TABLE 1 Size SEQ ID No Hospital ID Chr Start Stop (bp) Cytoband SEQ ID 1NA0174-000 14 66,255,943 66,292,122 36,180 14q23.3 SEQ ID 2 SS0054 1466,083,554 66,085,434 1,880 14q23.3 SEQ ID 3 SS0254 14 66,114,23166,206,726 92,495 14q23.3 SEQ ID 4 SS0100 14 66,114,231 66,189,11274,881 14q23.3 SEQ ID 5 SS0025 14 66,124,169 66,150,847 26,678 14q23.3SEQ ID 6 SS0711 14 66,124,169 66,150,847 26,678 14q23.3 SEQ ID 7 SS017514 66,256,143 66,291,922 35,779 14q23.3 SEQ ID 8 MM1094-004 2115,251,698 115,258,815 7,118 2q14.1 SEQ ID 9 MM1076-004 7 145,659,291145,666,871 7,581 7q35 SEQ ID 10 SK0388-003 14 78,094,937 78,108,99714,061 14q24.3 SEQ ID 11 MM1128-003 2 212,595,621 212,601,943 6,323 2q34SEQ ID 12 MM0198-003 2 124,820,246 124,830,494 10,249 2q14.3 SEQ ID 13SK0222-003 2 124,820,246 124,830,494 10,249 2q14.3 SEQ ID 14 MM0269-0042 133,432,106 133,451,626 19,521 2q21.2 SEQ ID 15 SK0353-003 2133,905,311 133,915,419 10,109 2q21.2 SEQ ID 16 MM0090-003 2 50,451,92950,458,853 6,925 2p16.3 SEQ ID 17 SK0148-005 4 20,027,378 20,046,39219,015 4p15.31 SEQ ID 18 SK0148-005 2 80,729,039 80,780,707 51,669 2p12SEQ ID 19 NA0050-000 1 97,937,467 97,947,871 10,405 1p21.3 SEQ ID 20MM0081-003 3 171,421,331 171,431,963 10,633 3q26.2 SEQ ID 21 SK0094-0051 239,422,540 239,435,803 13,264 1q43 SEQ ID 22 SK0184-003 1 239,422,540239,435,803 13,264 1q43 SEQ ID 23 SK0442-003 19 52,315,553 52,339,88124,329 19q13.32 SEQ ID 24 MM0177-003 22 21,328,084 21,984,363 656,28022q11.23, 22q11.22 SEQ ID 25 SK0433-003 4 94,025,204 94,160,887 135,6844q22.2 SEQ ID 26 SK0451-003 7 126,121,250 126,155,948 34,699 7q31.33 SEQID 27 SK0011-004 X 32,574,277 32,580,137 5,861 Xp21.1 SEQ ID 28SK0277-003 X 33,069,644 33,076,560 6,917 Xp21.1 SEQ ID 29 MM1165-003 2015,698,778 15,713,061 14,284 20p12.1 SEQ ID 30 MM1334-003 20 15,698,77815,713,061 14,284 20p12.1 SEQ ID 31 SK0291-003 6 161,924,151 161,941,86217,712 6q26 SEQ ID 32 MM0126-004 16 3,693,293 3,706,628 13,336 16p13.3SEQ ID 33 NA0002-000 3 116,104,105 116,114,108 10,004 3q13.31 SEQ ID 34SK0148-005 16 82,953,024 82,964,975 11,952 16q24.1 SEQ ID 35 SK0076-00322 16,366,405 16,373,681 7,277 22q11.21 SEQ ID 36 MM0022-003 842,689,776 42,703,550 13,775 8p11.21 SEQ ID 37 SK0256-003 8 42,691,58642,703,550 11,965 8p11.21 SEQ ID 38 SK0373-003 15 76,205,943 76,223,58117,639 15q25.1 SEQ ID 39 SK0009-004 15 76,205,943 76,226,626 20,68415q25.1 SEQ ID 40 SK0254-003 7 8,505,020 8,762,802 257,783 7p21.3 SEQ ID41 NA0066-000 7 8,748,267 8,761,257 12,991 7p21.3 SEQ ID 42 MM0262-00315 73,636,914 73,649,849 12,936 15q24.2 SEQ ID 43 NA0061-000 1 8,415,4718,424,072 8,602 1p36.23 SEQ ID 44 SK0192-003 1 8,578,840 8,591,52112,682 1p36.23 SEQ ID 45 MM1206-003 10 106,447,066 106,456,507 9,44210q25.1 SEQ ID 46 SK0002-003 3 150,841,628 150,849,596 7,969 3q25.1 SEQID 47 SK0413-003 7 124,324,707 124,335,800 11,094 7q31.33 SEQ ID 48MM0022-003 7 124,324,707 124,335,800 11,094 7q31.33 SEQ ID 49 SK0494-0033 77,559,671 77,571,280 11,610 3p12.3 SEQ ID 50 SK0179-003 3 77,559,67177,571,280 11,610 3p12.3 SEQ ID 51 MM1112-003 8 24,361,792 24,390,07228,281 8p21.2 SEQ ID 52 SK0517-003 5 19,717,165 19,733,656 16,492 p14.3SEQ ID 53 NA0099-000 11 61,261,340 61,276,498 15,159 11q12.2 SEQ ID 54SK0197-004 4 155,727,144 155,743,337 16,194 4q32.1 SEQ ID 55 SK0002-00314 63,987,698 63,996,124 8,427 14q23.2 SEQ ID 56 SK0144-004 5149,899,127 149,953,911 54,785 5q33.1 SEQ ID 57 SK0347-003 17 26,494,56126,507,432 12,872 17q11.2 SEQ ID 58 SK0455-003 9 14,194,914 14,203,2548,341 9p22.3 SEQ ID 59 SK0252-003 7 131,702,414 131,719,045 16,6327q32.3 SEQ ID 60 MM1131-003 1 45,759,003 45,768,207 9,205 1p34.1 SEQ ID61 SK0195/MM1003- X 16,688,462 16,707,232 18,771 Xp22.2 003 SEQ ID 62SK0196-005 X 16,688,462 16,707,232 18,771 Xp22.2 SEQ ID 63 NA0186-000 1774,398,583 74,447,566 48,984 17q25.3 SEQ ID 64 NA0176-000 11 118,439,435118,458,458 19,024 11q23.3 SEQ ID 65 SK0354-006 1 27,662,588 27,679,45016,863 1p36.11 SEQ ID 66 MM0211-004 X 151,729,935 151,853,805 123,871Xq28 SEQ ID 67 MM1226-003 1 70,149,725 70,161,066 11,342 1p31.1 SEQ ID68 SK0083-003 17 1,182,304 1,207,115 24,812 17p13.3 SEQ ID 69 SK0267-00317 1,182,533 1,206,944 24,412 17p13.3 SEQ ID 70 MM0270-003 8 145,990,558146,003,494 12,937 8q24.3 SEQ ID 71 MM1209-003 8 145,990,558 146,003,49412,937 8q24.3 SEQ ID 72 SK0218-003 X 1,513,747 1,571,540 57,794 Xp22.33SEQ ID 73 SK0095-003 12 67,309,307 67,318,585 9,279 12q15 SEQ ID 74MM1132-003 6 45,929,914 46,097,897 167,984 6p12.3 SEQ ID 75 MM0142-00417 8,310,684 8,318,441 7,758 17p13.1 SEQ ID 76 MM0277-003 4 77,833,96477,842,490 8,527 4q21.1 CNV Priority SEQ ID No Type Validation by qPCRNumber SEQ ID 1 loss validated (de novo) 1 SEQ ID 2 gain not done 2 SEQID 3 loss not done 3 SEQ ID 4 loss not done 4 SEQ ID 5 loss not done 5SEQ ID 6 loss not done 6 SEQ ID 7 loss not done 7 SEQ ID 8 lossvalidated (paternal inheritance) 8 SEQ ID 9 loss validated (maternalinheritance) 9 SEQ ID 10 loss Proband Validated (Loss), maternalinheritance 10 SEQ ID 11 loss validated (maternal inheritance), loss inmaternal grandmother, 11 detected in one unaffected sibling 99797 andnot in other unaffected sibling 99798 SEQ ID 12 loss validated (maternalinheritance), detected in proband and the 12 two affected siblings SEQID 13 loss validated (maternal inheritance) 13 SEQ ID 14 gain validated(paternal inheritance)-gain was present in the affected 14 sibling aswell, affected sib and the proband has both autism and ADHD. SEQ ID 15loss validated (maternal inheritance) 15 SEQ ID 16 loss validated(maternal inheritance) 16 SEQ ID 17 loss Proband Validated (Loss),maternal inheritance in proband, US1 17 (41344) and US3 (41347), DNAunavailable for US2 SEQ ID 18 gain validated (paternal inheritance),three unaffected siblings, none 18 of them have CNV SEQ ID 19 lossvalidated (maternal inheritance) 19 SEQ ID 20 loss Proband Validated(Loss), paternal inheritance in proband and 20 unaffected sibling, butnot in affected sibling SEQ ID 21 loss validated (parents unavailable),detected in proband and affected 21 sibling, not detected in the threeunaffected siblings SEQ ID 22 loss validated (paternally inherited) 22SEQ ID 23 gain validated (unknown inheritance), mother has no CNV and 23father's DNA not available SEQ ID 24 gain validated (maternallyinherited), detected in affected sibling as 24 well SEQ ID 25 lossvalidated (paternal inheritance) 25 SEQ ID 26 gain validated (paternallyinherited), not present in the unaffected 26 sibling SEQ ID 27 lossvalidated (maternal inheritance), present in unaffected sibling 27 SEQID 28 loss validated (maternal inheritance) 28 SEQ ID 29 loss loss inthe proband (maternally inherited), and present in 29 unaffected siblingMM1165-005 SEQ ID 30 loss loss in proband (paternally inherited), notpresent in unaffected 30 sibling, present in paternal grandfather SEQ ID31 loss validated (paternal inheritance), detected in proband and 31unaffected sibling 75743 SEQ ID 32 loss validated (maternallyinherited), present in unaffected sibling 32 60512 and not in theproband 60005. SEQ ID 33 loss Proband Validated (Loss), maternalinheritance 33 SEQ ID 34 loss validated (maternal inheritance), presentin all the 3 unaffected 34 siblings SEQ ID 35 loss validated, motherdoes not have the loss, father's DNA and sib's 35 DNA is not availableSEQ ID 36 gain validated (maternal inheritance), present in affectedsibling 36 (MM0022-004) and not in the other affected sibling (MM0022-005) SEQ ID 37 loss loss in the proband and two of the affectedsiblings, mother has 37 no CNV and father's DNA is unavailable SEQ ID 38gain validated (Paternal inheritance), not present in sibling 38 SEQ ID39 gain validated (maternal inheritance)-present in unaffected femalesib 39 SK0009-005, not present in other female unaffected sib SK0009-003 SEQ ID 40 loss validated (maternal inheritance), father's DNAunavailable 40 SEQ ID 41 loss validated (maternal inheritance), presentin unaffected sibling 41 (NA0066-002) but not in the other unaffectedsibling (NA0066- 003) and affected sibling (NA0066-001) SEQ ID 42 lossProband Validated (Loss) (paternal inheritance in proband only) 42 SEQID 43 gain paternally inherited gain 43 SEQ ID 44 loss Proband Validated(Loss), present in unaffected sibling, no 44 paternal DNA available SEQID 45 loss validated (maternally inherited), unaffected sibling does nothave 45 this loss SEQ ID 46 gain Proband validated (gain), parent DNAunavailable 46 SEQ ID 47 gain validated (paternal inheritance) 47 SEQ ID48 gain validated (maternal inheritance), present in affected sibling 48(MM0022-004) and not in the other affected sibling (MM0022- 005) SEQ ID49 loss Proband Validated (Loss), maternal inheritance, present in 49affected sibling and one unaffected sibling (167372) but not in theother unaffected sibling SEQ ID 50 loss Proband Validated (Loss),present in both affected siblings, 50 parent DNA unavailable SEQ ID 51gain validated (paternal inheritance), not present in unaffected sibling51 SEQ ID 52 gain gain in the proband (maternally inherited), notpresent in the 52 other two siblings SEQ ID 53 loss validated(paternally inherited), present in one affected sibling 53 and anotherunaffected sibling SEQ ID 54 gain validated (maternally inherited), notpresent in the proband 54 SEQ ID 55 gain validated, missing parents 55SEQ ID 56 gain validated (paternally inherited), not present inunaffected and 56 affected siblings SEQ ID 57 loss validated (maternalinheritance), not present in unaffected sib 57 SEQ ID 58 loss ProbandValidated (Loss), paternal inheritance in proband only 58 SEQ ID 59 lossProband Validated (Loss) 59 SEQ ID 60 loss paternally inherited loss inproband and in unaffected sibling 60 SEQ ID 61 gain validated(maternally inherited), not detected in unaffected 61 sibling SEQ ID 62gain validated (maternally inherited), detected in both unaffected 62siblings SEQ ID 63 gain Proband Validated (Gain)(maternally inherited),present in 63 unaffected sibling SEQ ID 64 gain validated (paternallyinherited) 64 SEQ ID 65 loss maternal inherited loss in proband,affected sibling and the third 65 unaffected sibling, not present in theother two unaffected sibling SEQ ID 66 gain Proband Validated (Gain),maternal inheritance in proband and 66 affected sibling SEQ ID 67 gainpaternally inherited gain in the proband, present in unaffected 67sibling and in paternal grandfather SEQ ID 68 gain validated (maternalinheritance), not present in unaffected sib 68 SEQ ID 69 gain validated(maternal inheritance) 69 SEQ ID 70 loss Proband Validated (Loss),maternal inheritance, not present in 70 the affected sibling SEQ ID 71loss Proband Validated (Loss), paternal inheritance, not present in 71unaffected sibling SEQ ID 72 gain validated (paternal inheritance), notpresent in affected sibling 72 SEQ ID 73 loss Proband Validated (Loss),maternal inheritance in proband and 73 third unaffected sibling, notpresent in first and second unaffected siblings (no paternal DNAavailable) SEQ ID 74 gain validated (maternally inherited), not presentin unaffected sibling 74 SEQ ID 75 gain validated (maternal inheritance)75 SEQ ID 76 loss Proband Validated (Loss) (paternal inheritance), notpresent in 76 the affected sibling Hg18 March 2006 (NCBI Build 36.1)

TABLE 2 Gene Number within Gene FEATURE FEATURE FEATURE CNV Names SEQ IDNo ACCESSION VERSION START STOP SIZE 1 GPHN SEQ ID 77 NM_001024218NM_001024218.1 66043877 66718278 674401 1 GPHN SEQ ID 78 NM_020806NM_020806.4 66043877 66718278 674401 1 GPHN SEQ ID 77 NM_001024218NM_001024218.1 66043877 66718278 674401 1 GPHN SEQ ID 78 NM_020806NM_020806.4 66043877 66718278 674401 1 GPHN SEQ ID 77 NM_001024218NM_001024218.1 66043877 66718278 674401 1 GPHN SEQ ID 78 NM_020806NM_020806.4 66043877 66718278 674401 1 GPHN SEQ ID 77 NM_001024218NM_001024218.1 66043877 66718278 674401 1 GPHN SEQ ID 78 NM_020806NM_020806.4 66043877 66718278 674401 1 GPHN SEQ ID 77 NM_001024218NM_001024218.1 66043877 66718278 674401 1 GPHN SEQ ID 78 NM_020806NM_020806.4 66043877 66718278 674401 1 GPHN SEQ ID 77 NM_001024218NM_001024218.1 66043877 66718278 674401 1 GPHN SEQ ID 78 NM_020806NM_020806.4 66043877 66718278 674401 1 GPHN SEQ ID 77 NM_001024218NM_001024218.1 66043877 66718278 674401 1 GPHN SEQ ID 78 NM_020806NM_020806.4 66043877 66718278 674401 1 DPP10 SEQ ID 79 NM_001178036NM_001178036.1 114935649 116318796 1383147 1 DPP10 SEQ ID 80 NM_020868NM_020868.3 114916368 116318796 1402428 1 CNTNAP2 SEQ ID 81 NM_014141NM_014141.5 145444385 147749021 2304636 1 NRXN3 SEQ ID 82 NM_004796NM_004796.4 77939845 79400513 1460668 1 ERBB4 SEQ ID 83 NM_001042599NM_001042599.1 211948686 213111597 1162911 1 ERBB4 SEQ ID 84 NM_005235NM_005235.2 211948686 213111597 1162911 1 CNTNAP5 SEQ ID 85 NM_130773NM_130773.2 124499333 125389333 890000 1 CNTNAP5 SEQ ID 85 NM_130773NM_130773.2 124499333 125389333 890000 1 NCKAP5 SEQ ID 86 NM_207363NM_207363.2 133145841 134042501 896660 1 NCKAP5 SEQ ID 87 NM_207481NM_207481.3 133145841 134042501 896660 1 NCKAP5 SEQ ID 86 NM_207363NM_207363.2 133145841 134042501 896660 1 NCKAP5 SEQ ID 87 NM_207481NM_207481.3 133145841 134042501 896660 1 NRXN1 SEQ ID 88 NM_001135659NM_001135659.1 49999146 51113178 1114032 1 NRXN1 SEQ ID 89 NM_004801NM_004801.4 49999146 51113178 1114032 1 SLIT2 SEQ ID 90 NM_004787NM_004787.1 19864332 20229886 365554 1 CTNNA2 SEQ ID 91 NM_001164883NM_001164883.1 79593567 80729499 1135932 1 CTNNA2 SEQ ID 92 NM_004389NM_004389.3 79593567 80729499 1135932 1 DPYD SEQ ID 93 NM_000110NM_000110.3 97315887 98159203 843316 1 PRKCI SEQ ID 94 NM_002740NM_002740.5 171422913 171506464 83551 1 RGS7 SEQ ID 95 NM_002924NM_002924.4 239005439 239587101 581662 1 RGS7 SEQ ID 95 NM_002924NM_002924.4 239005439 239587101 581662 1 SAE1 SEQ ID 96 NM_001145713NM_001145713.1 52325919 52405733 79814 1 SAE1 SEQ ID 97 NM_001145714NM_001145714.1 52325919 52405733 79814 1 SAE1 SEQ ID 98 NM_005500NM_005500.2 52325919 52405733 79814 1 SAE1 SEQ ID 99 NR_027280NR_027280.1 52325954 52405733 79779 7 IGLL5 SEQ ID 100 NM_001178126NM_001178126.1 21559959 21568013 8054 7 IGLL5 SEQ ID 101 NM_001256296NM_001256296.1 21559959 21568013 8054 7 GNAZ SEQ ID 102 NM_002073NM_002073.2 21742668 21797221 54553 7 BCR SEQ ID 103 NM_004327NM_004327.3 21852551 21990224 137673 7 RAB36 SEQ ID 104 NM_004914NM_004914.2 21817512 21836531 19019 7 RTDR1 SEQ ID 105 NM_014433NM_014433.2 21731592 21814241 82649 7 BCR SEQ ID 106 NM_021574NM_021574.2 21852551 21990224 137673 7 MIR650 SEQ ID 107 NR_030755NR_030755.1 21495269 21495365 96 7 FBXW4P1 SEQ ID 108 NR_033408NR_033408.1 21934953 21937186 2233 1 GRID2 SEQ ID 109 NM_001510NM_001510.2 93444572 94912672 1468100 1 GRM8 SEQ ID 110 NM_000845NM_000845.2 125865887 126670805 804918 1 GRM8 SEQ ID 111 NM_001127323NM_001127323.1 125865887 126679664 813777 1 GRM8 SEQ ID 112 NR_028041NR_028041.1 125865887 126670805 804918 1 DMD SEQ ID 113 NM_000109NM_000109.3 31047265 33267647 2220382 1 DMD SEQ ID 114 NM_004006NM_004006.2 31047265 33139594 2092329 1 DMD SEQ ID 115 NM_004007NM_004007.2 31047265 32948238 1900973 1 DMD SEQ ID 116 NM_004009NM_004009.3 31047265 33056466 2009201 1 DMD SEQ ID 117 NM_004010NM_004010.3 31047265 33056465 2009200 1 DMD SEQ ID 113 NM_000109NM_000109.3 31047265 33267647 2220382 1 DMD SEQ ID 114 NM_004006NM_004006.2 31047265 33139594 2092329 1 MACROD2 SEQ ID 118 NM_001033087NM_001033087.1 15125503 15981841 856338 1 MACROD2 SEQ ID 119 NM_80676NM_080676.5 13924145 15981841 2057696 1 MACROD2 SEQ ID 118 NM_001033087NM_001033087.1 15125503 15981841 856338 1 MACROD2 SEQ ID 119 NM_80676NM_080676.5 13924145 15981841 2057696 1 PARK2 SEQ ID 120 NM_004562NM_004562.2 161688579 163068824 1380245 1 PARK2 SEQ ID 121 NM_013987NM_013987.2 161688579 163068824 1380245 1 PARK2 SEQ ID 122 NM_013988NM_013988.2 161688579 163068824 1380245 1 TRAP1 SEQ ID 123 NM_016292NM_016292.2 3648038 3707599 59561 1 ZBTB20 SEQ ID 124 NM_001164343NM_001164343.1 115539636 116272951 733315 1 ZBTB20 SEQ ID 125 NM_015642NM_015642.4 115539636 116348817 809181 1 ATP2C2 SEQ ID 126 NM_014861NM_014861.2 82959633 83055294 95661 1 CECR2 SEQ ID 127 NM_031413NM_031413.3 16336627 16413845 77218 1 CHRNB3 SEQ ID 128 NM_000749NM_000749.3 42671718 42711366 39648 1 CHRNB3 SEQ ID 128 NM_000749NM_000749.3 42671718 42711366 39648 1 CIB2 SEQ ID 129 NM_006383NM_006383.2 76184045 76210933 26888 1 CIB2 SEQ ID 129 NM_006383NM_006383.2 76184045 76210933 26888 1 NXPH1 SEQ ID 130 NM_152745NM_152745.2 8440109 8759118 319009 1 NXPH1 SEQ ID 130 NM_152745NM_152745.2 8440109 8759118 319009 1 PTPN9 SEQ ID 131 NM_002833NM_002833.2 73546514 73658680 112166 1 RERE SEQ ID 132 NM_001042681NM_001042681.1 8335050 8800286 465236 1 RERE SEQ ID 133 NM_012102NM_012102.3 8335050 8800286 465236 1 RERE SEQ ID 132 NM_001042681NM_001042681.1 8335050 8800286 465236 1 RERE SEQ ID 133 NM_012102NM_012102.3 8335050 8800286 465236 1 SORCS3 SEQ ID 134 NM_014978NM_014978.1 106390848 107014983 624135 1 WWTR1 SEQ ID 135 NM_001168278NM_001168278.1 150717711 150903750 186039 1 WWTR1 SEQ ID 136NM_001168280 NM_001168280.1 150717711 150858502 140791 1 WWTR1 SEQ ID137 NM_015472 NM_015472.4 150717711 150858578 140867 1 POT1 SEQ ID 138NM_001042594 NM_001042594.1 124249675 124357273 107598 1 POT1 SEQ ID 139NM_015450 NM_015450.2 124249675 124357273 107598 1 POT1 SEQ ID 140NR_003102 NR_003102.1 124249675 124357273 107598 1 POT1 SEQ ID 141NR_003103 NR_003103.1 124249675 124357273 107598 1 POT1 SEQ ID 142NR_003104 NR_003104.1 124249675 124357273 107598 1 POT1 SEQ ID 138NM_001042594 NM_001042594 124249675 124357273 107598 1 POT1 SEQ ID 139NM_015450 NM_015450.2 124249675 124357273 107598 1 POT1 SEQ ID 140NR_003102 NR_003102.1 124249675 124357273 107598 1 POT1 SEQ ID 141NR_003103 NR_003103.1 124249675 124357273 107598 1 POT1 SEQ ID 142NR_003104 NR_003104.1 124249675 124357273 107598 1 ROBO2 SEQ ID 143NM_001128929 NM_001128929.2 77229852 77781804 551952 1 ROBO2 SEQ ID 144NM_002942 NM_002942.4 77171983 77781804 609821 1 ROBO2 SEQ ID 143NM_001128929 NM_001128929.2 77229852 77781804 551952 1 ROBO2 SEQ ID 144NM_002942 NM_002942.4 77171983 77781804 609821 1 ADAM7 SEQ ID 145NM_003817 NM_003817.3 24354453 24422967 68514 1 CDH18 SEQ ID 146NM_001167667 NM_001167667.1 19508911 20024110 515199 1 CDH18 SEQ ID 147NM_004934 NM_004934.3 19508911 20024110 515199 1 DAGLA SEQ ID 148NM_006133 NM_006133.2 61204480 61271050 66570 1 FGA SEQ ID 149 NM_000508NM_000508.3 155723729 155731347 7618 1 FGA SEQ ID 150 NM_021871NM_021871.2 155725878 155731347 5469 1 MTHFD1 SEQ ID 151 NM_005956NM_005956.3 63924511 63996478 71967 1 NDST1 SEQ ID 152 NM_001543NM_001543.4 149867866 149917966 50100 1 NF1 SEQ ID 153 NM_000267NM_000267.3 26446070 26728821 282751 1 NF1 SEQ ID 154 NM_001042492NM_001042492.2 26446070 26728821 282751 1 NF1 SEQ ID 155 NM_001128147NM_001128147.2 26446070 26573908 127838 1 NFIB SEQ ID 156 NM_001190737NM_001190737.1 14071841 14304045 232204 1 NFIB SEQ ID 157 NM_001190738NM_001190738.1 14071841 14388982 317141 1 NFIB SEQ ID 158 NM_005596NM_005596.3 14071841 14304045 232204 1 PLXNA4 SEQ ID 159 NM_001105543NM_001105543.1 131718786 131911863 193077 1 PLXNA4 SEQ ID 160 NM_020911NM_020911.1 131458630 131911863 453233 1 PRDX1 SEQ ID 161 NM_001202431NM_001202431.1 45749293 45761149 11856 1 PRDX1 SEQ ID 162 NM_002574NM_002574.3 45749293 45760197 10904 1 PRDX1 SEQ ID 163 NM_181696NM_181696.2 45749293 45760197 10904 1 PRDX1 SEQ ID 164 NM_181697NM_181697.2 45749293 45760197 10904 1 SYAP1 SEQ ID 165 NM_032796NM_032796.3 16647627 16690728 43101 1 SYAP1 SEQ ID 166 NR_033181NR_033181.1 16647627 16690728 43101 1 SYAP1 SEQ ID 165 NM_032796NM_032796.3 16647627 16690728 43101 1 SYAP1 SEQ ID 166 NR_033181NR_033181.1 16647627 16690728 43101 2 LOC100653515 SEQ ID 167NM_001243540 NM_001243540.1 74398256 74410894 12638 2 LOC100653515 SEQID 168 NM_001243541 NM_001243541.1 74398256 74410894 12638 2 TIMP2 SEQID 169 NM_003255 NM_003255.4 74360653 74433067 72414 1 VPS11 SEQ ID 170NM_021729 NM_021729.4 118443702 118457898 14196 1 WASF2 SEQ ID 171NM_001201404 NM_001201404.1 27603320 27689265 85945 1 WASF2 SEQ ID 172NM_006990 NM_006990.3 27603320 27689265 85945 3 NSDHL SEQ ID 173NM_001129765 NM_001129765.1 151750166 151788563 38397 3 ZNF185 SEQ ID174 NM_001178106 NM_001178106.1 151833641 151892681 59040 3 ZNF185 SEQID 175 NM_001178107 NM_001178107.1 151833641 151892681 59040 3 ZNF185SEQ ID 176 NM_001178108 NM_001178108.1 151833641 151892681 59040 3ZNF185 SEQ ID 177 NM_001178109 NM_001178109.1 151833641 151892681 590403 ZNF185 SEQ ID 178 NM_001178110 NM_001178110.1 151833641 15189268159040 3 ZNF185 SEQ ID 179 NM_001178113 NM_001178113.1 151837064151892681 55617 3 CETN2 SEQ ID 180 NM_004344 NM_004344.1 151746526151749957 3431 3 ZNF185 SEQ ID 181 NM_007150 NM_007150.3 151833641151892681 59040 3 NSDHL SEQ ID 182 NM_015922 NM_015922.2 151750166151788563 38397 2 LRRC7 SEQ ID 183 NM_020794 NM_020794.2 6999844570361759 363314 2 PIN1L SEQ ID 184 NR_023916 NR_023916.1 7015759270158588 996 1 YWHAE SEQ ID 185 NM_006761 NM_006761.4 1194583 125030655723 1 YWHAE SEQ ID 186 NR_024058 NR_024058.1 1194583 1250306 55723 1YWHAE SEQ ID 185 NM_006761 NM_006761.4 1194583 1250306 55723 1 YWHAE SEQID 186 NR_024058 NR_024058.1 1194583 1250306 55723 1 ZNF517 SEQ ID 187NM_213605 NM_213605.2 145995064 146005333 10269 1 ZNF517 SEQ ID 187NM_213605 NM_213605.2 145995064 146005333 10269 2 ASMTL SEQ ID 188NM_001173473 NM_001173473.1 1482031 1532655 50624 2 ASMTL SEQ ID 189NM_001173474 NM_001173474.1 1482031 1531870 49839 2 ASMTL SEQ ID 190NM_004192 NM_004192.3 1482031 1531870 49839 2 P2RY8 SEQ ID 191 NM_178129NM_178129.4 1541465 1616037 74572 1 RAP1B SEQ ID 192 NM_001010942NM_001010942.2 67290885 67340653 49768 1 RAP1B SEQ ID 193 NM_001251917NM_001251917.1 67290885 67340653 49768 1 RAP1B SEQ ID 194 NM_001251918NM_001251918.1 67290885 67340653 49768 1 RAP1B SEQ ID 195 NM_001251921NM_001251921.1 67290885 67340653 49768 1 RAP1B SEQ ID 196 NM_001251922NM_001251922.1 67290885 67340653 49768 1 RAP1B SEQ ID 197 NM_015646NM_015646.5 67290885 67340653 49768 1 CLIC5 SEQ ID 198 NM_001114086NM_001114086.1 45974165 46156044 181879 1 CLIC5 SEQ ID 199 NM_001256023NM_001256023.1 45987337 46091585 104248 1 CLIC5 SEQ ID 200 NM_016929NM_016929.4 45974165 46091585 117420 1 CLIC5 SEQ ID 201 NR_045672NR_045672.1 45974165 46013312 39147 1 CLIC5 SEQ ID 202 NR_045673NR_045673.1 45974165 46013312 39147 1 CLIC5 SEQ ID 203 NR_045674NR_045674.1 45987337 46013312 25975 2 NDEL1 SEQ ID 204 NM_001025579NM_001025579.2 8279894 8312220 32326 2 MYH10 SEQ ID 205 NM_001256012NM_001256012.1 8318247 8474804 156557 2 MYH10 SEQ ID 206 NM_001256095NM_001256095.1 8318247 8474804 156557 2 MYH10 SEQ ID 207 NM_005964NM_005964.3 8318247 8474804 156557 2 NDEL1 SEQ ID 208 NM_030808NM_030808.4 8279894 8312220 32326 1 SHROOM3 SEQ ID 209 NM_020859NM_020859.3 77575276 77923429 348153 Gene Number within Gene PriorityCNV Names SEQ ID No Gene Description Number 1 GPHN SEQ ID 77 gephyrin(GPHN), transcript variant 2, 1 mRNA 1 GPHN SEQ ID 78 gephyrin (GPHN),transcript variant 1, 1 mRNA 1 GPHN SEQ ID 77 gephyrin (GPHN),transcript variant 2, 1 mRNA 1 GPHN SEQ ID 78 gephyrin (GPHN),transcript variant 1, 1 mRNA 1 GPHN SEQ ID 77 gephyrin (GPHN),transcript variant 2, 1 mRNA 1 GPHN SEQ ID 78 gephyrin (GPHN),transcript variant 1, 1 mRNA 1 GPHN SEQ ID 77 gephyrin (GPHN),transcript variant 2, 1 mRNA 1 GPHN SEQ ID 78 gephyrin (GPHN),transcript variant 1, 1 mRNA 1 GPHN SEQ ID 77 gephyrin (GPHN),transcript variant 2, 1 mRNA 1 GPHN SEQ ID 78 gephyrin (GPHN),transcript variant 1, 1 mRNA 1 GPHN SEQ ID 77 gephyrin (GPHN),transcript variant 2, 1 mRNA 1 GPHN SEQ ID 78 gephyrin (GPHN),transcript variant 1, 1 mRNA 1 GPHN SEQ ID 77 gephyrin (GPHN),transcript variant 2, 1 mRNA 1 GPHN SEQ ID 78 gephyrin (GPHN),transcript variant 1, 1 mRNA 1 DPP10 SEQ ID 79 dipeptidyl-peptidase 10(non-functional) 1 (DPP10), transcript variant 5, mRNA 1 DPP10 SEQ ID 80dipeptidyl-peptidase 10 (non-functional) 1 (DPP10), transcript variant1, mRNA 1 CNTNAP2 SEQ ID 81 contactin associated protein-like 2 1(CNTNAP2), mRNA 1 NRXN3 SEQ ID 82 neurexin 3 (NRXN3), transcript variant1, 1 mRNA 1 ERBB4 SEQ ID 83 v-erb-a erythroblastic leukemia viral 1oncogene homolog 4 (avian) (ERBB4), transcript variant JM-a/CVT-2, mRNA1 ERBB4 SEQ ID 84 v-erb-a erythroblastic leukemia viral 1 oncogenehomolog 4 (avian) (ERBB4), transcript variant JM-a/CVT-1, mRNA 1 CNTNAP5SEQ ID 85 contactin associated protein-like 5 1 (CNTNAP5), mRNA 1CNTNAP5 SEQ ID 85 contactin associated protein-like 5 1 (CNTNAP5), mRNA1 NCKAP5 SEQ ID 86 NCK-associated protein 5 (NCKAP5), 1 transcriptvariant 1, mRNA 1 NCKAP5 SEQ ID 87 Homo sapiens NCK-associated protein 51 (NCKAP5), transcript variant 2, mRNA 1 NCKAP5 SEQ ID 86 NCK-associatedprotein 5 (NCKAP5), 1 transcript variant 1, mRNA 1 NCKAP5 SEQ ID 87 Homosapiens NCK-associated protein 5 1 (NCKAP5), transcript variant 2, mRNA1 NRXN1 SEQ ID 88 neurexin 1 (NRXN1), transcript variant 1 alpha2, mRNA1 NRXN1 SEQ ID 89 neurexin 1 (NRXN1), transcript variant 1 alpha1, mRNA1 SLIT2 SEQ ID 90 slit homolog 2 (Drosophila) (SLIT2), 1 mRNA 1 CTNNA2SEQ ID 91 catenin (cadherin-associated protein), 1 alpha 2 (CTNNA2),transcript variant 2, mRNA 1 CTNNA2 SEQ ID 92 catenin(cadherin-associated protein), 1 alpha 2 (CTNNA2), transcript variant 1,mRNA 1 DPYD SEQ ID 93 dihydropyrimidine dehydrogenase 1 (DPYD),transcript variant 1, mRNA 1 PRKCI SEQ ID 94 protein kinase C, iota(PRKCI), mRNA 1 1 RGS7 SEQ ID 95 regulator of G-protein signaling 7(RGS7), 1 mRNA 1 RGS7 SEQ ID 95 regulator of G-protein signaling 7(RGS7), 1 mRNA 1 SAE1 SEQ ID 96 SUMO1 activating enzyme subunit 1 1(SAE1), transcript variant 2, mRNA 1 SAE1 SEQ ID 97 SUMO1 activatingenzyme subunit 1 1 (SAE1), transcript variant 3, mRNA 1 SAE1 SEQ ID 98SUMO1 activating enzyme subunit 1 1 (SAE1), transcript variant 1, mRNA 1SAE1 SEQ ID 99 SUMO1 activating enzyme subunit 1 1 (SAE1), transcriptvariant 4, non-coding RNA 7 IGLL5 SEQ ID 100 immunoglobulin lambda-likepolypeptide 5 7 (IGLL5), transcript variant 1, mRNA 7 IGLL5 SEQ ID 101Homo sapiens immunoglobulin lambda- 7 like polypeptide 5 (IGLL5),transcript variant 2, mRNA 7 GNAZ SEQ ID 102 guanine nucleotide bindingprotein (G 7 protein), alpha z polypeptide (GNAZ), mRNA 7 BCR SEQ ID 103breakpoint cluster region (BCR), transcript 7 variant 1, mRNA 7 RAB36SEQ ID 104 RAB36, member RAS oncogene family 7 (RAB36), mRNA 7 RTDR1 SEQID 105 rhabdoid tumor deletion region gene 1 7 (RTDR1), mRNA 7 BCR SEQID 106 breakpoint cluster region (BCR), transcript 7 variant 2, mRNA 7MIR650 SEQ ID 107 microRNA 650 (MIR650), microRNA 7 7 FBXW4P1 SEQ ID 108F-box and WD repeat domain containing 4 1 pseudogene 1 (FBXW4P1),non-coding RNA 1 GRID2 SEQ ID 109 glutamate receptor, ionotropic, delta2 1 (GRID2), mRNA 1 GRM8 SEQ ID 110 glutamate receptor, metabotropic 8 1(GRM8), transcript variant 1, mRNA 1 GRM8 SEQ ID 111 glutamate receptor,metabotropic 8 1 (GRM8), transcript variant 2, mRNA 1 GRM8 SEQ ID 112glutamate receptor, metabotropic 8 1 (GRM8), transcript variant 3,non-coding RNA 1 DMD SEQ ID 113 dystrophin (DMD), transcript variant 1Dp427c, mRNA 1 DMD SEQ ID 114 dystrophin (DMD), transcript variant 1Dp427m, mRNA 1 DMD SEQ ID 115 dystrophin (DMD), transcript variant 1Dp427l, mRNA 1 DMD SEQ ID 116 dystrophin (DMD), transcript variant 1Dp427p1, mRNA 1 DMD SEQ ID 117 dystrophin (DMD), transcript variant 1Dp427p2, mRNA 1 DMD SEQ ID 113 dystrophin (DMD), transcript variant 1Dp427c, mRNA 1 DMD SEQ ID 114 dystrophin (DMD), transcript variant 1Dp427m, mRNA 1 MACROD2 SEQ ID 118 MACRO domain containing 2 1 (MACROD2),transcript variant 2, mRNA 1 MACROD2 SEQ ID 119 MACRO domain containing2 1 (MACROD2), transcript variant 1, mRNA 1 MACROD2 SEQ ID 118 MACROdomain containing 2 1 (MACROD2), transcript variant 2, mRNA 1 MACROD2SEQ ID 119 MACRO domain containing 2 1 (MACROD2), transcript variant 1,mRNA 1 PARK2 SEQ ID 120 parkinson protein 2, E3 ubiquitin protein 1ligase (parkin) (PARK2), transcript variant 1, mRNA 1 PARK2 SEQ ID 121parkinson protein 2, E3 ubiquitin protein 1 ligase (parkin) (PARK2),transcript variant 2, mRNA 1 PARK2 SEQ ID 122 parkinson protein 2, E3ubiquitin protein 1 ligase (parkin) (PARK2), transcript variant 3, mRNA1 TRAP1 SEQ ID 123 TNF receptor-associated protein 1 1 (TRAP1), mRNA 1ZBTB20 SEQ ID 124 zinc finger and BTB domain containing 20 1 (ZBTB20),transcript variant 3, mRNA 1 ZBTB20 SEQ ID 125 zinc finger and BTBdomain containing 20 1 (ZBTB20), transcript variant 2, mRNA 1 ATP2C2 SEQID 126 ATPase, Ca++ transporting, type 2C, 1 member 2 (ATP2C2), mRNA 1CECR2 SEQ ID 127 cat eye syndrome chromosome region, 1 candidate 2(CECR2), mRNA 1 CHRNB3 SEQ ID 128 cholinergic receptor, nicotinic, beta3 1 (CHRNB3), mRNA 1 CHRNB3 SEQ ID 128 cholinergic receptor, nicotinic,beta 3 1 (CHRNB3), mRNA 1 CIB2 SEQ ID 129 calcium and integrin bindingfamily 1 member 2 (CIB2), mRNA 1 CIB2 SEQ ID 129 calcium and integrinbinding family 1 member 2 (CIB2), mRNA 1 NXPH1 SEQ ID 130 neurexophilin1 (NXPH1), mRNA 1 1 NXPH1 SEQ ID 130 neurexophilin 1 (NXPH1), mRNA 1 1PTPN9 SEQ ID 131 protein tyrosine phosphatase, non- 1 receptor type 9(PTPN9), mRNA 1 RERE SEQ ID 132 Homo sapiens arginine-glutamic acid 1dipeptide (RE) repeats (RERE), transcript variant 2, mRNA. 1 RERE SEQ ID133 Homo sapiens arginine-glutamic acid 1 dipeptide (RE) repeats (RERE),transcript variant 1, mRNA 1 RERE SEQ ID 132 Homo sapiensarginine-glutamic acid 1 dipeptide (RE) repeats (RERE), transcriptvariant 2, mRNA. 1 RERE SEQ ID 133 Homo sapiens arginine-glutamic acid 1dipeptide (RE) repeats (RERE), transcript variant 1, mRNA 1 SORCS3 SEQID 134 sortilin-related VPS10 domain containing 1 receptor 3 (SORCS3),mRNA 1 WWTR1 SEQ ID 135 WW domain containing transcription 1 regulator 1(WWTR1), transcript variant 2, mRNA 1 WWTR1 SEQ ID 136 WW domaincontaining transcription 1 regulator 1 (WWTR1), transcript variant 3,mRNA 1 WWTR1 SEQ ID 137 WW domain containing transcription 1 regulator 1(WWTR1), transcript variant 1, mRNA 1 POT1 SEQ ID 138 protection oftelomeres 1 homolog (S. pombe) 1 (POT1), transcript variant 4, mRNA 1POT1 SEQ ID 139 protection of telomeres 1 homolog (S. pombe) 1 (POT1),transcript variant 1, mRNA 1 POT1 SEQ ID 140 protection of telomeres 1homolog (S. pombe) 1 (POT1), transcript variant 2, non- coding RNA 1POT1 SEQ ID 141 protection of telomeres 1 homolog (S. pombe) 1 (POT1),transcript variant 3, non- coding RNA 1 POT1 SEQ ID 142 protection oftelomeres 1 homolog (S. pombe) 1 (POT1), transcript variant 5, non-coding RNA 1 POT1 SEQ ID 138 protection of telomeres 1 homolog (S.pombe) 1 (POT1), transcript variant 4, mRNA 1 POT1 SEQ ID 139 protectionof telomeres 1 homolog (S. pombe) 1 (POT1), transcript variant 1, mRNA 1POT1 SEQ ID 140 protection of telomeres 1 homolog (S. pombe) 1 (POT1),transcript variant 2, non- coding RNA 1 POT1 SEQ ID 141 protection oftelomeres 1 homolog (S. pombe) 1 (POT1), transcript variant 3, non-coding RNA 1 POT1 SEQ ID 142 protection of telomeres 1 homolog (S.pombe) 1 (POT1), transcript variant 5, non- coding RNA 1 ROBO2 SEQ ID143 roundabout, axon guidance receptor, 1 homolog 2 (Drosophila)(ROBO2), transcript variant 1, mRNA 1 ROBO2 SEQ ID 144 roundabout, axonguidance receptor, 1 homolog 2 (Drosophila) (ROBO2), transcript variant2, mRNA 1 ROBO2 SEQ ID 143 roundabout, axon guidance receptor, 1 homolog2 (Drosophila) (ROBO2), transcript variant 1, mRNA 1 ROBO2 SEQ ID 144roundabout, axon guidance receptor, 1 homolog 2 (Drosophila) (ROBO2),transcript variant 2, mRNA 1 ADAM7 SEQ ID 145 ADAM metallopeptidasedomain 7 1 (ADAM7), mRNA 1 CDH18 SEQ ID 146 cadherin 18, type 2 (CDH18),transcript 1 variant 2, mRNA 1 CDH18 SEQ ID 147 cadherin 18, type 2(CDH18), transcript 1 variant 1, mRNA 1 DAGLA SEQ ID 148 diacylglycerollipase, alpha (DAGLA), 1 mRNA 1 FGA SEQ ID 149 fibrinogen alpha chain(FGA), transcript 1 variant alpha-E, mRNA 1 FGA SEQ ID 150 fibrinogenalpha chain (FGA), transcript 1 variant alpha, mRNA 1 MTHFD1 SEQ ID 151methylenetetrahydrofolate dehydrogenase 1 (NADP+ dependent) 1,methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolatesynthetase (MTHFD1), mRNA 1 NDST1 SEQ ID 152N-deacetylase/N-sulfotransferase 1 (heparan glucosaminyl) 1 (NDST1),mRNA 1 NF1 SEQ ID 153 neurofibromin 1 (NF1), transcript variant 2, 1mRNA 1 NF1 SEQ ID 154 neurofibromin 1 (NF1), transcript variant 1, 1mRNA 1 NF1 SEQ ID 155 neurofibromin 1 (NF1), transcript variant 3, 1mRNA 1 NFIB SEQ ID 156 nuclear factor I/B (NFIB), transcript variant 11, mRNA 1 NFIB SEQ ID 157 nuclear factor I/B (NFIB), transcript variant1 2, mRNA 1 NFIB SEQ ID 158 nuclear factor I/B (NFIB), transcriptvariant 1 3, mRNA 1 PLXNA4 SEQ ID 159 plexin A4 (PLXNA4), transcriptvariant 3, 1 mRNA 1 PLXNA4 SEQ ID 160 plexin A4 (PLXNA4), transcriptvariant 1, 1 mRNA 1 PRDX1 SEQ ID 161 peroxiredoxin 1 (PRDX1), transcript1 variant 4, mRNA 1 PRDX1 SEQ ID 162 peroxiredoxin 1 (PRDX1), transcript1 variant 1, mRNA 1 PRDX1 SEQ ID 163 peroxiredoxin 1 (PRDX1), transcript1 variant 2, mRNA 1 PRDX1 SEQ ID 164 peroxiredoxin 1 (PRDX1), transcript1 variant 3, mRNA 1 SYAP1 SEQ ID 165 synapse associated protein 1(SYAP1), 1 transcript variant 1, mRNA 1 SYAP1 SEQ ID 166 synapseassociated protein 1 (SYAP1), 1 transcript variant 2, non-coding RNA 1SYAP1 SEQ ID 165 synapse associated protein 1 (SYAP1), 1 transcriptvariant 1, mRNA 1 SYAP1 SEQ ID 166 synapse associated protein 1 (SYAP1),1 transcript variant 2, non-coding RNA 2 LOC100653515 SEQ ID 167differential display clone 8 2 (LOC100653515), transcript variant 2,mRNA 2 LOC100653515 SEQ ID 168 differential display clone 8 2(LOC100653515), transcript variant 2, mRNA 2 TIMP2 SEQ ID 169 TIMPmetallopeptidase inhibitor 2 2 (TIMP2), mRNA 1 VPS11 SEQ ID 170 vacuolarprotein sorting 11 homolog (S. cerevisiae) 1 (VPS11), mRNA 1 WASF2 SEQID 171 WAS protein family, member 2 (WASF2), 1 transcript variant 2,mRNA 1 WASF2 SEQ ID 172 WAS protein family, member 2 (WASF2), 1transcript variant 1, mRNA 3 NSDHL SEQ ID 173 NAD(P) dependent steroid 3dehydrogenase-like (NSDHL), transcript variant 2, mRNA 3 ZNF185 SEQ ID174 zinc finger protein 185 (LIM domain) 3 (ZNF185), transcript variant1, mRNA 3 ZNF185 SEQ ID 175 zinc finger protein 185 (LIM domain) 3(ZNF185), transcript variant 2, mRNA 3 ZNF185 SEQ ID 176 Homo sapienszinc finger protein 185 (LIM 3 domain) (ZNF185), transcript variant 3,mRNA 3 ZNF185 SEQ ID 177 zinc finger protein 185 (LIM domain) 3(ZNF185), transcript variant 5, mRNA 3 ZNF185 SEQ ID 178 zinc fingerprotein 185 (LIM domain) 3 (ZNF185), transcript variant 6, mRNA 3 ZNF185SEQ ID 179 zinc finger protein 185 (LIM domain) 3 (ZNF185), transcriptvariant 7, mRNA 3 CETN2 SEQ ID 180 centrin, EF-hand protein, 2 (CETN2),3 mRNA 3 ZNF185 SEQ ID 181 zinc finger protein 185 (LIM domain) 3(ZNF185), transcript variant 4, mRNA 3 NSDHL SEQ ID 182 NAD(P) dependentsteroid 3 dehydrogenase-like (NSDHL), transcript variant 1, mRNA 2 LRRC7SEQ ID 183 leucine rich repeat containing 7 (LRRC7), 2 mRNA 2 PIN1L SEQID 184 peptidylprolyl cis/trans isomerase, NIMA- 2 interacting 1pseudogene 1 (PIN1P1), non-coding RNA 1 YWHAE SEQ ID 185 tyrosine3-monooxygenase/tryptophan 5- 1 monooxygenase activation protein,epsilon polypeptide (YWHAE), transcript variant 1, mRNA 1 YWHAE SEQ ID186 tyrosine 3-monooxygenase/tryptophan 5- 1 monooxygenase activationprotein, epsilon polypeptide (YWHAE), transcript variant 2, non-codingRNA 1 YWHAE SEQ ID 185 tyrosine 3-monooxygenase/tryptophan 5- 1monooxygenase activation protein, epsilon polypeptide (YWHAE),transcript variant 1, mRNA 1 YWHAE SEQ ID 186 tyrosine3-monooxygenase/tryptophan 5- 1 monooxygenase activation protein,epsilon polypeptide (YWHAE), transcript variant 2, non-coding RNA 1ZNF517 SEQ ID 187 zinc finger protein 517 (ZNF517), mRNA 1 1 ZNF517 SEQID 187 zinc finger protein 517 (ZNF517), mRNA 2 ASMTL SEQ ID 188acetylserotonin O-methyltransferase-like 2 (ASMTL), transcript variant2, mRNA 2 ASMTL SEQ ID 189 acetylserotonin O-methyltransferase-like 2(ASMTL), transcript variant 3, mRNA 2 ASMTL SEQ ID 190 acetylserotoninO-methyltransferase-like 2 (ASMTL), transcript variant 1, mRNA 2 P2RY8SEQ ID 191 purinergic receptor P2Y, G-protein 2 coupled, 8 (P2RY8), mRNA1 RAP1B SEQ ID 192 RAP1B, member of RAS oncogene family 1 (RAP1B),transcript variant 2, mRNA 1 RAP1B SEQ ID 193 Homo sapiens RAP1B, memberof RAS 1 oncogene family (RAP1B), transcript variant 3, mRNA 1 RAP1B SEQID 194 Homo sapiens RAP1B, member of RAS 1 oncogene family (RAP1B),transcript variant 4, mRNA 1 RAP1B SEQ ID 195 Homo sapiens RAP1B, memberof RAS 1 oncogene family (RAP1B), transcript variant 5, mRNA 1 RAP1B SEQID 196 Homo sapiens RAP1B, member of RAS 1 oncogene family (RAP1B),transcript variant 6, mRNA 1 RAP1B SEQ ID 197 RAP1B, member of RASoncogene family 1 (RAP1B), transcript variant 1, mRNA 1 CLIC5 SEQ ID 198chloride intracellular channel 5 (CLIC5), 1 nuclear gene encodingmitochondrial protein, transcript variant 1, mRNA 1 CLIC5 SEQ ID 199Homo sapiens chloride intracellular 1 channel 5 (CLIC5), nuclear geneencoding mitochondrial protein, transcript variant 3, mRNA 1 CLIC5 SEQID 200 chloride intracellular channel 5 (CLIC5), 1 nuclear gene encodingmitochondrial protein, transcript variant 2, mRNA 1 CLIC5 SEQ ID 201Homo sapiens chloride intracellular 1 channel 5 (CLIC5), transcriptvariant 4, non-coding RNA 1 CLIC5 SEQ ID 202 Homo sapiens chlorideintracellular 1 channel 5 (CLIC5), transcript variant 5, non-coding RNA1 CLIC5 SEQ ID 203 Homo sapiens chloride intracellular 1 channel 5(CLIC5), transcript variant 6, non-coding RNA 2 NDEL1 SEQ ID 204 nudEnuclear distribution gene E homolog 2 (A. nidulans)-like 1 (NDEL1),transcript variant 1, mRNA 2 MYH10 SEQ ID 205 Homo sapiens myosin, heavychain 10, 2 non-muscle (MYH10), transcript variant 1, mRNA 2 MYH10 SEQID 206 Homo sapiens myosin, heavy chain 10, 2 non-muscle (MYH10),transcript variant 3, mRNA 2 MYH10 SEQ ID 207 myosin, heavy chain 10,non-muscle 2 (MYH10), mRNA 2 NDEL1 SEQ ID 208 nudE nuclear distributiongene E homolog 2 (A. nidulans)-like 1 (NDEL1), transcript variant 2,mRNA 1 SHROOM3 SEQ ID 209 shroom family member 3 (SHROOM3), 1 mRNA Hg18March 2006 (NCBI Build 36.1)

Computer-Implemented Aspects

As understood by those of ordinary skill in the art, the methods andinformation described herein (genetic variation association withdevelopmental disorders) can be implemented, in all or in part, ascomputer execuTable instructions on known computer readable media. Forexample, the methods described herein can be implemented in hardware.Alternatively, the method can be implemented in software stored in, forexample, one or more memories or other computer readable medium andimplemented on one or more processors. As is known, the processors canbe associated with one or more controllers, calculation units and/orother units of a computer system, or implanted in firmware as desired.If implemented in software, the routines can be stored in any computerreadable memory such as in RAM, ROM, flash memory, a magnetic disk, alaser disk, or other storage medium, as is also known. Likewise, thissoftware can be delivered to a computing device via any known deliverymethod including, for example, over a communication channel such as atelephone line, the Internet, a wireless connection, etc., or via atransporTable medium, such as a computer readable disk, flash drive,etc.

More generally, and as understood by those of ordinary skill in the art,the various steps described above can be implemented as various blocks,operations, tools, modules and techniques which, in turn, can beimplemented in hardware, firmware, software, or any combination ofhardware, firmware, and/or software. When implemented in hardware, someor all of the blocks, operations, techniques, etc. can be implementedin, for example, a custom integrated circuit (IC), an applicationspecific integrated circuit (ASIC), a field programmable logic array(FPGA), a programmable logic array (PLA), etc.

Results from such genotyping can be stored in a data storage unit, suchas a data carrier, including computer databases, data storage disks, orby other convenient data storage means. In certain embodiments, thecomputer database is an object database, a relational database or apost-relational database. Data can be retrieved from the data storageunit using any convenient data query method.

When implemented in software, the software can be stored in any knowncomputer readable medium such as on a magnetic disk, an optical disk, orother storage medium, in a RAM or ROM or flash memory of a computer,processor, hard disk drive, optical disk drive, tape drive, etc.Likewise, the software can be delivered to a user or a computing systemvia any known delivery method including, for example, on a computerreadable disk or other transporTable computer storage mechanism.

The steps of the claimed methods can be operational with numerous othergeneral purpose or special purpose computing system environments orconfigurations. Examples of well known computing systems, environments,and/or configurations that can be suitable for use with the methods orsystem of the claims include, but are not limited to, personalcomputers, server computers, hand-held or laptop devices, multiprocessorsystems, microprocessor-based systems, set top boxes, programmableconsumer electronics, network PCs, minicomputers, mainframe computers,distributed computing environments that include any of the above systemsor devices, and the like.

The steps of the claimed method and system can be described in thegeneral context of computer-execuTable instructions, such as programmodules, being executed by a computer. Generally, program modulesinclude routines, programs, objects, components, and/or data structuresthat perform particular tasks or implement particular abstract datatypes. The methods and apparatus can also be practiced in distributedcomputing environments where tasks are performed by remote processingdevices that are linked through a communications network. In bothintegrated and distributed computing environments, program modules canbe located in both local and remote computer storage media includingmemory storage devices. Numerous alternative embodiments could beimplemented, using either current technology or technology developedafter the filing date of this application, which would still fall withinthe scope of the claims defining the disclosure.

While the risk evaluation system and method, and other elements, havebeen described as preferably being implemented in software, they can beimplemented in hardware, firmware, etc., and can be implemented by anyother processor. Thus, the elements described herein can be implementedin a standard multi-purpose CPU or on specifically designed hardware orfirmware such as an application-specific integrated circuit (ASIC) orother hard-wired device as desired. When implemented in software, thesoftware routine can be stored in any computer readable memory such ason a magnetic disk, a laser disk, or other storage medium, in a RAM orROM of a computer or processor, in any database, etc. Likewise, thissoftware can be delivered to a user or a screening system via any knownor desired delivery method including, for example, on a computerreadable disk or other transporTable computer storage mechanism or overa communication channel, for example, a telephone line, the internet, orwireless communication. Modifications and variations can be made in thetechniques and structures described and illustrated herein withoutdeparting from the spirit and scope of the present disclosure.

ASD Therapeutics

Resarch into a cure for Pervasive Developmental Disorders (PDD), such asASD or Pervasive Developmental Disorders—Not Otherwise Specified(PDD-NOS), such as Asperger Syndrome, Rett Syndrome, fragile X syndrome,and/or Childhood Disintegrative Disorder is ongoing. Ways to helpminimize the symptoms of autism and to maximize learning exist,including but not limited to, behavioral therapy, educational and/orschool-based options, and medication options, although currently thereare no medications that can cure autism spectrum disorders or all of thesymptoms. The U.S. Food and Drug Administration has not yet approved anymedications specifically for the treatment of autism, but in many casesmedication can treat some of the symptoms associated with autism. Thesetreatments can include behavior management therapy to help reinforcewanted behaviors and reduce unwanted behaviors, which is often based onApplied Behavior Analysis (ABA), use of speech-language therapists tohelp people with autism improve their ability to communicate andinteract with others, use of occupational therapists to help people findways to adjust tasks to match their needs and abilities, and physicaltherapists design activities and exercise to build motor control andimprove posture and balance, free appropriate public education from age3 through high school or age 21, integration of a team of people,including the parents, teachers, caregivers, school psychologists, andother child development specialists to work together to design anIndividualized Education Plan (IEP) to help guide the child's schoolexperiences, selective serotonin reuptake inhibitors (SSRIs),tricyclics, psychoactive/anti-psychotics, stimulants, and anti-anxietydrugs are among the medications that a health care provider might use totreat symptoms of autism spectrum disorders.

A person skilled in the art will appreciate and understand that thegenetic variants described herein in general may not, by themselves,provide an absolute identification of individuals who will develop adevelopmental disorder or related conditions. The variants describedherein can indicate increased and/or decreased likelihood thatindividuals carrying the at-risk or protective variants of thedisclosure will develop symptoms associated with a developmentaldisorder. This information can be used to, for example, initiatepreventive measures at an early stage, perform regular physical and/ormental exams to monitor the progress and/or appearance of symptoms, orto schedule exams at a regular interval to identify early symptoms, soas to be able to apply treatment at an early stage. This is inparticular important since developmental disorders and related disordersare heterogeneous disorders with symptoms that can be individuallyvague. Screening criteria require a number of symptoms to be presentover a period of time; therefore, it is important to be able toestablish additional risk factors that can aid in the screening, orfacilitate the screening through in-depth phenotyping and/or morefrequent examination, or both. For example, individuals with earlysymptoms that typically are not individually associated with a clinicalscreening of a developmental disorder and carry an at-risk geneticvariation can benefit from early therapeutic treatment, or otherpreventive measure, or more rigorous supervision or more frequentexamination. Likewise, individuals that have a family history of thedisease, or are carriers of other risk factors associated with adevelopmental disorder can, in the context of additionally carrying atleast one at-risk genetic variation, benefit from early therapy or othertreatment.

Early symptoms of behavioral disorders such as a developmental disorderand related conditions may not be sufficient to fulfill standardizedscreening criteria. To fulfill those, a certain pattern of symptoms andbehavioral disturbance needs to manifest itself over a period of time.Sometimes, certain physical characteristics can also be present. Thismakes at-risk genetic variants valuable in a screening setting, inparticular high-risk variants. Determination of the presence of suchvariants warrants increased monitoring of the individual in question.Appearance of symptoms combined with the presence of such variantsfacilitates early screening, which makes early treatment possible.Genetic testing can thus be used to aid in the screening of disease inits early stages, before all criteria for formal screening criteria areall fulfilled. It is well established that early treatment is extremelyimportant for developmental disorders and related disorders, which lendsfurther support to the value of genetic testing for early diagnosis,prognosis, or theranosis of these disorders.

The present disclosure provides methods for identifying compounds oragents that can be used to treat a developmental disorder. Thus, thegenetic variations and associated proteins of the disclosure are usefulas targets for the identification and/or development of therapeuticagents. In certain embodiments, such methods include assaying theability of an agent or compound to modulate the activity and/orexpression of a nucleic acid that is associated with at least onegenetic variation described herein (Table 1), encoded products of thegene sequence, and any other molecules or proteins associated with thesegenes. This in turn can be used to identify agents or compounds thatinhibit, enhance, or alter the undesired activity, localization, bindingand/or expression of the encoded nucleic acid product, such as mRNA orpolypeptides. For example, in some embodiments, small molecule drugs canbe developed to target the aberrant protein(s) or RNA(s) resulting fromspecific disease-causing mutation(s) within a gene, such as describedin: Peitz et al. (2009) RNA Biology 6(3):329-34; Van Goor et al. (2009)Proc. Natl. Acad. Sci. USA 106(44):18825-30; Van Goor et al. (2011)Proc. Natl. Acad. Sci. USA 108(46):18843-8; Ramsey et al. (2011) N.Engl. J. Med. 365(18):1663-72. The proteins associated with the CNVslisted in Table 1 are described in Table 2 as the accession number(accession) of mRNAs that would encode said proteins. Assays forperforming such experiments can be performed in cell-based systems or incell-free systems, as known to the skilled person. Cell-based systemsinclude cells naturally expressing the nucleic acids of interest, orrecombinant cells that have been genetically modified so as to express acertain desired nucleic acid molecule.

Variant gene expression in a subject can be assessed by expression of avariant-containing nucleic acid sequence or by altered expression of anormal/wild-type nucleic acid sequence due to variants affecting thelevel or pattern of expression of the normal transcripts, for example,variants in the regulatory or control region of the gene. Assays forgene expression include direct nucleic acid assays (mRNA), assays forexpressed protein levels, or assays of collateral compounds involved ina pathway, for example, a signal pathway. Furthermore, the expression ofgenes that are up- or down-regulated in response to the signal pathwaycan also be assayed. Some embodiments includes operably linking areporter gene, such as luciferase, to the regulatory region of one ormore gene of interest.

Modulators of gene expression can in some embodiments be identified whena cell is contacted with a candidate compound or agent, and theexpression of mRNA is determined. The expression level of mRNA in thepresence of the candidate compound or agent is compared to theexpression level in the absence of the compound or agent. Based on thiscomparison, candidate compounds or agents for treating a developmentaldisorder can be identified as those modulating the gene expression ofthe variant gene, or gene expression of one or more other genesoccurring within the same biological pathway or known, for example, tobe binding partners of the variant gene. When expression of mRNA or theencoded protein is statistically significantly greater in the presenceof the candidate compound or agent than in its absence, then thecandidate compound or agent is identified as a stimulator orup-regulator of expression of the nucleic acid. When nucleic acidexpression or protein level is statistically significantly less in thepresence of the candidate compound or agent than in its absence, thenthe candidate compound can be identified as an inhibitor ordown-regulator of the nucleic acid expression. The disclosure furtherprovides methods of treatment using a compound identified through drug(compound and/or agent) screening as a gene modulator.

The genetic variations described herein can be used to identify noveltherapeutic targets for a developmental disorder. For example, genescontaining, or in linkage disequilibrium with, the genetic variations,or their products, as well as genes or their products that are directlyor indirectly regulated by or interact with these variant genes or theirproducts, can be targeted for the development of therapeutic agents totreat a developmental disorder, or prevent or delay onset of symptomsassociated with a developmental disorder. Therapeutic agents cancomprise one or more of, for example, small non-protein and non-nucleicacids, proteins, peptides, protein fragments, nucleic acids (DNA, RNAJ,PNA (peptide nucleic acids), or their derivatives or mimetics which canmodulate the function and/or levels of the target genes or their geneproducts. In some embodiments, treatment of ASD can comprise treatmentof one of the genes, or gene products derived thereof, such as mRNA or apolypeptide, with one or more of the therapeutics disclosed herein. Insome embodiments, treatment of ASD can comprise treatment of 2 or 3, or4, or 5, or 6, or 7, or 8, or 9, or 10 or more of the genes, or geneproducts derived there from, with 2 or 3, or 4, or 5, or 6, or 7, or 8,or 9, or 10 or more of the therapeutics disclosed herein.

RNA therapeutics

The nucleic acids and/or variants of the disclosure, or nucleic acidscomprising their complementary sequence, can be used as antisenseconstructs to control gene expression in cells, tissues or organs. Themethodology associated with antisense techniques is well known to theskilled artisan, and is described and reviewed in Antisense DrugTechnology: Principles, Strategies, and Applications, Crooke, MarcelDekker Inc., New York (2001) In general, antisense nucleic acids aredesigned to be complementary to a region of mRNA expressed by a gene, sothat the antisense molecule hybridizes to the mRNA, thus blockingtranslation of the mRNA into protein Several classes of antisenseoligonucleotide are known to those skilled in the art, includingcleavers and blockers. The former bind to target RNA sites, activateintracellular nucleases {e.g., Rnase H or Rnase L) that cleave thetarget RNA. Blockers bind to target RNA, inhibit protein translation bysteric hindrance of the ribosomes. Examples of blockers include nucleicacids, morpholino compounds, locked nucleic acids and methylphosphonates(Thompson, Drug Discovery Today, 7:912-917 (2002)) Antisenseoligonucleotides are useful directly as therapeutic agents, and are alsouseful for determining and validating gene function, for example, bygene knock-out or gene knock-down experiments. Antisense technology isfurther described in Layery et al., Curr. Opin. Drug Discov Devel 6561-569 (2003), Stephens et al., Curr. Opin. Mol. Ther. 5.118-122(2003), Kurreck, Eur. J. Biochem. 270.1628-44 (2003), Dias et al, MolCancer Ter. 1-347-55 (2002), Chen, Methods Mol. Med. 75:621-636 (2003),Wang et al., Curr Cancer Drug Targets 1.177-96 (2001), and Bennett,Antisense Nucleic Acid Drug. Dev. 12 215-24 (2002)

The variants described herein can be used for the selection and designof antisense reagents that are specific for particular variants (e.g.,particular genetic variations, or polymorphic markers in LD withparticular genetic variations). Using information about the variantsdescribed herein, antisense oligonucleotides or other antisensemolecules that specifically target mRNA molecules that contain one ormore variants of the disclosure can be designed. In this manner,expression of mRNA molecules that contain one or more variant of thepresent disclosure (markers and/or haplotypes) can be inhibited orblocked. In some embodiments, the antisense molecules are designed tospecifically bind a particular allelic form (i.e., one or severalvariants (alleles and/or haplotypes)) of the target nucleic acid,thereby inhibiting translation of a product originating from thisspecific allele or haplotype, but which do not bind other or alternatevariants at the specific polymorphic sites of the target nucleic acidmolecule.

As antisense molecules can be used to inactivate mRNA so as to inhibitgene expression, and thus protein expression, the molecules can be usedto treat a disease or disorder, such as a developmental disorder. Themethodology can involve cleavage by means of ribozymes containingnucleotide sequences complementary to one or more regions in the mRNAthat attenuate the ability of the mRNA to be translated. Such mRNAregions include, for example, protein-coding regions, in particularprotein-coding regions corresponding to catalytic activity, substrateand/or ligand binding sites, or other functional domains of a protein.

The phenomenon of RNA interference (RNAi) has been actively studied forthe last decade, since its original discovery in C. elegans (Fire etal., Nature 391:806-11 (1998)), and in recent years its potential use intreatment of human disease has been actively pursued (reviewed in Kim &Rossi, Nature Rev, Genet. 8: 173-204 (2007)). RNA interference (RNAi),also called gene silencing, is based on using double-stranded RNAmolecules (dsRNA) to turn off specific genes. In the cell, cytoplasmicdouble-stranded RNA molecules (dsRNA) are processed by cellularcomplexes into small interfering RNA (siRNA). The siRNA guide thetargeting of a protein-RNA complex to specific sites on a target mRNA,leading to cleavage of the mRNA (Thompson, Drug Discovery Today,7:912-917 (2002)). The siRNA molecules are typically about 20, 21, 22 or23 nucleotides in length. Thus, one aspect of the disclosure relates toisolated nucleic acid sequences, and the use of those molecules for RNAinterference, for example, as small interfering RNA molecules (siRNA).In some embodiments, the isolated nucleic acid sequences can be 18-26nucleotides in length, preferably 19-25 nucleotides in length, morepreferably 20-24 nucleotides in length, and more preferably 21, 22 or 23nucleotides in length.

Another pathway for RNAi-mediated gene silencing originates inendogenously encoded primary microRNA (pn-miRNA) transcripts, which areprocessed in the cell to generate precursor miRNA (pre-miRNA). ThesemiRNA molecules are exported from the nucleus to the cytoplasm, wherethey undergo processing to generate mature miRNA molecules (miRNA),which direct translational inhibition by recognizing target sites in the3′ untranslated regions of mRNAs, and subsequent mRNA degradation byprocessing P-bodies (reviewed in Kim & Rossi, Nature Rev. Genet. 8:173-204 (2007)).

Clinical applications of RNAi include the incorporation of syntheticsiRNA duplexes, which preferably are approximately 20-23 nucleotides insize, and preferably have 3′ overlaps of 2 nucleotides. Knockdown ofgene expression is established by sequence-specific design for thetarget mRNA. Several commercial sites for optimal design and synthesisof such molecules are known to those skilled in the art.

Other applications provide longer siRNA molecules (typically 25-30nucleotides in length, preferably about 27 nucleotides), as well assmall hairpin RNAs (shRNAs; typically about 29 nucleotides in length).The latter are naturally expressed, as described in Amarzguioui et al.(FEBS Lett. 579:5974-81 (2005)). Chemically synthetic siRNAs and shRNAsare substrates for in vivo processing, and in some cases provide morepotent gene-silencing than shorter designs (Kim et al., NatureBiotechnol. 23:222-226 (2005); Siola et al., Nature Biotechnol.23:227-231 (2005)). In general siRNAs provide for transient silencing ofgene expression, because their intracellular concentration is diluted bysubsequent cell divisions. By contrast, expressed shRNAs mediatelong-term, stable knockdown of target transcripts, for as long astranscription of the snRNA takes place (Marques et al., NatureBiotechnol. 23.559-565 (2006), Brummelkamp et al., Science 296. 550-553(2002)).

Since RNAi molecules, including siRNA, miRNA and snRNA, act in asequence-dependent manner, variants described herein can be used todesign RNAi reagents that recognize specific nucleic acids comprisingspecific genetic variations, alleles and/or haplotypes, while notrecognizing nucleic acid sequences not comprising the genetic variation,or comprising other alleles or haplotypes. These RNAi reagents can thusrecognize and destroy the target nucleic acid sequences. As withantisense reagents, RNAi reagents can be useful as therapeutic agents(i.e., for turning off disease-associated genes or disease-associatedgene variants), but can also be useful for characterizing and validatinggene function (e.g., by gene knock-out or gene knock-down experiments).

Delivery of RNAi can be performed by a range of methodologies known tothose skilled in the art. Methods utilizing non-viral delivery includecholesterol, stable nucleic acid-lipid particle (SNALP), heavy-chainantibody fragment (Fab), aptamers and nanoparticles Viral deliverymethods include use of lentivirus, adenovirus and adeno-associated virusThe siRNA molecules are in some embodiments chemically modified toincrease their stability. This can include modifications at the 2′position of the ribose, including 2′-β-methylpunnes and2′-fluoropyrimidmes, which provide resistance to RNase activity. Otherchemical modifications are possible and known to those skilled in theart.

The following references provide a further summary of RNAi, andpossibilities for targeting specific genes using RNAi: Kim & Rossi, Nat.Rev. Genet. 8: 173-184 (2007), Chen & Rajewsky, Nat. Rev. Genet. 8:93-103 (2007), Reynolds, et al., Nat. Biotechnol 22 326-330 (2004), Chiet al., Proc. Natl. Acad. Sa. USA 100-6343-6346 (2003), Vickers et al.,J Biol. Chem. 278:7108-7118 (2003), Agami, Curr Opin. Chem. Biol.6:829-834 (2002), Layery, et al., Curr. Opin. Drug Discov. Devel.6:561-569 (2003), Shi, Trends Genet. 19:9-12 (2003), Shuey et al., DrugDiscov. Today 7 1040-46 (2002), McManus et al., Nat. Rev. Genet.3.737-747 (2002), Xia et al., Nat. Biotechnol. 20.1006-10 (2002),Plasterk et al., Curr. Opin Genet. Dev. 10 562-7 (2000), Bosher et al.,Nat. Cell Biol. 2:E31-6 (2000), and Hunter, Curr. Biol. 9:R440-442(1999).

A genetic defect leading to increased predisposition or risk fordevelopment of a disease, including a developmental disorder, or adefect causing the disease, can be corrected permanently byadministering to a subject carrying the defect a nucleic acid fragmentthat incorporates a repair sequence that supplies the normal/wild-typenucleotide(s) at the site of the genetic defect. Such site-specificrepair sequence can encompass an RNA/DNA oligonucleotide that operatesto promote endogenous repair of a subject's genomic DNA. Theadministration of the repair sequence can be performed by an appropriatevehicle, such as a complex with polyethelamine, encapsulated in anionicliposomes, a viral vector such as an adenovirus vector, or otherpharmaceutical compositions suitable for promoting intracellular uptakeof the administered nucleic acid. The genetic defect can then beovercome, since the chimeric oligonucleotides induce the incorporationof the normal sequence into the genome of the subject, leading toexpression of the normal/wild-type gene product. The replacement ispropagated, thus rendering a permanent repair and alleviation of thesymptoms associated with the disease or condition.

Double stranded oligonucleotides are formed by the assembly of twodistinct oligonucleotide sequences where the oligonucleotide sequence ofone strand is complementary to the oligonucleotide sequence of thesecond strand; such double stranded oligonucleotides are generallyassembled from two separate oligonucleotides (e.g., siRNA), or from asingle molecule that folds on itself to form a double stranded structure(e.g., shRNA or short hairpin RNA). These double strandedoligonucleotides known in the art all have a common feature in that eachstrand of the duplex has a distinct nucleotide sequence, wherein onlyone nucleotide sequence region (guide sequence or the antisensesequence) has complementarity to a target nucleic acid sequence and theother strand (sense sequence) comprises nucleotide sequence that ishomologous to the target nucleic acid sequence.

Double stranded RNA induced gene silencing can occur on at least threedifferent levels: (i) transcription inactivation, which refers to RNAguided DNA or histone methylation; (ii) siRNA induced mRNA degradation;and (iii) mRNA induced transcriptional attenuation. It is generallyconsidered that the major mechanism of RNA induced silencing (RNAinterference, or RNAi) in mammalian cells is mRNA degradation. RNAinterference (RNAi) is a mechanism that inhibits gene expression at thestage of translation or by hindering the transcription of specificgenes. Specific RNAi pathway proteins are guided by the dsRNA to thetargeted messenger RNA (mRNA), where they “cleave” the target, breakingit down into smaller portions that can no longer be translated intoprotein. Initial attempts to use RNAi in mammalian cells focused on theuse of long strands of dsRNA. However, these attempts to induce RNAi metwith limited success, due in part to the induction of the interferonresponse, which results in a general, as opposed to a target-specific,inhibition of protein synthesis. Thus, long dsRNA is not a viable optionfor RNAi in mammalian systems. Another outcome is epigenetic changes toa gene—histone modification and DNA methylation—affecting the degree thegene is transcribed.

More recently it has been shown that when short (18-30 bp) RNA duplexesare introduced into mammalian cells in culture, sequence-specificinhibition of target mRNA can be realized without inducing an interferonresponse. Certain of these short dsRNAs, referred to as small inhibitoryRNAs (“siRNAs”), can act catalytically at sub-molar concentrations tocleave greater than 95% of the target mRNA in the cell. A description ofthe mechanisms for siRNA activity, as well as some of its applicationsare described in Provost et al., Ribonuclease Activity and RNA Bindingof Recombinant Human Dicer, E.M.B.O. J., 2002 Nov. 1; 21(21): 5864-5874;Tabara et al. The dsRNA Binding Protein RDE-4 Interacts with RDE-1,DCR-1 and a DexH-box Helicase to Direct RNAi in C. elegans, Cell 2002,June 28; 109(7):861-71; Ketting et al., Dicer Functions in RNAInterference and in Synthesis of Small RNA Involved in DevelopmentalTiming in C. elegans; Martinez et al., Single-Stranded Antisense siRNAsGuide Target RNA Cleavage in RNAi, Cell 2002, September. 6; 110(5):563;Hutvagner & Zamore, A microRNA in a multiple-turnover RNAi enzymecomplex, Science 2002, 297:2056.

From a mechanistic perspective, introduction of long double stranded RNAinto plants and invertebrate cells is broken down into siRNA by a TypeIII endonuclease known as Dicer. Sharp, RNA interference—2001, GenesDev. 2001, 15:485. Dicer, a ribonuclease-III-like enzyme, processes thedsRNA into 19-23 base pair short interfering RNAs with characteristictwo base 3′ overhangs. Bernstein, Caudy, Hammond, & Hannon, Role for abidentate ribonuclease in the initiation step of RNA interference,Nature 2001, 409:363. The siRNAs are then incorporated into anRNA-induced silencing complex (RISC) where one or more helicases unwindthe siRNA duplex, enabling the complementary antisense strand to guidetarget recognition (Nykanen, Haley, & Zamore, ATP requirements and smallinterfering RNA structure in the RNA interference pathway, Cell 2001,107:309). Upon binding to the appropriate target mRNA, one or moreendonucleases within the RISC cleaves the target to induce silencing.Elbashir, Lendeckel, & Tuschl, RNA interference is mediated by 21- and22-nucleotide RNAs, Genes Dev 2001, 15:188, FIG. 1.

Generally, the antisense sequence is retained in the active RISC complexand guides the RISC to the target nucleotide sequence by means ofcomplementary base-pairing of the antisense sequence with the targetsequence for mediating sequence-specific RNA interference. It is knownin the art that in some cell culture systems, certain types ofunmodified siRNAs can exhibit “off target” effects. It is hypothesizedthat this off-target effect involves the participation of the sensesequence instead of the antisense sequence of the siRNA in the RISCcomplex (see for example, Schwarz et al., 2003, Cell, 115, 199-208). Inthis instance the sense sequence is believed to direct the RISC complexto a sequence (off-target sequence) that is distinct from the intendedtarget sequence, resulting in the inhibition of the off-target sequence.In these double stranded nucleic acid sequences, each strand iscomplementary to a distinct target nucleic acid sequence. However, theoff-targets that are affected by these dsRNAs are not entirelypredicTable and are non-specific.

The term “siRNA” refers to small inhibitory RNA duplexes that induce theRNA interference (RNAi) pathway. These molecules can vary in length(generally between 18-30 basepairs) and contain varying degrees ofcomplementarity to their target mRNA in the antisense strand. Some, butnot all, siRNA have unpaired overhanging bases on the 5′ or 3′ end ofthe sense strand and/or the antisense strand. The term “siRNA” includesduplexes of two separate strands, as well as single strands that canform hairpin structures comprising a duplex region. Small interferingRNA (siRNA), sometimes known as short interfering RNA or silencing RNA,are a class of 20-25 nucleotide-long double-stranded RNA molecules thatplay a variety of roles in biology.

While the two RNA strands do not need to be completely complementary,the strands should be sufficiently complementary to hybridize to form aduplex structure. In some instances, the complementary RNA strand can beless than 30 nucleotides, preferably less than 25 nucleotides in length,more preferably 19 to 24 nucleotides in length, more preferably 20-23nucleotides in length, and even more preferably 22 nucleotides inlength. The dsRNA of the present disclosure can further comprise atleast one single-stranded nucleotide overhang. The dsRNA of the presentdisclosure can further comprise a substituted or chemically modifiednucleotide. As discussed in detail below, the dsRNA can be synthesizedby standard methods known in the art.

siRNA can be divided into five (5) groups including non-functional,semi-functional, functional, highly functional, and hyper-functionalbased on the level or degree of silencing that they induce in culturedcell lines. As used herein, these definitions are based on a set ofconditions where the siRNA is transfected into said cell line at aconcentration of 100 nM and the level of silencing is tested at a timeof roughly 24 hours after transfection, and not exceeding 72 hours aftertransfection. In this context, “non-functional siRNA” are defined asthose siRNA that induce less than 50% (<50%) target silencing.“Semi-functional siRNA” induce 50-79% target silencing. “FunctionalsiRNA” are molecules that induce 80-95% gene silencing.“Highly-functional siRNA” are molecules that induce greater than 95%gene silencing. “Hyperfunctional siRNA” are a special class ofmolecules. For purposes of this document, hyperfunctional siRNA aredefined as those molecules that: (1) induce greater than 95% silencingof a specific target when they are transfected at subnanomolarconcentrations (i.e., less than one nanomolar); and/or (2) inducefunctional (or better) levels of silencing for greater than 96 hours.These relative functionalities (though not intended to be absolutes) canbe used to compare siRNAs to a particular target for applications suchas functional genomics, target identification and therapeutics.

microRNAs (miRNA) are single-stranded RNA molecules of about 21-23nucleotides in length, which regulate gene expression. miRNAs areencoded by genes that are transcribed from DNA but not translated intoprotein (non-coding RNA); instead they are processed from primarytranscripts known as pri-miRNA to short stem-loop structures calledpre-miRNA and finally to functional miRNA. Mature miRNA molecules arepartially complementary to one or more messenger RNA (mRNA) molecules,and their main function is to downregulate gene expression.

Antibody-Based Therapeutics

The present disclosure embodies agents that modulate a peptide sequenceor RNA expressed from a gene associated with a developmental disorder.The term biomarker, as used herein, can comprise a genetic variation ofthe present disclosure or a gene product, for example, RNA andpolypeptides, of any one of the genes listed in Table 2. Such modulatingagents include, but are not limited to, proteins, peptides,peptidomimetics, peptoids, or any other forms of a molecule, which bindto, and alter the signaling or function associated with the adevelopmental disorder associated biomarker, have an inhibitory orstimulatory effect on the developmental disorder associated biomarkers,or have a stimulatory or inhibitory effect on the expression or activityof the a developmental disorder associated biomarkers' ligands, forexample, polyclonal antibodies and/or monoclonal antibodies thatspecifically bind one form of the gene product but not to the other formof the gene product are also provided, or which bind a portion of eitherthe variant or the reference gene product that contains the polymorphicsite or sites.

In some embodiments, the present disclosure provides antibody-basedagents targeting a developmental disorder associated biomarkers. Theantibody-based agents in any suitable form of an antibody e.g.,monoclonal, polyclonal, or synthetic, can be utilized in the therapeuticmethods disclosed herein. The antibody-based agents include anytarget-binding fragment of an antibody and also peptibodies, which areengineered therapeutic molecules that can bind to human drug targets andcontain peptides linked to the constant domains of antibodies. In someembodiments, the antibodies used for targeting a developmental disorderassociated biomarkers are humanized antibodies. Methods for humanizingantibodies are well known in the art. In another embodiment, thetherapeutic antibodies comprise an antibody generated against adevelopmental disorder associated biomarkers described in the presentdisclosure, wherein the antibodies are conjugated to another agent oragents, for example, a cytotoxic agent or agents.

The term “antibody” as used herein refers to immunoglobulin moleculesand immunologically active portions of immunoglobulin molecules, i.e.,molecules that contain antigen-binding sites that specifically bind anantigen. A molecule that specifically binds to a polypeptide of thedisclosure is a molecule that binds to that polypeptide or a fragmentthereof, but does not substantially bind other molecules in a sample,e.g., a biological sample, which naturally contains the polypeptide.Examples of immunologically active portions of immunoglobulin moleculesinclude F(ab) and F(ab′)2 fragments which can be generated by treatingthe antibody with an enzyme such as pepsin. The disclosure providespolyclonal and monoclonal antibodies that bind to a polypeptide of thedisclosure. The term “monoclonal antibody” or “monoclonal antibodycomposition”, as used herein, refers to a population of antibodymolecules that contain only one species of an antigen binding sitecapable of immunoreacting with a particular epitope of a polypeptide ofthe disclosure. A monoclonal antibody composition thus typicallydisplays a single binding affinity for a particular polypeptide of thedisclosure with which it immunoreacts.

Polyclonal antibodies can be prepared as described above by immunizing asuitable subject with a desired immunogen, e.g., polypeptide of thedisclosure or a fragment thereof. The antibody titer in the immunizedsubject can be monitored over time by standard techniques, such as withan enzyme linked immunosorbent assay (ELISA) using immobilizedpolypeptide. If desired, the antibody molecules directed against thepolypeptide can be isolated from the mammal (e.g., from the blood) andfurther purified by well-known techniques, such as protein Achromatography to obtain the IgG fraction. At an appropriate time afterimmunization, e.g., when the antibody titers are highest,antibody-producing cells can be obtained from the subject and used toprepare monoclonal antibodies by standard techniques, such as thehybndoma technique originally described by Kohler and Milstein, Nature256:495-497 (1975), the human B cell hybridoma technique (Kozbor et al.,Immunol. Today 4: 72 (1983)), the EBV-hybndoma technique (Cole et al.,Monoclonal Antibodies and Cancer Therapy, Alan R. Liss (1985) Inc., pp.77-96) or trioma techniques. The technology for producing hybndomas iswell known (see generally Current Protocols in Immunology (1994) Coliganet al., (eds.) John Wiley & Sons, Inc., New York, N.Y.). Briefly, animmortal cell line (typically a myeloma) is fused to lymphocytes(typically splenocytes) from a mammal immunized with an immunogen asdescribed above, and the culture supernatants of the resulting hybridomacells are screened to identify a hybridoma producing a monoclonalantibody that binds a polypeptide of the disclosure.

Any of the many well known protocols used for fusing lymphocytes andimmortalized cell lines can be applied for the purpose of generating amonoclonal antibody to a polypeptide of the disclosure (see, e.g.,Current Protocols in Immunology, supra; Galfre et al., Nature 266:55052(1977); R. H. Kenneth, in Monoclonal Antibodies: A New Dimension InBiological Analyses, Plenum Publishing Corp., New York, N.Y. (1980); andLerner, Yale J. Biol. Med. 54:387-402 (1981)). Moreover, the ordinarilyskilled worker can appreciate that there are many variations of suchmethods that also would be useful. Alternative to preparing monoclonalantibody-secreting hybridomas, a monoclonal antibody to a polypeptide ofthe disclosure can be identified and isolated by screening a recombinantcombinatorial immunoglobulin library (e.g., an antibody phage displaylibrary) with the polypeptide to thereby isolate immunoglobulin librarymembers that bind the polypeptide. Kits for generating and screeningphage display libraries are commercially available (e.g., the PharmaciaRecombinant Phage Antibody System, Catalog No. 27-9400-01; and theStratagene SurfZAPa Phage Display Kit, Catalog No. 240612).Additionally, examples of methods and reagents particularly amenable foruse in generating and screening antibody display library can be foundin, for example, U.S. Pat. No. 5,223,409; PCT Publication Nos. WO92/18619, WO 91/17271, WO 92/20791, WO 92/15679; WO 93/01288, WO92/01047, WO 92/09690, and WO 90/02809; Fuchs et al., Bio/Technology 9:1370-1372 (1991); Hay et al., Hum. Antibod. Hybndomas 3:81-85 (1992);Huse et al., Science 246: 1275-1281 (1989); and Griffiths et al., EMBOJ. 12:725-734 (1993).

Additionally, recombinant antibodies, such as chimeric and humanizedmonoclonal antibodies, comprising both human and non-human portions,which can be made using standard recombinant DNA techniques, are withinthe scope of the disclosure. Such chimeric and humanized monoclonalantibodies can be produced by recombinant DNA techniques known in theart.

In general, antibodies of the disclosure (e.g., a monoclonal antibody)can be used to isolate a polypeptide of the disclosure by standardtechniques, such as affinity chromatography or immunoprecipitation. Apolypeptide-specific antibody can facilitate the purification of naturalpolypeptide from cells and of recombinants produced polypeptideexpressed in host cells. Moreover, an antibody specific for apolypeptide of the disclosure can be used to detect the polypeptide(e.g., in a cellular lysate, cell supernatant, or tissue sample) inorder to evaluate the abundance and pattern of expression of thepolypeptide. Antibodies can be used diagnostically, prognostically, ortheranostically to monitor protein levels in tissue as part of aclinical testing procedure, e.g., to, for example, determine theefficacy of a given treatment regimen. The antibody can be coupled to adetecTable substance to facilitate its detection. Examples of detecTablesubstances include various enzymes, prosthetic groups, fluorescentmaterials, luminescent materials, bioluminescent materials, andradioactive materials. Examples of suitable enzymes include horseradishperoxidase, alkaline phosphatase, beta-galactosidase, oracetylcholinesterase; examples of suitable prosthetic group complexesinclude streptavidin/biotin and avidin/biotin; examples of suitablefluorescent materials include umbelliferone, fluorescein, fluoresceinisothiocyanate, rhodamine, dichlorotnazinylamine fluorescein, dansylchloride or phycoerythnn; an example of a luminescent material includesluminol; examples of bioluminescent materials include luciferase,luciferin, and aequorin, and examples of suitable radioactive materialinclude ¹²⁵I, ¹³¹I, ³⁵S or ³H. Antibodies can also be useful inpharmacogenomic analysis. In such embodiments, antibodies againstvariant proteins encoded by nucleic acids according to the disclosure,such as variant proteins that are encoded by nucleic acids that containat least one genetic variation of the disclosure, can be used toidentify individuals that require modified treatment modalities.

Antibodies can furthermore be useful for assessing expression of variantproteins in disease states, such as in active stages of a disease, or inan individual with a predisposition to a disease related to the functionof the protein, in particular a developmental disorder. Antibodiesspecific for a variant protein of the present disclosure that is encodedby a nucleic acid that comprises at least one polymorphic marker orhaplotype as described herein can be used to screen for the presence ofthe variant protein, for example, to screen for a predisposition to adevelopmental disorder as indicated by the presence of the variantprotein.

Antibodies can be used in other methods. Thus, antibodies are useful asscreening tools for evaluating proteins, such as variant proteins of thedisclosure, in conjunction with analysis by electrophoretic mobility,isoelectric point, tryptic or other protease digest, or for use in otherphysical assays known to those skilled in the art. Antibodies can alsobe used in tissue typing. In one such embodiment, a specific variantprotein has been correlated with expression in a specific tissue type,and antibodies specific for the variant protein can then be used toidentify the specific tissue type.

Subcellular localization of proteins, including variant proteins, canalso be determined using antibodies, and can be applied to assessaberrant subcellular localization of the protein in cells in varioustissues. Such use can be applied in genetic testing, but also inmonitoring a particular treatment modality. In the case where treatmentis aimed at correcting the expression level or presence of the variantprotein or aberrant tissue distribution or developmental expression ofthe variant protein, antibodies specific for the variant protein orfragments thereof can be used to monitor therapeutic efficacy.

Antibodies are further useful for inhibiting variant protein function,for example, by blocking the binding of a variant protein to a bindingmolecule or partner. Such uses can also be applied in a therapeuticcontext in which treatment involves inhibiting a variant protein'sfunction. An antibody can be for example, be used to block orcompetitively inhibit binding, thereby modulating (i.e., agonizing orantagonizing) the activity of the protein. Antibodies can be preparedagainst specific protein fragments containing sites required forspecific function or against an intact protein that is associated with acell or cell membrane.

The present disclosure also embodies the use of any pharmacologic agentthat can be conjugated to an antibody or an antibody binding fragment,and delivered in active form. Examples of such agents includecytotoxins, radioisotopes, hormones such as a steroid, anti-metabolitessuch as cytosines, and chemotherapeutic agents. Other embodiments caninclude agents such as a coagulant, a cytokine, growth factor, bacterialendotoxin or a moiety of bacterial endotoxin. The targetingantibody-based agent directs the toxin to, and thereby selectivelymodulates the cell expressing the targeted surface receptor. In someembodiments, therapeutic antibodies employ cross-linkers that providehigh in vivo stability (Thorpe et al., Cancer Res., 48:6396, 1988). Inany event, it is proposed that agents such as these can, if desired, besuccessfully conjugated to antibodies or antibody binding fragments, ina manner that will allow their targeting, internalization, release orpresentation at the site of the targeted cells expressing the ASDassociated biomarkers as required using known conjugation technology.For administration in vivo, for example, an antibody can be linked withan additional therapeutic payload, such as radionuclide, an enzyme, animmunogenic epitope, or a cytotoxic agent, including bacterial toxins(diphtheria or plant toxins, such as ricin). The in vivo half-life of anantibody or a fragment thereof can be increased by pegylation throughconjugation to polyethylene glycol.

Gene Therapy

In some embodiments, gene therapy can be used as as therapeutic tomodulate a peptide sequence or RNA expressed from a gene associated witha developmental disorder. Gene therapy involves the use of DNA as apharmaceutical agent to treat disease. DNA can be used to supplement oralter genes within an individual's cells as a therapy to treat disease.Gene therapy can be used to alter the signaling or function associatedwith the a developmental disorder associated biomarker, have aninhibitory or stimulatory effect on the developmental disorderassociated biomarkers, or have a stimulatory or inhibitory effect on theexpression or activity of the a developmental disorder associatedbiomarkers' ligands. In one embodiement, gene therapy involves using DNAthat encodes a functional, therapeutic gene in order to replace amutated gene. Other forms involve directly correcting a mutation, orusing DNA that encodes a therapeutic protein drug (rather than a naturalhuman gene) to provide treatment. DNA that encodes a therapeutic proteincan be packaged within a vector, which can used to introduce the DNAinside cells within the body. Once inside, the DNA becomes expressed bythe cell machinery, resulting in the production of the therapeutic,which in turn can treat the subject's disease.

Gene therapy agents and other agents for testing therapeutics caninclude plasmids, viral vectors, artificial chromosomes and the likecontaining therapeutic genes or polynucleotides encoding therapeuticproducts, including coding sequences for small interfering RNA (siRNA),ribozymes and antisense RNA, which in certain further embodiments cancomprise an operably linked promoter such as a constitutive promoter ora regulaTable promoter, such as an inducible promoter (e.g., IPTGinducible), a tightly regulated promoter (e.g., a promoter that permitslittle or no detecTable transcription in the absence of its cognateinducer or derepressor) or a tissue-specific promoter. Methodologies forpreparing, testing and using these and related agents are known in theart. See, e.g., Ausubel (Ed.), Current Protocols in Molecular Biology(2007 John Wiley & Sons, NY); Rosenzweig and Nabel (Eds), CurrentProtocols in Human Genetics (esp. Ch. 13 therein, “Delivery Systems forGene Therapy”, 2008 John Wiley & Sons, NY); Abell, Advances in AminoAcid Mimetics and Peptidomimetics, 1997 Elsevier, N.Y. In anotherembodiment, gene therapy agents may encompass zinc finger nuclease (ZFN)or transcription activator-like effector nuclease (TALEN) strategies,see for example: Urnov et al. (2010), Nature Reviews Genetics11(9):636-46; Yusa et al. (2011), Nature 478(7369):391-4; Bedell et al.(2012), Nature ePub September 23, PubMed ID 23000899.

As a non-limiting example, one such embodiment contemplates introductionof a gene therapy agent for treating ASD (e.g., an engineeredtherapeutic virus, a therapeutic agent-carrying nanoparticle, etc.) toone or more injection sites in a subject, without the need for imaging,surgery, or histology on biopsy specimens. Of course, periodicmonitoring of the circulation for leaked therapeutic agent and/orsubsequent analysis of a biopsy specimen, e.g., to assess the effects ofthe agent on the target tissue, can also be considered. A gene therapyincludes a therapeutic polynucleotide administered before, after, or atthe same time as any other therapy described herein. In someembodiments, therapeutic genes may include an antisense version of abiomarker disclosed herein, a sequenceof a biomarker described herein,or an inhibitor of a biomarker disclosed herein.

Methods of Treatment

Some embodiments of the present disclosure relates to methods of usingpharmaceutical compositions and kits comprising agents that inhibit adevelopmental disorder associated biomarker or a developmental disorderassociated biomarkers to inhibit or decrease a developmental disorderprogression. Another embodiment of the present disclosure providesmethods, pharmaceutical compositions, and kits for the treatment ofanimal subjects. The term “animal subject” as used herein includeshumans as well as other mammals. The term “treating” as used hereinincludes achieving a therapeutic benefit and/or a prophylactic benefit.By therapeutic benefit is meant eradication or amelioration of theunderlying viral infection. Also, a therapeutic benefit is achieved withthe eradication or amelioration of one or more of the physiologicalsymptoms associated a developmental disorder such that an improvement isobserved in the animal subject, notwithstanding the fact that the animalsubject can still be afflicted with a developmental disorder.

For embodiments where a prophylactic benefit is desired, apharmaceutical composition of the disclosure can be administered to asubject at risk of developing a developmental disorder, or to a subjectreporting one or more of the physiological symptoms of a developmentaldisorder, even though a screening of the condition cannot have beenmade. Administration can prevent a developmental disorder fromdeveloping, or it can reduce, lessen, shorten and/or otherwiseameliorate the progression of a developmental disorder, or symptoms thatdevelop. The pharmaceutical composition can modulate or target adevelopmental disorder's associated biomarker. Wherein, the termmodulate includes inhibition of a developmental disorder's associatedbiomarkers or alternatively activation of a developmental disorderassociated biomarkers.

Reducing the activity of a developmental disorder's associatedbiomarkers, is also referred to as “inhibiting” the developmentaldisorder's associated biomarkers. The term “inhibits” and itsgrammatical conjugations, such as “inhibitory,” do not require completeinhibition, but refer to a reduction in a developmental disorder'sassociated biomarkers' activities. In some embodiments such reduction isby at least 5%, at least 10%, at least 20%, at least 30%, at least 40%,at least 50%, at least 75%, at least 90%, and can be by at least 95% ofthe activity of the enzyme or other biologically important molecularprocess in the absence of the inhibitory effect, e.g., in the absence ofan inhibitor. Conversely, the phrase “does not inhibit” and itsgrammatical conjugations refer to situations where there is less than20%, less than 10%, and can be less than 5%, of reduction in enzymeactivity in the presence of the agent. Further the phrase “does notsubstantially inhibit” and its grammatical conjugations refer tosituations where there is less than 30%, less than 20%, and in someembodiments less than 10% of reduction in enzyme or other biologicallyimportant molecular activity in the presence of the agent.

Increasing the activity a developmental disorder's associated biomarkersis also referred to as “activating” the developmental disorder'sassociated biomarkers. The term “activated” and its grammaticalconjugations, such as “activating,” do not require complete activation,but refer to an increase in a developmental disorder associatedbiomarkers' activities. In some embodiments such increase is by at least5%, at least 10%, at least 20%, at least 30%, at least 40%, at least50%, at least 60%, at least 70%, at least 75%, at least 80%, at least85%, at least 90%, and can be by at least 95% of the activity of theenzyme or other biologically important molecular process in the absenceof the activation effect, e.g., in the absence of an activator.Conversely, the phrase “does not activate” and its grammaticalconjugations refer to situations where there can be less than 20%, lessthan 10%, and less than 5%, of an increase in enzyme or otherbiologically important molecular activity in the presence of the agent.Further the phrase “does not substantially activate” and its grammaticalconjugations refer to situations where there is less than 30%, less than20%, and in some embodiments less than 10% of an increase in enzyme orother biologically important molecular activity in the presence of theagent.

The ability to reduce enzyme or other biologically important molecularactivity is a measure of the potency or the activity of an agent, orcombination of agents, towards or against the enzyme or otherbiologically important molecular process. Potency can be measured bycell free, whole cell and/or in vivo assays in terms of IC50, Ki and/orED50 values. An IC50 value represents the concentration of an agentrequired to inhibit enzyme activity by half (50%) under a given set ofconditions. A Ki value represents the equilibrium affinity constant forthe binding of an inhibiting agent to the enzyme or other relevantbiomolecule. An ED50 value represents the dose of an agent required toaffect a half-maximal response in a biological assay. Further details ofthese measures will be appreciated by those of ordinary skill in theart, and can be found in standard texts on biochemistry, enzymology, andthe like.

The present disclosure also includes kits that can be used to treatdevelopmental disorders. These kits comprise an agent or combination ofagents that inhibits a developmental disorder associated biomarker or adevelopmental disorder's associated biomarkers and in some embodimentsinstructions teaching the use of the kit according to the variousmethods and approaches described herein. Such kits can also includeinformation, such as scientific literature references, package insertmaterials, clinical trial results, and/or summaries of these and thelike, which indicate or establish the activities and/or advantages ofthe agent. Such information can be based on the results of variousstudies, for example, studies using experimental animals involving invivo models and studies based on human clinical trials. Kits describedherein can be provided, marketed and/or promoted to health providers,including physicians, nurses, pharmacists, formulary officials, and thelike.

In some aspects a host cell can be used for testing or administeringtherapeutics. In some embodiments, a host cell can comprise a nucleicacid comprising expression control sequences operably-linked to a codingregion. The host cell can be natural or non-natural. The non-naturalhost used in aspects of the method can be any cell capable of expressinga nucleic acid of the disclosure including, bacterial cells, fungalcells, insect cells, mammalian cells and plant cells. In some aspectsthe natural host is a mammalian tissue cell and the non-natural host isa different mammalian tissue cell. Other aspects of the method include anatural host that is a first cell normally residing in a first mammalianspecies and the non-natural host is a second cell normally residing in asecond mammalian species. In another alternative aspect, the method usesa first cell and the second cell that are from the same tissue type. Inthose aspects of the method where the coding region encodes a mammalianprotein, the mammalian protein may be a hormone. In other aspects thecoding region may encode a neuropeptide, an antibody, an antimetabolitesor a protein or nucleotide therapeutic.

Expression control sequencescan be those nucleotide sequences, both 5′and 3′ to a coding region, that are required for the transcription andtranslation of the coding region in a host organism. Regulatorysequences include a promoter, ribosome binding site, optional inducibleelements and sequence elements required for efficient 3′ processing,including polyadenylation. When the structural gene has been isolatedfrom genomic DNA, the regulatory sequences also include those intronicsequences required for splicing of the introns as part of mRNA formationin the target host.

Formulations, Routes of Administration, and Effective Doses

Yet another aspect of the present disclosure relates to formulations,routes of administration and effective doses for pharmaceuticalcompositions comprising an agent or combination of agents of the instantdisclosure. Such pharmaceutical compositions can be used to treat adevelopmental disorder progression and a developmental disorderassociated symptoms as described above.

Compounds of the disclosure can be administered as pharmaceuticalformulations including those suitable for oral (including buccal andsub-lingual), rectal, nasal, topical, transdermal patch, pulmonary,vaginal, suppository, or parenteral (including intramuscular,intraarterial, intrathecal, intradermal, intraperitoneal, subcutaneousand intravenous) administration or in a form suitable for administrationby aerosolization, inhalation or insufflation. General information ondrug delivery systems can be found in Ansel et al., PharmaceuticalDosage Forms and Drug Delivery Systems (Lippencott Williams & Wilkins,Baltimore Md. (1999).

In various embodiments, the pharmaceutical composition includes carriersand excipients (including but not limited to buffers, carbohydrates,mannitol, proteins, polypeptides or amino acids such as glycine,antioxidants, bacteriostats, chelating agents, suspending agents,thickening agents and/or preservatives), water, oils including those ofpetroleum, animal, vegeTable or synthetic origin, such as peanut oil,soybean oil, mineral oil, sesame oil and the like, saline solutions,aqueous dextrose and glycerol solutions, flavoring agents, coloringagents, detackifiers and other accepTable additives, adjuvants, orbinders, other pharmaceutically accepTable auxiliary substances asrequired to approximate physiological conditions, such as pH bufferingagents, tonicity adjusting agents, emulsifying agents, wetting agentsand the like. Examples of excipients include starch, glucose, lactose,sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate,glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol,propylene, glycol, water, ethanol and the like. In some embodiments, thepharmaceutical preparation is substantially free of preservatives. Inother embodiments, the pharmaceutical preparation can contain at leastone preservative. General methodology on pharmaceutical dosage forms isfound in Ansel et al., Pharmaceutical Dosage Forms and Drug DeliverySystems (Lippencott, Williams, & Wilkins, Baltimore Md. (1999)). It willbe recognized that, while any suitable carrier known to those ofordinary skill in the art can be employed to administer the compositionsof this disclosure, the type of carrier will vary depending on the modeof administration.

Compounds can also be encapsulated within liposomes using well-knowntechnology. Biodegradable microspheres can also be employed as carriersfor the pharmaceutical compositions of this disclosure. Suitablebiodegradable microspheres are disclosed, for example, in U.S. Pat. Nos.4,897,268, 5,075,109, 5,928,647, 5,811,128, 5,820,883, 5,853,763,5,814,344 and 5,942,252.

The compound can be administered in liposomes or microspheres (ormicroparticles). Methods for preparing liposomes and microspheres foradministration to a subject are well known to those of skill in the art.U.S. Pat. No. 4,789,734, the contents of which are hereby incorporatedby reference, describes methods for encapsulating biological materialsin liposomes. Essentially, the material is dissolved in an aqueoussolution, the appropriate phospholipids and lipids added, along withsurfactants if required, and the material dialyzed or sonicated, asnecessary. A review of known methods is provided by G. Gregoriadis,Chapter 14, “Liposomes,” Drug Carriers in Biology and Medicine, pp.2.sup.87-341 (Academic Press, 1979).

Microspheres formed of polymers or proteins are well known to thoseskilled in the art, and can be tailored for passage through thegastrointestinal tract directly into the blood stream. Alternatively,the compound can be incorporated and the microspheres, or composite ofmicrospheres, implanted for slow release over a period of time rangingfrom days to months. See, for example, U.S. Pat. Nos. 4,906,474,4,925,673 and 3,625,214, and Jein, TIPS 19:155-157 (1998), the contentsof which are hereby incorporated by reference.

The concentration of drug can be adjusted, the pH of the solutionbuffered and the isotonicity adjusted to be compatible with intravenousinjection, as is well known in the art.

The compounds of the disclosure can be formulated as a sterile solutionor suspension, in suitable vehicles, well known in the art. Thepharmaceutical compositions can be sterilized by conventional,well-known sterilization techniques, or can be sterile filtered. Theresulting aqueous solutions can be packaged for use as is, orlyophilized, the lyophilized preparation being combined with a sterilesolution prior to administration. Suitable formulations and additionalcarriers are described in Remington “The Science and Practice ofPharmacy” (20th Ed., Lippincott Williams & Wilkins, Baltimore Md.), theteachings of which are incorporated by reference in their entiretyherein.

The agents or their pharmaceutically accepTable salts can be providedalone or in combination with one or more other agents or with one ormore other forms. For example, a formulation can comprise one or moreagents in particular proportions, depending on the relative potencies ofeach agent and the intended indication. For example, in compositions fortargeting two different host targets, and where potencies are similar,about a 1:1 ratio of agents can be used. The two forms can be formulatedtogether, in the same dosage unit e.g., in one cream, suppository,tablet, capsule, aerosol spray, or packet of powder to be dissolved in abeverage; or each form can be formulated in a separate unit, e.g., twocreams, two suppositories, two tablets, two capsules, a tablet and aliquid for dissolving the tablet, two aerosol sprays, or a packet ofpowder and a liquid for dissolving the powder, etc.

The term “pharmaceutically accepTable salt” means those salts whichretain the biological effectiveness and properties of the agents used inthe present disclosure, and which are not biologically or otherwiseundesirable. For example, a pharmaceutically accepTable salt does notinterfere with the beneficial effect of an agent of the disclosure ininhibiting a developmental disorder associated biomarkers' components

Typical salts are those of the inorganic ions, such as, for example,sodium, potassium, calcium, magnesium ions, and the like. Such saltsinclude salts with inorganic or organic acids, such as hydrochloricacid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid,methanesulfonic acid, p toluenesulfonic acid, acetic acid, fumaric acid,succinic acid, lactic acid, mandelic acid, malic acid, citric acid,tartaric acid or maleic acid. In addition, if the agent(s) contain acarboxy group or other acidic group, it can be converted into apharmaceutically accepTable addition salt with inorganic or organicbases. Examples of suitable bases include sodium hydroxide, potassiumhydroxide, ammonia, cyclohexylamine, dicyclohexyl-amine, ethanolamine,diethanolamine, triethanolamine, and the like.

A pharmaceutically accepTable ester or amide refers to those whichretain biological effectiveness and properties of the agents used in thepresent disclosure, and which are not biologically or otherwiseundesirable. For example, the ester or amide does not interfere with thebeneficial effect of an agent of the disclosure in inhibiting adevelopmental disorder associated biomarkers' components. Typical estersinclude ethyl, methyl, isobutyl, ethylene glycol, and the like. Typicalamides include unsubstituted amides, alkyl amides, dialkyl amides, andthe like.

In some embodiments, an agent can be administered in combination withone or more other compounds, forms, and/or agents, e.g., as describedabove. Pharmaceutical compositions comprising combinations of adevelopmental disorder associated biomarkers' inhibitors with one ormore other active agents can be formulated to comprise certain molarratios. For example, molar ratios of about 99:1 to about 1:99 of adevelopmental disorder's associated biomarkers' inhibitors to the otheractive agent can be used. In some subset of the embodiments, the rangeof molar ratios of developmental disorder's associated biomarkers'inhibitors: other active agents are selected from about 80:20 to about20:80; about 75:25 to about 25:75, about 70:30 to about 30:70, about66:33 to about 33:66, about 60:40 to about 40:60; about 50:50; and about90:10 to about 10:90. The molar ratio of a developmental disorder'sassociated biomarkers' inhibitors: other active agents can be about 1:9,and in some embodiments can be about 1:1. The two agents, forms and/orcompounds can be formulated together, in the same dosage unit e.g., inone cream, suppository, tablet, capsule, or packet of powder to bedissolved in a beverage; or each agent, form, and/or compound can beformulated in separate units, e.g., two creams, suppositories, tablets,two capsules, a tablet and a liquid for dissolving the tablet, anaerosol spray a packet of powder and a liquid for dissolving the powder,etc.

If necessary or desirable, the agents and/or combinations of agents canbe administered with still other agents. The choice of agents that canbe co-administered with the agents and/or combinations of agents of theinstant disclosure can depend, at least in part, on the condition beingtreated. Agents of particular use in the formulations of the presentdisclosure include, for example, any agent having a therapeutic effectfor a viral infection, including, e.g., drugs used to treat inflammatoryconditions. For example, in treatments for influenza, in someembodiments formulations of the instant disclosure can additionallycontain one or more conventional anti-inflammatory drugs, such as anNSAID, e.g., ibuprofen, naproxen, acetaminophen, ketoprofen, or aspirin.In some alternative embodiments for the treatment of influenzaformulations of the instant disclosure can additionally contain one ormore conventional influenza antiviral agents, such as amantadine,rimantadine, zanamivir, and oseltamivir. In treatments for retroviralinfections, such as HIV, formulations of the instant disclosure canadditionally contain one or more conventional antiviral drug, such asprotease inhibitors (lopinavir/ritonavir {Kaletra}, indinavir{Crixivan}, ritonavir {Norvir}, nelfinavir {Viracept}, saquinavir hardgel capsules {Invirase}, atazanavir {Reyataz}, amprenavir {Agenerase},fosamprenavir {Telzir}, tipranavir{Aptivus}), reverse transcriptaseinhibitors, including non-Nucleoside and Nucleoside/nucleotideinhibitors (AZT {zidovudine, Retrovir}, ddI {didanosine, Videx}, 3TC{lamivudine, Epivir}, d4T {stavudine, Zerit}, abacavir {Ziagen}, FTC{emtricitabine, Emtriva}, tenofovir {Viread}, efavirenz {Sustiva} andnevirapine {Viramune}), fusion inhibitors T20 {enfuvirtide, Fuzeon},integrase inhibitors (MK-0518 and GS-9137), and maturation inhibitors(PA-457 {Bevirimat}). As another example, formulations can additionallycontain one or more supplements, such as vitamin C, E or otheranti-oxidants.

The agent(s) (or pharmaceutically accepTable salts, esters or amidesthereof) can be administered per se or in the form of a pharmaceuticalcomposition wherein the active agent(s) is in an admixture or mixturewith one or more pharmaceutically accepTable carriers. A pharmaceuticalcomposition, as used herein, can be any composition prepared foradministration to a subject. Pharmaceutical compositions for use inaccordance with the present disclosure can be formulated in conventionalmanner using one or more physiologically accepTable carriers, comprisingexcipients, diluents, and/or auxiliaries, e.g., which facilitateprocessing of the active agents into preparations that can beadministered. Proper formulation can depend at least in part upon theroute of administration chosen. The agent(s) useful in the presentdisclosure, or pharmaceutically accepTable salts, esters, or amidesthereof, can be delivered to a subject using a number of routes or modesof administration, including oral, buccal, topical, rectal, transdermal,transmucosal, subcutaneous, intravenous, and intramuscular applications,as well as by inhalation.

For oral administration, the agents can be formulated readily bycombining the active agent(s) with pharmaceutically accepTable carrierswell known in the art. Such carriers enable the agents of the disclosureto be formulated as tablets, including chewable tablets, pills, dragees,capsules, lozenges, hard candy, liquids, gels, syrups, slurries,powders, suspensions, elixirs, wafers, and the like, for oral ingestionby a subject to be treated. Such formulations can comprisepharmaceutically accepTable carriers including solid diluents orfillers, sterile aqueous media and various non-toxic organic solvents. Asolid carrier can be one or more substances which can also act asdiluents, flavoring agents, solubilizers, lubricants, suspending agents,binders, preservatives, tablet disintegrating agents, or anencapsulating material. In powders, the carrier generally is a finelydivided solid which is a mixture with the finely divided activecomponent. In tablets, the active component generally is mixed with thecarrier having the necessary binding capacity in suitable proportionsand compacted in the shape and size desired. The powders and tabletspreferably contain from about one (1) to about seventy (70) percent ofthe active compound. Suitable carriers include but are not limited tomagnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin,dextrin, starch, gelatin, tragacanth, methylcellulose, sodiumcarboxymethylcellulose, a low melting wax, cocoa butter, and the like.Generally, the agents of the disclosure will be included atconcentration levels ranging from about 0.5%, about 5%, about 10%, about20%, or about 30% to about 50%, about 60%, about 70%, about 80% or about90% by weight of the total composition of oral dosage forms, in anamount sufficient to provide a desired unit of dosage.

Aqueous suspensions for oral use can contain agent(s) of this disclosurewith pharmaceutically accepTable excipients, such as a suspending agent(e.g., methyl cellulose), a wetting agent (e.g., lecithin, lysolecithinand/or a long-chain fatty alcohol), as well as coloring agents,preservatives, flavoring agents, and the like.

In some embodiments, oils or non-aqueous solvents can be required tobring the agents into solution, due to, for example, the presence oflarge lipophilic moieties. Alternatively, emulsions, suspensions, orother preparations, for example, liposomal preparations, can be used.With respect to liposomal preparations, any known methods for preparingliposomes for treatment of a condition can be used. See, for example,Bangham et al., J. Mol. Biol. 23: 238-252 (1965) and Szoka et al., Proc.Natl. Acad. Sci. USA 75: 4194-4198 (1978), incorporated herein byreference. Ligands can also be attached to the liposomes to direct thesecompositions to particular sites of action. Agents of this disclosurecan also be integrated into foodstuffs, e.g., cream cheese, butter,salad dressing, or ice cream to facilitate solubilization,administration, and/or compliance in certain subject populations.

Pharmaceutical preparations for oral use can be obtained as a solidexcipient, optionally grinding a resulting mixture, and processing themixture of granules, after adding suitable auxiliaries, if desired, toobtain tablets or dragee cores. Suitable excipients are, in particular,fillers such as sugars, including lactose, sucrose, mannitol, orsorbitol; flavoring elements, cellulose preparations such as, forexample, maize starch, wheat starch, rice starch, potato starch,gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone(PVP). If desired, disintegrating agents can be added, such as the crosslinked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereofsuch as sodium alginate. The agents can also be formulated as asustained release preparation.

Dragee cores can be provided with suitable coatings. For this purpose,concentrated sugar solutions can be used, which can optionally containgum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethyleneglycol, and/or titanium dioxide, lacquer solutions, and suitable organicsolvents or solvent mixtures. Dyestuffs or pigments can be added to thetablets or dragee coatings for identification or to characterizedifferent combinations of active agents.

Pharmaceutical preparations that can be used orally include push fitcapsules made of gelatin, as well as soft, sealed capsules made ofgelatin and a plasticizer, such as glycerol or sorbitol. The push fitcapsules can contain the active ingredients in admixture with fillersuch as lactose, binders such as starches, and/or lubricants such astalc or magnesium stearate and, optionally, stabilizers. In softcapsules, the active agents can be dissolved or suspended in suitableliquids, such as fatty oils, liquid paraffin, or liquid polyethyleneglycols. In addition, stabilizers can be added. All formulations fororal administration should be in dosages suitable for administration.

Other forms suitable for oral administration include liquid formpreparations including emulsions, syrups, elixirs, aqueous solutions,aqueous suspensions, or solid form preparations which are intended to beconverted shortly before use to liquid form preparations. Emulsions canbe prepared in solutions, for example, in aqueous propylene glycolsolutions or can contain emulsifying agents, for example, such aslecithin, sorbitan monooleate, or acacia. Aqueous solutions can beprepared by dissolving the active component in water and adding suitablecolorants, flavors, stabilizers, and thickening agents. Aqueoussuspensions can be prepared by dispersing the finely divided activecomponent in water with viscous material, such as natural or syntheticgums, resins, methylcellulose, sodium carboxymethylcellulose, and otherwell known suspending agents. Suitable fillers or carriers with whichthe compositions can be administered include agar, alcohol, fats,lactose, starch, cellulose derivatives, polysaccharides,polyvinylpyrrolidone, silica, sterile saline and the like, or mixturesthereof used in suitable amounts. Solid form preparations includesolutions, suspensions, and emulsions, and can contain, in addition tothe active component, colorants, flavors, stabilizers, buffers,artificial and natural sweeteners, dispersants, thickeners, solubilizingagents, and the like.

A syrup or suspension can be made by adding the active compound to aconcentrated, aqueous solution of a sugar, e.g., sucrose, to which canalso be added any accessory ingredients. Such accessory ingredients caninclude flavoring, an agent to retard crystallization of the sugar or anagent to increase the solubility of any other ingredient, e.g., as apolyhydric alcohol, for example, glycerol or sorbitol.

When formulating compounds of the disclosure for oral administration, itcan be desirable to utilize gastroretentive formulations to enhanceabsorption from the gastrointestinal (GI) tract. A formulation which isretained in the stomach for several hours can release compounds of thedisclosure slowly and provide a sustained release that can be preferredin some embodiments of the disclosure. Disclosure of suchgastro-retentive formulations are found in Klausner, E. A.; Lavy, E.;Barta, M.; Cserepes, E.; Friedman, M.; Hoffman, A. 2003 “Novelgastroretentive dosage forms: evaluation of gastroretentivity and itseffect on levodopa in humans.” Pharm. Res. 20, 1466-73, Hoffman, A.;Stepensky, D.; Lavy, E.; Eyal, S. Klausner, E.; Friedman, M. 2004“Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosageforms” Int. J. Pharm. 11, 141-53, Streubel, A.; Siepmann, J.; Bodmeier,R.; 2006 “Gastroretentive drug delivery systems” Expert Opin. DrugDeliver. 3, 217-3, and Chavanpatil, M. D.; Jain, P.; Chaudhari, S.;Shear, R.; Vavia, P. R.

“Novel sustained release, swellable and bioadhesive gastroretentive drugdelivery system for olfoxacin” Int. J. Pharm. 2006. Expandable, floatingand bioadhesive techniques can be utilized to maximize absorption of thecompounds of the disclosure.

The compounds of the disclosure can be formulated for parenteraladministration (e.g., by injection, for example, bolus injection orcontinuous infusion) and can be presented in unit dose form in ampoules,pre-filled syringes, small volume infusion or in multi-dose containerswith an added preservative. The compositions can take such forms assuspensions, solutions, or emulsions in oily or aqueous vehicles, forexample, solutions in aqueous polyethylene glycol.

For injecTable formulations, the vehicle can be chosen from those knownin art to be suitable, including aqueous solutions or oil suspensions,or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil,as well as elixirs, mannitol, dextrose, or a sterile aqueous solution,and similar pharmaceutical vehicles. The formulation can also comprisepolymer compositions which are biocompatible, biodegradable, such aspoly(lactic-co-glycolic)acid. These materials can be made into micro ornanospheres, loaded with drug and further coated or derivatized toprovide superior sustained release performance. Vehicles suitable forperiocular or intraocular injection include, for example, suspensions oftherapeutic agent in injection grade water, liposomes and vehiclessuitable for lipophilic substances. Other vehicles for periocular orintraocular injection are well known in the art.

In a preferred embodiment, the composition is formulated in accordancewith routine procedures as a pharmaceutical composition adapted forintravenous administration to human beings. Typically, compositions forintravenous administration are solutions in sterile isotonic aqueousbuffer. Where necessary, the composition can also include a solubilizingagent and a local anesthetic such as lidocaine to ease pain at the siteof the injection. Generally, the ingredients are supplied eitherseparately or mixed together in unit dosage form, for example, as a drylyophilized powder or water free concentrate in a hermetically sealedcontainer such as an ampoule or sachette indicating the quantity ofactive agent. Where the composition is to be administered by infusion,it can be dispensed with an infusion bottle containing sterilepharmaceutical grade water or saline. Where the composition isadministered by injection, an ampoule of sterile water for injection orsaline can be provided so that the ingredients can be mixed prior toadministration.

When administration is by injection, the active compound can beformulated in aqueous solutions, specifically in physiologicallycompatible buffers such as Hanks solution, Ringer's solution, orphysiological saline buffer. The solution can contain formulatory agentssuch as suspending, stabilizing and/or dispersing agents. Alternatively,the active compound can be in powder form for constitution with asuitable vehicle, e.g., sterile pyrogen-free water, before use. In someembodiments, the pharmaceutical composition does not comprise anadjuvant or any other substance added to enhance the immune responsestimulated by the peptide. In some embodiments, the pharmaceuticalcomposition comprises a substance that inhibits an immune response tothe peptide. Methods of formulation are known in the art, for example,as disclosed in Remington's Pharmaceutical Sciences, latest edition,Mack Publishing Co., Easton P.

In addition to the formulations described previously, the agents canalso be formulated as a depot preparation. Such long acting formulationscan be administered by implantation or transcutaneous delivery (forexample, subcutaneously or intramuscularly), intramuscular injection oruse of a transdermal patch. Thus, for example, the agents can beformulated with suitable polymeric or hydrophobic materials (forexample, as an emulsion in an accepTable oil) or ion exchange resins, oras sparingly soluble derivatives, for example, as a sparingly solublesalt.

In some embodiments, pharmaceutical compositions comprising one or moreagents of the present disclosure exert local and regional effects whenadministered topically or injected at or near particular sites ofinfection. Direct topical application, e.g., of a viscous liquid,solution, suspension, dimethylsulfoxide (DMSO)-based solutions,liposomal formulations, gel, jelly, cream, lotion, ointment,suppository, foam, or aerosol spray, can be used for localadministration, to produce for example, local and/or regional effects.Pharmaceutically appropriate vehicles for such formulation include, forexample, lower aliphatic alcohols, polyglycols (e.g., glycerol orpolyethylene glycol), esters of fatty acids, oils, fats, silicones, andthe like. Such preparations can also include preservatives (e.g.,p-hydroxybenzoic acid esters) and/or antioxidants (e.g., ascorbic acidand tocopherol). See also Dermatological Formulations: Percutaneousabsorption, Barry (Ed.), Marcel Dekker Incl, 1983.

Pharmaceutical compositions of the present disclosure can contain acosmetically or dermatologically accepTable carrier. Such carriers arecompatible with skin, nails, mucous membranes, tissues and/or hair, andcan include any conventionally used cosmetic or dermatological carriermeeting these requirements. Such carriers can be readily selected by oneof ordinary skill in the art. In formulating skin ointments, an agent orcombination of agents of the instant disclosure can be formulated in anoleaginous hydrocarbon base, an anhydrous absorption base, awater-in-oil absorption base, an oil-in-water water-removable baseand/or a water-soluble base. Examples of such carriers and excipientsinclude, but are not limited to, humectants (e.g., urea), glycols (e.g.,propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleicacid), surfactants (e.g., isopropyl myristate and sodium laurylsulfate), pyrrolidones, glycerol monolaurate, sulfoxides, terpenes(e.g., menthol), amines, amides, alkanes, alkanols, water, calciumcarbonate, calcium phosphate, various sugars, starches, cellulosederivatives, gelatin, and polymers such as polyethylene glycols.

Ointments and creams can, for example, be formulated with an aqueous oroily base with the addition of suitable thickening and/or gellingagents. Lotions can be formulated with an aqueous or oily base and willin general also containing one or more emulsifying agents, stabilizingagents, dispersing agents, suspending agents, thickening agents, orcoloring agents. The construction and use of transdermal patches for thedelivery of pharmaceutical agents is well known in the art. See, e.g.,U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches can beconstructed for continuous, pulsatile, or on demand delivery ofpharmaceutical agents.

Lubricants which can be used to form pharmaceutical compositions anddosage forms of the disclosure include, but are not limited to, calciumstearate, magnesium stearate, mineral oil, light mineral oil, glycerin,sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid,sodium lauryl sulfate, talc, hydrogenated vegeTable oil (e.g., peanutoil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, andsoybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, ormixtures thereof. Additional lubricants include, for example, a syloidsilica gel, a coagulated aerosol of synthetic silica, or mixturesthereof A lubricant can optionally be added, in an amount of less thanabout 1 weight percent of the pharmaceutical composition.

The compositions according to the present disclosure can be in any formsuitable for topical application, including aqueous, aqueous-alcoholicor oily solutions, lotion or serum dispersions, aqueous, anhydrous oroily gels, emulsions obtained by dispersion of a fatty phase in anaqueous phase (O/W or oil in water) or, conversely, (W/O or water inoil), microemulsions or alternatively microcapsules, microparticles orlipid vesicle dispersions of ionic and/or nonionic type. Thesecompositions can be prepared according to conventional methods. Otherthan the agents of the disclosure, the amounts of the variousconstituents of the compositions according to the disclosure are thoseconventionally used in the art. These compositions in particularconstitute protection, treatment or care creams, milks, lotions, gels orfoams for the face, for the hands, for the body and/or for the mucousmembranes, or for cleansing the skin. The compositions can also consistof solid preparations constituting soaps or cleansing bars.

Compositions of the present disclosure can also contain adjuvants commonto the cosmetic and dermatological fields, such as hydrophilic orlipophilic gelling agents, hydrophilic or lipophilic active agents,preserving agents, antioxidants, solvents, fragrances, fillers,sunscreens, odor-absorbers and dyestuffs. The amounts of these variousadjuvants are those conventionally used in the fields considered and,for example, are from about 0.01% to about 20% of the total weight ofthe composition. Depending on their nature, these adjuvants can beintroduced into the fatty phase, into the aqueous phase and/or into thelipid vesicles.

In some embodiments, ocular viral infections can be effectively treatedwith ophthalmic solutions, suspensions, ointments or inserts comprisingan agent or combination of agents of the present disclosure. Eye dropscan be prepared by dissolving the active ingredient in a sterile aqueoussolution such as physiological saline, buffering solution, etc., or bycombining powder compositions to be dissolved before use. Other vehiclescan be chosen, as is known in the art, including but not limited to:balance salt solution, saline solution, water soluble polyethers such aspolyethyene glycol, polyvinyls, such as polyvinyl alcohol and povidone,cellulose derivatives such as methylcellulose and hydroxypropylmethylcellulose, petroleum derivatives such as mineral oil and whitepetrolatum, animal fats such as lanolin, polymers of acrylic acid suchas carboxypolymethylene gel, vegeTable fats such as peanut oil andpolysaccharides such as dextrans, and glycosaminoglycans such as sodiumhyaluronate. If desired, additives ordinarily used in the eye drops canbe added. Such additives include isotonizing agents (e.g., sodiumchloride, etc.), buffer agent (e.g., boric acid, sodium monohydrogenphosphate, sodium dihydrogen phosphate, etc.), preservatives (e.g.,benzalkonium chloride, benzethonium chloride, chlorobutanol, etc.),thickeners (e.g., saccharide such as lactose, mannitol, maltose, etc.;e.g., hyaluronic acid or its salt such as sodium hyaluronate, potassiumhyaluronate, etc.; e.g., mucopolysaccharide such as chondroitin sulfate,etc.; e.g., sodium polyacrylate, carboxyvinyl polymer, crosslinkedpolyacrylate, polyvinyl alcohol, polyvinyl pyrrolidone, methylcellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose,carboxymethyl cellulose, hydroxy propyl cellulose or other agents knownto those skilled in the art).

The solubility of the components of the present compositions can beenhanced by a surfactant or other appropriate co-solvent in thecomposition. Such cosolvents include polysorbate 20, 60, and 80,Pluronic F68, F-84 and P-103, cyclodextrin, or other agents known tothose skilled in the art. Such co-solvents can be employed at a level offrom about 0.01% to 2% by weight.

The compositions of the disclosure can be packaged in multidose form.Preservatives can be preferred to prevent microbial contamination duringuse. Suitable preservatives include: benzalkonium chloride, thimerosal,chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol,edetate disodium, sorbic acid, Onamer M, or other agents known to thoseskilled in the art. In the prior art ophthalmic products, suchpreservatives can be employed at a level of from 0.004% to 0.02%. In thecompositions of the present application the preservative, preferablybenzalkonium chloride, can be employed at a level of from 0.001% to lessthan 0.01%, e.g. from 0.001% to 0.008%, preferably about 0.005% byweight. It has been found that a concentration of benzalkonium chlorideof 0.005% can be sufficient to preserve the compositions of the presentdisclosure from microbial attack.

In some embodiments, developmental disorder associated symptoms of theear can be effectively treated with otic solutions, suspensions,ointments or inserts comprising an agent or combination of agents of thepresent disclosure.

In some embodiments, the agents of the present disclosure are deliveredin soluble rather than suspension form, which allows for more rapid andquantitative absorption to the sites of action. In general, formulationssuch as jellies, creams, lotions, suppositories and ointments canprovide an area with more extended exposure to the agents of the presentdisclosure, while formulations in solution, e.g., sprays, provide moreimmediate, short-term exposure.

In some embodiments relating to topical/local application, thepharmaceutical compositions can include one or more penetrationenhancers. For example, the formulations can comprise suitable solid orgel phase carriers or excipients that increase penetration or helpdelivery of agents or combinations of agents of the disclosure across apermeability barrier, e.g., the skin. Many of thesepenetration-enhancing compounds are known in the art of topicalformulation, and include, e.g., water, alcohols (e.g., terpenes likemethanol, ethanol, 2-propanol), sulfoxides (e.g., dimethyl sulfoxide,decylmethyl sulfoxide, tetradecylmethyl sulfoxide), pyrrolidones (e.g.,2-pyrrolidone, N-methyl-2-pyrrolidone, N-(2-hydroxyethyl)pyrrolidone),laurocapram, acetone, dimethylacetamide, dimethylformamide,tetrahydrofurfuryl alcohol, L-α-amino acids, anionic, cationic,amphoteric or nonionic surfactants (e.g., isopropyl myristate and sodiumlauryl sulfate), fatty acids, fatty alcohols (e.g., oleic acid), amines,amides, clofibric acid amides, hexamethylene lauramide, proteolyticenzymes, α-bisabolol, d-limonene, urea and N,N-diethyl-m-toluamide, andthe like. Additional examples include humectants (e.g., urea), glycols(e.g., propylene glycol and polyethylene glycol), glycerol monolaurate,alkanes, alkanols, ORGELASE, calcium carbonate, calcium phosphate,various sugars, starches, cellulose derivatives, gelatin, and/or otherpolymers. In some embodiments, the pharmaceutical compositions willinclude one or more such penetration enhancers.

In some embodiments, the pharmaceutical compositions for local/topicalapplication can include one or more antimicrobial preservatives such asquaternary ammonium compounds, organic mercurials, p-hydroxy benzoates,aromatic alcohols, chlorobutanol, and the like.

Gastrointestinal developmental disorder symptoms can be effectivelytreated with orally- or rectally delivered solutions, suspensions,ointments, enemas and/or suppositories comprising an agent orcombination of agents of the present disclosure.

Respiratory developmental disorder symptoms can be effectively treatedwith aerosol solutions, suspensions or dry powders comprising an agentor combination of agents of the present disclosure. Administration byinhalation is particularly useful in treating viral infections of thelung, such as influenza. The aerosol can be administered through therespiratory system or nasal passages. For example, one skilled in theart will recognize that a composition of the present disclosure can besuspended or dissolved in an appropriate carrier, e.g., apharmaceutically accepTable propellant, and administered directly intothe lungs using a nasal spray or inhalant. For example, an aerosolformulation comprising a developmental disorder associated biomarkers'inhibitors can be dissolved, suspended or emulsified in a propellant ora mixture of solvent and propellant, e.g., for administration as a nasalspray or inhalant. Aerosol formulations can contain any accepTablepropellant under pressure, such as a cosmetically or dermatologically orpharmaceutically accepTable propellant, as conventionally used in theart.

An aerosol formulation for nasal administration is generally an aqueoussolution designed to be administered to the nasal passages in drops orsprays. Nasal solutions can be similar to nasal secretions in that theyare generally isotonic and slightly buffered to maintain a pH of about5.5 to about 6.5, although pH values outside of this range canadditionally be used. Antimicrobial agents or preservatives can also beincluded in the formulation.

An aerosol formulation for inhalations and inhalants can be designed sothat the agent or combination of agents of the present disclosure iscarried into the respiratory tree of the subject when administered bythe nasal or oral respiratory route. Inhalation solutions can beadministered, for example, by a nebulizer. Inhalations or insufflations,comprising finely powdered or liquid drugs, can be delivered to therespiratory system as a pharmaceutical aerosol of a solution orsuspension of the agent or combination of agents in a propellant, e.g.,to aid in disbursement. Propellants can be liquefied gases, includinghalocarbons, for example, fluorocarbons such as fluorinated chlorinatedhydrocarbons, hydrochlorofluorocarbons, and hydrochlorocarbons, as wellas hydrocarbons and hydrocarbon ethers.

Halocarbon propellants useful in the present disclosure includefluorocarbon propellants in which all hydrogens are replaced withfluorine, chlorofluorocarbon propellants in which all hydrogens arereplaced with chlorine and at least one fluorine, hydrogen-containingfluorocarbon propellants, and hydrogen-containing chlorofluorocarbonpropellants. Halocarbon propellants are described in Johnson, U.S. Pat.No. 5,376,359; Byron et al., U.S. Pat. No. 5,190,029; and Purewal etal., U.S. Pat. No. 5,776,434. Hydrocarbon propellants useful in thedisclosure include, for example, propane, isobutane, n-butane, pentane,isopentane and neopentane. A blend of hydrocarbons can also be used as apropellant. Ether propellants include, for example, dimethyl ether aswell as the ethers. An aerosol formulation of the disclosure can alsocomprise more than one propellant. For example, the aerosol formulationcan comprise more than one propellant from the same class, such as twoor more fluorocarbons; or more than one, more than two, more than threepropellants from different classes, such as a fluorohydrocarbon and ahydrocarbon. Pharmaceutical compositions of the present disclosure canalso be dispensed with a compressed gas, e.g., an inert gas such ascarbon dioxide, nitrous oxide or nitrogen.

Aerosol formulations can also include other components, for example,ethanol, isopropanol, propylene glycol, as well as surfactants or othercomponents such as oils and detergents. These components can serve tostabilize the formulation and/or lubricate valve components.

The aerosol formulation can be packaged under pressure and can beformulated as an aerosol using solutions, suspensions, emulsions,powders and semisolid preparations. For example, a solution aerosolformulation can comprise a solution of an agent of the disclosure suchas a developmental disorder associated biomarkers' inhibitors in(substantially) pure propellant or as a mixture of propellant andsolvent. The solvent can be used to dissolve the agent and/or retard theevaporation of the propellant. Solvents useful in the disclosureinclude, for example, water, ethanol and glycols. Any combination ofsuitable solvents can be use, optionally combined with preservatives,antioxidants, and/or other aerosol components.

An aerosol formulation can also be a dispersion or suspension. Asuspension aerosol formulation can comprise a suspension of an agent orcombination of agents of the instant disclosure, e.g., a developmentaldisorder associated biomarkers' inhibitors, and a dispersing agent.Dispersing agents useful in the disclosure include, for example,sorbitan trioleate, oleyl alcohol, oleic acid, lecithin and corn oil. Asuspension aerosol formulation can also include lubricants,preservatives, antioxidant, and/or other aerosol components.

An aerosol formulation can similarly be formulated as an emulsion. Anemulsion aerosol formulation can include, for example, an alcohol suchas ethanol, a surfactant, water and a propellant, as well as an agent orcombination of agents of the disclosure, e.g., a developmental disorderassociated biomarkers' inhibitors. The surfactant used can be nonionic,anionic or cationic. One example of an emulsion aerosol formulationcomprises, for example, ethanol, surfactant, water and propellant.Another example of an emulsion aerosol formulation comprises, forexample, vegeTable oil, glyceryl monostearate and propane.

The compounds of the disclosure can be formulated for administration assuppositories. A low melting wax, such as a mixture of triglycerides,fatty acid glycerides, Witepsol S55 (trademark of Dynamite NobelChemical, Germany), or cocoa butter is first melted and the activecomponent is dispersed homogeneously, for example, by stirring. Themolten homogeneous mixture is then poured into convenient sized molds,allowed to cool, and to solidify.

The compounds of the disclosure can be formulated for vaginaladministration. Pessaries, tampons, creams, gels, pastes, foams orsprays containing in addition to the active ingredient such carriers asare known in the art to be appropriate.

It is envisioned additionally, that the compounds of the disclosure canbe attached releasably to biocompatible polymers for use in sustainedrelease formulations on, in or attached to inserts for topical,intraocular, periocular, or systemic administration. The controlledrelease from a biocompatible polymer can be utilized with a watersoluble polymer to form an instillable formulation, as well. Thecontrolled release from a biocompatible polymer, such as for example,PLGA microspheres or nanospheres, can be utilized in a formulationsuitable for intra ocular implantation or injection for sustainedrelease administration, as well any suitable biodegradable andbiocompatible polymer can be used.

In one aspect of the disclosure, the subject's carrier status of any ofthe genetic variation risk variants described herein, or geneticvariants identified via other analysis methods within the genes orregulatory loci that are identified by the CNVs described herein, can beused to help determine whether a particular treatment modality for adevelopmental disorder, such as any one of the above, or a combinationthereof, should be administered. The present disclosure also relates tomethods of monitoring progress or effectiveness of a treatment optionfor a developmental disorder. The treatment option can include any ofthe above mentioned treatment options commonly used. This can be donebased on the outcome of determination of the presence of a particulargenetic variation risk variant in the individual, or by monitoringexpression of genes that are associated with the variants of the presentdisclosure. Expression levels and/or mRNA levels can thus be determinedbefore and during treatment to monitor its effectiveness. Alternatively,or concomitantly, the status with respect to a genetic variation, and orgenotype and/or haplotype status of at least one risk variant for adevelopmental disorder presented herein can determined before and duringtreatment to monitor its effectiveness. It can also be appreciated bythose skilled in the art that aberrant expression levels of a geneimpacted by a CNV or other mutations found as a consequence of targetedsequencing of the CNV-identified gene can be assayed or diagnosticallytested for by measuring the protein expression level of said aberrantlyexpressed gene. In another embodiment, aberrant expression levels of agene may result from a CNV impacting a DNA sequence (e.g., transcriptionfactor binding site) that regulates a gene who's aberrant expressionlevel is involved in or causes a developmental disorder, or othermutations found as a consequence of targeted sequencing of theCNV-identified gene regulatory sequence, can be assayed ordiagnostically tested for by measuring the protein expression level ofthe gene involved in or causative of a developmental disorder. In someembodiments, a specific CNV mutation within a gene, or other specificmutations found upon targeted sequencing of a CNV-identified gene foundto be involved in or causative of a developmental disorder, may cause anaberrant structural change in the expressed protein that results fromsaid gene mutations and the altered protein structure(s) can be assayedvia various methods know to those skilled in the art.

Alternatively, biological networks or metabolic pathways related to thegenes within, or associated with, the genetic variations describedherein can be monitored by determining mRNA and/or polypeptide levels.This can be done for example, by monitoring expression levels orpolypeptides for several genes belonging to the network and/or pathway,in samples taken before and during treatment. Alternatively, metabolitesbelonging to the biological network or metabolic pathway can bedetermined before and during treatment. Effectiveness of the treatmentis determined by comparing observed changes in expressionlevels/metabolite levels during treatment to corresponding data fromhealthy subjects.

In a further aspect, the genetic variations described herein, and/orthose subsequently found (e.g., via other genetic analysis methods suchas sequencing) via targeted analysis of those genes initially identifiedby the genetic variations described herein, can be used to increasepower and effectiveness of clinical trials. Thus, individuals who arecarriers of at least one at-risk genetic variation can be more likely torespond to a particular treatment modality for a developmental disorder.In some embodiments, individuals who carry at-risk variants for gene(s)in a pathway and/or metabolic network for which a particular treatmentis targeting are more likely to be responders to the treatment. Inanother embodiment, individuals who carry at-risk variants for a gene,which expression and/or function is altered by the at-risk variant, aremore likely to be responders to a treatment modality targeting thatgene, its expression or its gene product. This application can improvethe safety of clinical trials, but can also enhance the chance that aclinical trial can demonstrate statistically significant efficacy, whichcan be limited to a certain sub-group of the population. Thus, onepossible outcome of such a trial is that carriers of certain geneticvariants, are statistically significant and likely to show positiveresponse to the therapeutic agent. Further, one or more of the geneticvariations employed during clinical trials for a given therapeutic agentcan be used in a companion diagnostic test that is administered to thepatient prior to administration of the therapeutic agent to determine ifthe patient is likely to have favorable response to the therapeuticagent.

In a further aspect, the genetic variations described herein can be usedfor targeting the selection of pharmaceutical agents for specificindividuals. The pharmaceutical agent can be any of the agents describedin the above. Personalized selection of treatment modalities, lifestylechanges or combination of the two, can be realized by the utilization ofthe at-risk genetic variations or surrogate markers in linkagedisequilibrium with the genetic variations. Thus, the knowledge of anindividual's status for particular genetic variations can be useful forselection of treatment options, for example, for treatments that targetgenes or gene products affected by one or more of the geneticvariations. Certain combinations of variants, including those describedherein, but also combinations with other risk variants for adevelopmental disorder, can be suitable for one selection of treatmentoptions, while other variant combinations can target other treatmentoptions. Such combinations of variants can include one variant, twovariants, three variants, or four or more variants, as needed todetermine with clinically reliable accuracy the selection of treatmentmodule.

Animal and Cell Models of Developmental disorders

Also provided herein are engineered cells that can harbor one or morepolymorphism described herein, for example, one or more geneticvariations associated with a developmental disorder, for example, a SNPor CNV. Such cells can be useful for studying the effect of apolymorphism on physiological function, and for identifying and/orevaluating potential therapeutic agents such as anti-psychotics for thetreatment of a developmental disorder.

Methods are known in the art for generating cells, for example, byhomologous recombination between the endogenous gene and an exogenousDNA molecule introduced into a cell, for example, a cell of an animal.In some cases, cells can be used to generate transgenic animals usingmethods known in the art.

The cells are preferably mammalian cells in which an endogenous gene hasbeen altered to include a genetic variation as described herein.Techniques such as targeted homologous recombination, can be used toinsert the heterologous DNA as described in, e.g., Chappel, U.S. Pat.No. 5,272,071; WO 91/06667. In another embodiment induced pluripotentstem cells with specific disease-causing or disease-associated mutations(such as CNVs and SNVs) can be used for disease modeling and drugdiscovery, for example, as described in Grskovic et al. (2011) Nat. Rev.Drug. Discov. 10(12):915-29.

Autism Spectrum Disorder is not known to occur naturally in any speciesother than humans, although recently, an animal model has been developedthat shows some features of the disease. This mouse model was created byreplacing the normal mouse neuroligin-3 gene with a mutated neuroligin-3gene associated with autism in humans (Siidhof, M. D., et al., UTSouthwestern; Tabuchi et al. (2007) Science 318(5847):71-6). By doingso, a gene was created in mice similar to the human autism disease gene.While the result amounted to a very small change in their geneticmakeup, it mimics the same small change occurring in some patients withhuman autism. This and any other models described in the literature canbe used with the methods of the disclosure.

Pharmaceutical compositions suitable for use in the present disclosureinclude compositions wherein the active ingredients are present in aneffective amount, i.e., in an amount effective to achieve therapeuticand/or prophylactic benefit in a host with at least one a developmentaldisorder associated symptom. The actual amount effective for aparticular application will depend on the condition or conditions beingtreated, the condition of the subject, the formulation, and the route ofadministration, as well as other factors known to those of skill in theart. Determination of an effective amount of a developmental disorderassociated biomarkers' inhibitors is well within the capabilities ofthose skilled in the art, in light of the disclosure herein, and will bedetermined using routine optimization techniques.

The effective amount for use in humans can be determined from animalmodels. For example, a dose for humans can be formulated to achievecirculating, liver, topical and/or gastrointestinal concentrations thathave been found to be effective in animals. One skilled in the art candetermine the effective amount for human use, especially in light of theanimal model experimental data described herein. Based on animal data,and other types of similar data, those skilled in the art can determinethe effective amounts of compositions of the present disclosureappropriate for humans.

The effective amount when referring to an agent or combination of agentsof the disclosure will generally mean the dose ranges, modes ofadministration, formulations, etc., that have been recommended orapproved by any of the various regulatory or advisory organizations inthe medical or pharmaceutical arts (e.g., FDA, AMA) or by themanufacturer or supplier.

Further, appropriate doses for a developmental disorder's associatedbiomarkers' inhibitors can be determined based on in vitro experimentalresults. For example, the in vitro potency of an agent in inhibiting adevelopmental disorder's associated biomarkers' components, providesinformation useful in the development of effective in vivo dosages toachieve similar biological effects. In some embodiments, administrationof agents of the present disclosure can be intermittent, for example,administration once every two days, every three days, every five days,once a week, once or twice a month, and the like. In some embodiments,the amount, forms, and/or amounts of the different forms can be variedat different times of administration.

A person of skill in the art would be able to monitor in a subject theeffect of administration of a particular agent. Other techniques wouldbe apparent to one of skill in the art, wherein the active ingredientsare present in an effective amount, for example, in an amount effectiveto achieve therapeutic and/or prophylactic benefit in a host with atleast one developmental disorder associated symptom. The actual amounteffective for a particular application will depend on the condition orconditions being treated, the condition of the subject, the formulation,and the route of administration, as well as other factors known to thoseof skill in the art. Determination of an effective amount of adevelopmental disorder's associated biomarkers' inhibitors is wellwithin the capabilities of those skilled in the art, in light of thedisclosure herein, and will be determined using routine optimizationtechniques.

Further, appropriate doses for a developmental disorder's associatedbiomarkers' inhibitors can be determined based on in vitro experimentalresults. For example, the in vitro potency of an agent in inhibiting adevelopmental disorder's associated biomarkers' components can provideinformation useful in the development of effective in vivo dosages toachieve similar biological effects.

Kits

Kits useful in the methods of the disclosure comprise components usefulin any of the methods described herein, including for example, primersfor nucleic acid amplification, hybridization probes for detectinggenetic variation, or other marker detection, restriction enzymes,nucleic acid probes, optionally labeled with suitable labels,allele-specific oligonucleotides, antibodies that bind to an alteredpolypeptide encoded by a nucleic acid of the disclosure as describedherein or to a wild type polypeptide encoded by a nucleic acid of thedisclosure as described herein, means for amplification of geneticvariations or fragments thereof, means for analyzing the nucleic acidsequence of nucleic acids comprising genetic variations as describedherein, means for analyzing the amino acid sequence of a polypeptideencoded by a genetic variation, or a nucleic acid associated with agenetic variation, etc. The kits can for example, include necessarybuffers, nucleic acid primers for amplifying nucleic acids, and reagentsfor allele-specific detection of the fragments amplified using suchprimers and necessary enzymes (e.g., DNA polymerase). Additionally, kitscan provide reagents for assays to be used in combination with themethods of the present disclosure, for example, reagents for use withother screening assays for a developmental disorder.

In some embodiments, the disclosure pertains to a kit for assaying asample from a subject to detect the presence of a genetic variation,wherein the kit comprises reagents necessary for selectively detectingat least one particular genetic variation in the genome of theindividual. In another embodiment, the disclosure pertains to a kit forassaying a sample from a subject to detect the presence of at leastparticular allele of at least one polymorphism associated with a geneticvariation in the genome of the subject. In some embodiments, thereagents comprise at least one contiguous oligonucleotide thathybridizes to a fragment of the genome of the individual comprising atleast genetic variation. In another embodiment, the reagents comprise atleast one pair of oligonucleotides that hybridize to opposite strands ofa genomic segment obtained from a subject, wherein each oligonucleotideprimer pair is designed to selectively amplify a fragment of the genomeof the individual that includes at least one genetic variation, or afragment of a genetic variation. Such oligonucleotides or nucleic acidscan be designed using the methods described herein. In anotherembodiment, the kit comprises one or more labeled nucleic acids capableof allele-specific detection of one or more specific polymorphic markersor haplotypes with a genetic variation, and reagents for detection ofthe label. In some embodiments, a kit for detecting SNP markers cancomprise a detection oligonucleotide probe, that hybridizes to a segmentof template DNA containing a SNP polymorphisms to be detected, anenhancer oligonucleotide probe, detection probe, primer and/or anendonuclease, for example, as described by Kutyavin et al. (Nucleic AcidRes. 34:e128 (2006)).

In some embodiments, the DNA template is amplified by any means of thepresent disclosure, prior to assessment for the presence of specificgenetic variations as described herein. Standard methods well known tothe skilled person for performing these methods can be utilized, and arewithin scope of the disclosure. In one such embodiment, reagents forperforming these methods can be included in the reagent kit.

In a further aspect of the present disclosure, a pharmaceutical pack(kit) is provided, the pack comprising a therapeutic agent and a set ofinstructions for administration of the therapeutic agent to humansscreened for one or more variants of the present disclosure, asdisclosed herein. The therapeutic agent can be a small molecule drug, anantibody, a peptide, an antisense or RNAi molecule, or other therapeuticmolecules as described herein. In some embodiments, an individualidentified as a carrier of at least one variant of the presentdisclosure is instructed to take a prescribed dose of the therapeuticagent. In one such embodiment, an individual identified as a carrier ofat least one variant of the present disclosure is instructed to take aprescribed dose of the therapeutic agent. In another embodiment, anindividual identified as a non-carrier of at least one variant of thepresent disclosure is instructed to take a prescribed dose of thetherapeutic agent.

Also provided herein are articles of manufacture, comprising a probethat hybridizes with a region of human chromosome as described hereinand can be used to detect a polymorphism described herein. For example,any of the probes for detecting polymorphisms described herein can becombined with packaging material to generate articles of manufacture orkits. The kit can include one or more other elements including:instructions for use; and other reagents such as a label or an agentuseful for attaching a label to the probe. Instructions for use caninclude instructions for screening applications of the probe for makinga diagnosis, prognosis, or theranosis to a developmental disorder in amethod described herein. Other instructions can include instructions forattaching a label to the probe, instructions for performing in situanalysis with the probe, and/or instructions for obtaining a sample tobe analyzed from a subject. In some cases, the kit can include a labeledprobe that hybridizes to a region of human chromosome as describedherein.

The kit can also include one or more additional reference or controlprobes that hybridize to the same chromosome or another chromosome orportion thereof that can have an abnormality associated with aparticular endophenotype. A kit that includes additional probes canfurther include labels, e.g., one or more of the same or differentlabels for the probes. In other embodiments, the additional probe orprobes provided with the kit can be a labeled probe or probes. When thekit further includes one or more additional probe or probes, the kit canfurther provide instructions for the use of the additional probe orprobes. Kits for use in self-testing can also be provided. Such testkits can include devices and instructions that a subject can use toobtain a biological sample (e.g., buccal cells, blood) without the aidof a health care provider. For example, buccal cells can be obtainedusing a buccal swab or brush, or using mouthwash.

Kits as provided herein can also include a mailer (e.g., a postage paidenvelope or mailing pack) that can be used to return the sample foranalysis, e.g., to a laboratory. The kit can include one or morecontainers for the sample, or the sample can be in a standard bloodcollection vial. The kit can also include one or more of an informedconsent form, a test requisition form, and instructions on how to usethe kit in a method described herein. Methods for using such kits arealso included herein. One or more of the forms (e.g., the testrequisition form) and the container holding the sample can be coded, forexample, with a bar code for identifying the subject who provided thesample.

In some embodiments, an in vitro screening test can comprise one or moredevices, tools, and equipment configured to collect a genetic samplefrom an individual. In some embodiments of an in vitro screening test,tools to collect a genetic sample can include one or more of a swab, ascalpel, a syringe, a scraper, a container, and other devices andreagents designed to facilitate the collection, storage, and transportof a genetic sample. In some embodiments, an in vitro screening test caninclude reagents or solutions for collecting, stabilizing, storing, andprocessing a genetic sample.

Such reagents and solutions for nucleotide collecting, stabilizing,storing, and processing are well known by those of skill in the art andcan be indicated by specific methods used by an in vitro screening testas described herein. In another embodiment, an in vitro screening testas disclosed herein, can comprise a microarray apparatus and reagents, aflow cell apparatus and reagents, a multiplex nucleotide sequencer andreagents, and additional hardware and software necessary to assay agenetic sample for certain genetic markers and to detect and visualizecertain genetic markers.

The present disclosure further relates to kits for using antibodies inthe methods described herein. This includes, but is not limited to, kitsfor detecting the presence of a variant protein in a test sample. Onepreferred embodiment comprises antibodies such as a labeled or labelableantibody and a compound or agent for detecting variant proteins in abiological sample, means for determining the amount or the presenceand/or absence of variant protein in the sample, and means for comparingthe amount of variant protein in the sample with a standard, as well asinstructions for use of the kit. In certain embodiments, the kit furthercomprises a set of instructions for using the reagents comprising thekit.

Unless otherwise explained, all technical and scientific terms usedherein have the same meaning as commonly understood by one of ordinaryskill in the art to which this disclosure belongs. The followingreferences contain embodiments of the methods and compositions that canbe used herein: The Merck Manual of Diagnosis and Therapy, 18th Edition,published by Merck Research Laboratories, 2006 (ISBN 0-911910-18-2);Benjamin Lewin, Genes IX, published by Jones & Bartlett Publishing, 2007(ISBN-13: 9780763740634); Kendrew et al. (eds.), The Encyclopedia ofMolecular Biology, published by Blackwell Science Ltd., 1994 (ISBN0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology andBiotechnol-ogy: a Comprehensive Desk Reference, published by VCHPublishers, Inc., 1995 (ISBN 1-56081-569-8). Standard procedures of thepresent disclosure are described, e.g., in Maniatis et al., MolecularCloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y., USA (1982); Sambrook et al., Molecular Cloning: ALaboratory Manual (2 ed.), Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y., USA (1989); Davis et al., Basic Methods inMolecular Biology, Elsevier Science Publishing, Inc., New York, USA(1986); or Methods in Enzymology: Guide to Molecular Cloning TechniquesVol. 152, S. L. Berger and A. R. Kimmerl (eds.), Academic Press Inc.,San Diego, USA (1987)). Current Protocols in Molecular Biology (CPMB)(Fred M. Ausubel, et al. ed., John Wiley and Sons, Inc.), CurrentProtocols in Protein Science (CPPS) (John E. Coligan, et. al., ed., JohnWiley and Sons, Inc.), Current Protocols in Immunology (CPI) (John E.Coligan, et. al., ed. John Wiley and Sons, Inc.), Current Protocols inCell Biology (CPCB) (Juan S. Bonifacino et. al. ed., John Wiley andSons, Inc.), Culture of Animal Cells: A Manual of Basic Technique by R.Ian Freshney, Publisher: Wiley-Liss; 5th edition (2005), and Animal CellCulture Methods (Methods in Cell Biology, Vol. 57, Jennie P. Mather andDavid Barnes editors, Academic Press, 1st edition, 1998), which are allincorporated by reference herein in their entireties.

It should be understood that the following examples should not beconstrued as being limiting to the particular methodology, protocols,and compositions, etc., described herein and, as such, can vary. Thefollowing terms used herein is for the purpose of describing particularembodiments only, and is not intended to limit the scope of theembodiments disclosed herein.

Disclosed herein are molecules, materials, compositions, and componentsthat can be used for, can be used in conjunction with, can be used inpreparation for, or are products of methods and compositions disclosedherein. It is understood that when combinations, subsets, interactions,groups, etc. of these materials are disclosed and while specificreference of each various individual and collective combinations andpermutation of these molecules and compounds cannot be explicitlydisclosed, each is specifically contemplated and described herein. Forexample, if a nucleotide or nucleic acid is disclosed and discussed anda number of modifications that can be made to a number of moleculesincluding the nucleotide or nucleic acid are discussed, each and everycombination and permutation of nucleotide or nucleic acid and themodifica-tions that are possible are specifically contemplated unlessspecifically indicated to the contrary. This concept applies to allaspects of this application including, but not limited to, steps inmethods of making and using the disclosed molecules and compositions.Thus, if there are a variety of additional steps that can be performedit is understood that each of these additional steps can be performedwith any specific embodiment or combination of embodiments of thedisclosed methods, and that each such combination is specificallycontemplated and should be considered disclosed.

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the method and compositions described herein. Suchequivalents are intended to be encompassed by the following claims.

It is understood that the disclosed methods and compositions are notlimited to the particular methodology, protocols, and reagents describedas these can vary. It is also to be understood that the terminology usedherein is for the purpose of describing particular embodiments only, andis not intended to limit the scope of the present disclosure which willbe limited only by the appended claims.

Unless defined otherwise, all technical and scientific terms used hereinhave the meanings that would be commonly understood by one of skill inthe art in the context of the present specification.

It must be noted that as used herein and in the appended claims, thesingular forms “a,” “an,” and “the” include plural reference unless thecontext clearly dictates otherwise. Thus, for example, reference to “anucleotide” includes a plurality of such nucleotides; reference to “thenucleotide” is a reference to one or more nucleotides and equivalentsthereof known to those skilled in the art, and so forth.

The term “and/or” shall in the present context be understood to indicatethat either or both of the items connected by it are involved. Whilepreferred embodiments of the present disclosure have been shown anddescribed herein, it will be obvious to those skilled in the art thatsuch embodiments are provided by way of example only. Numerousvariations, changes, and substitutions will now occur to those skilledin the art without departing from the disclosure. It should beunderstood that various alternatives to the embodiments of thedisclosure described herein can be employed in practicing thedisclosure. It is intended that the following claims define the scope ofthe disclosure and that methods and structures within the scope of theseclaims and their equivalents be covered thereby.

EXAMPLES Example 1

In the present study, an Agilent 1M CGH array was used to detect novel,rare CNVs in a total of 818 individuals, including 703 unrelated ASDprobands, 35 affected ASD siblings, 45 parents, 34 unaffected siblingsand one individual with developmental delay. A vast majority of thesesamples have been previously run on other SNP microarrays. The ASD caseswere competitively hybridized to a pool of fifty sex-matched Caucasiancontrols as a reference. The CNV calling was performed using AberrationDetection Module 2 (ADM2) algorithm of DNA Analytics 4.0.85 and acircular binary segmentation (CBS) algorithm implemented in the DNAcopypackage. The CNVs detected by both algorithms were defined as stringentand were utilized for further analyses. The calls were compared with theCNV data from Illumina 1M single and duo, Affymetrix 500K, Affymetrix6.0, and Illumina 2.5M arrays. For example, 350 samples in the datasetwere run previously on Illumina 1M single array which was analyzed usingtwo algorithms iPattern and QuantiSNP. The average number of stringentcalls generated for Agilent 1M and Illumina 1M is 36 and 18,respectively. Only 27% of the total Agilent 1M call sets were found tobe detected using the Illumina 1M platform. Conversely, 46% of theIllumina 1M calls were not detected using the Agilent 1M platform. Thedifference in the CNVs detected using multiple platforms is mainly dueto the differences in probe distribution and sensitivity of thedetection algorithms used. For example, the probe distribution on theAgilent 1M array is more evenly spaced across the genome as compared toSNP genotyping platforms such as the Illumina 1M array.

Stringent ASD CNVs were classified as rare if they were not detected inany of the 4,139 controls (1,782 subjects from the SAGE study, 1,234unrelated controls from the OHI study, and 1,123 European controls fromthe PopGen study). The SAGE controls were genotyped with Illumina Human1M-single BeadChip arrays and a subset of stringent CNVs detected byboth iPattern and QuantiSNP were used. The OHI and PopGen controls weregenotyped with Affymetrix Genome-Wide Human SNP 6.0 arrays and thestringent subset consisted of regions that were detected by at least twoof the three different CNV calling algorithms, Birdsuite, iPattern andAffymetrix Genotyping Console.

For each sample for which CNV calls from SNP microarrays were available,stringent CNVs detected using the Agilent 1M array were overlapped withthe stringent CNVs detected by corresponding SNP microarray experiments.The CNVs from the SNP arrays were filtered to include only the regionswith five probes or more. The CNVs were considered to be novel when 50%or more by length of the detected call was unique to a platform.

A threshold log2ratio value was used to determine losses and gains. ForDNA Analytics, a log2ratio cutoff of 0.25 and −0.25 to classify gainsand losses respectively was used. For DNAcopy, a log2ratio cutoff of 0.1and −0.13 to classify gains and losses respectively was used. An exampleof a CNV detected by the DNA Analytics log2ratio algorithm can be seenin FIG. 1. The genomic DNA was isolated using standard Autopure (Qiagen)method. Methods and settings recommended by Agilent for processing ofthe samples and microarray hybridization techniques were followed.Agilent DNA Microarray Scanner was used to quantify the Cy3/Cy5 signals.Standard conditions were used for the Agilent 1M microarray andstringent settings were used for the analysis. A minimum of 50%reciprocal overlap to tag the CNVs as identified was used. Parametersfor ADM2 (DNA Analytics 4.0.85) were set as follows: Threshold: 6.0,Centralization: OFF, Fuzzy Zero: OFF, Combine Replicates (Intra Array):ON, Combine Replicates (Inter Array): OFF, Genome: hg18, AberrationFilters: minProbes=5 AND minAvgAbsLogRatio=0.25 AND maxAberrations=10000AND percentPenetrance=0 Feature Level Filters: glsSaturated=true ORrIsSaturated=true OR glsFeatNonUnifOL=true OR rlsFeatNonUnifOL=true,Array Level Filters: NONE, Expand Non Unique Probes: ON, GenomicBoundaries: Not Applied, Parameters for CBS algorithms (DNA copy version1.22.1): smooth.CNA (x, smooth.region=2, outlier.SD.scale=4,smooth.SD.scale=2, trim=0.025), segment (x, weights=NULL, alpha=0.01,nperm=10000, p.method=c (“hybrid”, “perm”), min width=2, kmax=25,nmin=200, eta=0.05, sbdry=NULL, trim=0.025, undo.splits=c (“none”),verbose=1)

Details on the parameters used for iPattern and QuantiSNP algorithms canbe found in Pinto et al. (2010), Nature 466(7304):368-72.

Example 2

Another interesting recurrent CNV of size 24.8 kb was detected in twounrelated ASD cases, a duplication event disrupting two exons of YWHAE(tyrosine 3/tryptophan 5-monooxygenase gene) gene at the 17p13.3 locus(FIG. 2). It was maternally inherited in both ASD cases and was notpresent in controls. YWHAE belongs to the 14-3-3 family of proteins,which mediate signal transduction, and is highly conserved in bothplants and mammals Only micro-duplications in YWHAE gene have beenreported in ASD. It has been shown that the phenotype of patients with a17p13.3 micro-duplication involving YWHAE gene show autisticmanifestation, behavioral symptoms, speech and motor delay, subtledysmorphic facial features, and subtle hand-foot malformation.

Example 3

FIG. 3 represents an example of intronic CNVs clustered within anintronic region of the gene GPHN (gephyrin) located on chromosome 14.There are 7 ASD cases in total and 6 of these are depicted. The CNVsinclude a gain (log2ratio>0.35) and losses (log2ratio<−0.35).

In the figure, two types of data track information are shown, from topto bottom: 1) RefSeq gene annotation showing the genome location(x-axis) of genes demarcated in light gray (introns) and dark gray(exons) and with multiple entries depicted if multiple transcriptvariants are annotated that correspond to the gene, and 2) array CGHdata (black dots correspond to the probes on the microarray) for ASDcases (6 total) with a CNV wherein the y-axis is the log2ratio value ofthe test (ASD case) and reference (healthy control) genomic DNAs and thex-axis corresponds to the genome location of the probes and CNVs, whichare depicted as line segments shifted positively (copy number gain) ornegatively (copy number loss) relative to the baseline (log2 ratio=0).Order of ASD patient Hospital IDs (top to bottom) are: SS0054, SSO254,SS0100, SS0025, SS0711, SS0175.

Example 4

One of the ASD-specific CNVs was a maternally inherited duplication at15q25.1 in three unrelated ASD cases FIG. 4) disrupting the exon of CIB2(Calcium and integrin binding family member 2). The transcript andprotein of CIB2 gene is found to be present mainly in the hippocampusand cortex of the brain. The encoded protein of this gene is shown to beinvolved in Ca²⁺ signaling, which controls a variety of processes inmany cell types. In neurons, Ca2⁺ signaling maintains synaptictransmission, neuronal development and plasticity.

Example 5

In three unrelated male ASD probands, a recurrent novel CNV wasobserved, a 24.3 kb duplication encompassing two exons of the SAE1(SUMO1 activating enzyme subunit 1) gene at the 19q13.32 locus (FIG. 5).The same CNV was also found in one control. Interestingly, anotherduplication of size 50.8 kb disrupting six exons of SAE1 was observed ina fourth unrelated ASD case using the Agilent 1M CGH array and was alsodetected by previous SNP microarray study. The SAE1 gene is involved inprotein sumoylation process and is shown to interact with the ARX gene,which is involved in Autistic disorder.

Eample 6

In one ASD case, a 16.6 kb loss impacting the PLXNA4 (plexin A4) gene atthe 7q32.3 locus (FIG. 6) was identified. PLXNA4 is involved in axonguidance as well as nervous system development.

Example 7

It was validated that at least one CNV affecting GPHN was de novo inorigin (the other 6 GPHN CNVs reported herein were not tested for parentof origin), a 36.1 kb loss encompassing the intron of the GPHN(Gephyrin) gene at the 14q23.3 locus. This de novo CNV (FIG. 7) wasfound in a male ASD proband and was not picked up on the previous SNParray and it was not found in any of the controls. Gephyrin is suggestedto play a central organizer role in assembling and stabilizinginhibitory postsynaptic membranes in human brain. The lack of novel,rare de novo CNVs described herein may be due to the study designemployed because nearly all the de novo CNVs reported for the ASD cohortdescribed herein are relatively larger in size and therefore werealready detected using SNP microarrays (e.g., in Pinto et al. 2010). Allthe novel rare CNVs that were experimentally validated were inheritedfrom either parent. Also detected were other novel, rare CNVs present inonly one unrelated ASD case in previously identified genes associatedwith ASD such as ERBB4, CTNND2, CDH18, PARK2, NXPH1, MTHFD1 and NF1.

Example 8

In a female ASD case, a 7.2 kb loss disrupting an exon of the CECR2 (cateye syndrome chromosome region, candidate 2) gene at the 22q11.21 locus(FIG. 8) was observed, which was not observed in controls. CECR2 is achromatin remodeling factor that has been proposed to play a role inembryonic nervous system development (Banting et al. 2005).

Example 9

In another unrelated male ASD proband, a 15.1 kb paternally inheriteddeletion (FIG. 9) disrupting seven exons of the DAGLA (diacylglycerollipase, alpha) gene at the 11q12.2 locus was identified and was notfound in controls. DAGLA is known to synthesize an endocannabinoid thathas been associated with retrograde synaptic signaling and plasticity.

Example 10

Some pathway analysis software will be used to identify whether thecandidate gene will be a drug target, which may be FDA-approved or inclinical trials. Such information will assist in the design of clinicaltrials (e.g., patient stratification for genetic subtypes) or will beused to facilitate clinical trials that are in progress, therebyreducing the attrition rate (failure to receive FDA approval) andreducing the time and cost of drug development. When a candidate ASDgene is identified as a known drug target of an FDA-approvedtherapeutic, the drug can be repurposed and approved for use in a newindication (e.g., a cancer or anti-inflammatory agent may be beneficialto ASD patients as well). Those skilled in the art will recognize thatPhase II and III failures may be rescued with additional clinical trialdata that accounts for genetic subtypes, particularly when the drugfails for lack of efficacy. For example, if a drug will be designed orestablished to target a particular gene defect (e.g., use of an RNAitherapeutic to decrease aberrant overexpression of the gene that iscaused by a CNV or other type of genetic variant), it will be expectedthat only ASD patients with that particular genetic subtype will benefitfrom the targeted therapy.

Example 11 Creation of Table 2 and Sequence Listing

A subset of the refGene table (hg18 freeze) was downloaded from the UCSCGenome Browser (http://genome.ucsc.edu/) using the Table Browserinterface, utilizing the coordinates of the CNVs of interest (i.e., fromTable 1) as a filter. The information for those transcripts wasextracted, and the transcriptional start and stop sites for eachtranscript identified. The genomic sequence between, and including, thetranscriptional start site and the transcriptional stop site wasobtained. A file with the coordinate information, as well as thetranscript name and genomic sequence was generated. Individual overlapsbetween the prioritized list of CNVs of interest and the genomicsequence of the subset of RefGene transcripts was then obtained. Theoutput table listing the coordinates of the transcripts, as well as theCNVs to which they relate, is Table 2. The SEQ ID in Table 2 is theidentifier found in the PatentIn software and the text output. Thesequence file 121009_ASD_SK.txt contains genomic sequence informationfor all CNVs listed in Table 1 as well as for the full genomic extent ofthe transcripts referred to in Table 2.

For example, row 1 of Table 1 contains information related to a CNVwhose coordinates are chr14:66,255,943-66,292,122 and was discovered asa 36,180 bp loss in patient NA0174-000. The sequence for this CNV isfound in 121009_ASD_SK.txt and is referred to as SEQ ID 1 (sequencetruncated for brevity):

Sequence entry starts: <210> 1 <211> 36180 <212> DNA <213> Homo sapiens<400> 1gtcacattat ctcaggtgtc tcctgggtcc tgcaggagcg gtcctctttc ttcagagggt    60.....................................................................tatggttctg taaaatctta cctcagtgtg tagctagaat tatttagtca catattttta 36180Sequence entry ends.

For an example of a transcript sequence, consider row 1 of Table 2 whichrelates to the first CNV in Table 1 and which overlaps the gene GPHN.There are two transcripts reported within this CNV and the first ofthese is dealt with on row 1: NM_(—)001024218. This transcript has startand stop coordinates 66,043,877 and 66,718,278 (on chromosome 14)respectively and spans 674,401 of genomic sequence. This sequence isreferred to as SEQ ID 77 and appears as such in 121009_ASD_SK.txt(sequence truncated for brevity):

Sequence entry starts: <210> 77 <211> 674402 <212> DNA <213>Homo sapiens <400> 77aagcagcgct catggcgaag aggcttaagg ccacaaaacc gtgggacagc aggaggaaga     60...............................................................tctgtaatga tactgaaact taatgaataa aaaaattcct tgatcattat ttaaaaatgt 674400aa                                                                674402Sequence entry ends.

Row 2 of Table 2 relates to the same CNV in the same patients (as inTable 1) but a different transcript (NM_(—)020806). This sequence isidentified as SEQ ID 78 and is thus labeled in 121009 ASD_SK.txt.

1. A method of screening one or more subjects for at least one geneticvariation that disrupts or modulates one or more genes in Table 2,comprising: assaying at least one genetic sample obtained from each ofthe one or more subjects for the at least one genetic variation in oneor more genes in Table 20
 2. The method of claim 1, wherein the at leastone genetic variation is associated with a Pervasive DevelopmentalDisorders (PDD) or a Pervasive Developmental Disorder-Not OtherwiseSpecified (PDD-NOS), wherein the PDD is Autism Spectrum Disorder (ASD)and wherein the PDD-NOS is Asperger Syndrome, Rett Syndrome or ChildhoodDisintegrative Disorder.
 3. The method of claim 1, wherein the at leastgenetic variation is one encoded by any one of SEQ ID NOs 1 to
 76. 4.The method of claim 1, wherein the at least one genetic variationcomprises one or more point mutations, polymorphisms, translocations,insertions, deletions, amplifications, inversions, microsatellites,interstitial deletions, copy number variations (CNVs); or anycombination thereof, wherein the at least one genetic variation resultsin a loss of gene function or a gain of gene function.
 5. (canceled) 6.The method of claim 1, wherein the at least one genetic variationdisrupts or modulates one or more genomic sequences of SEQ ID NOs 77 to209 or one or more RNA transcripts, one or more polypeptides, or acombination thereof, expressed from the one or more genomic sequences ofSEQ ID NOs 77 to
 209. 7. (canceled)
 8. The method of claim 1, whereinthe assaying comprises detecting nucleic acid information from the atleast one genetic sample by one or more methods selected from the groupconsisting of PCR, sequencing, Northern blots, or any combinationthereof.
 9. (canceled)
 10. The method of claim 8, wherein the sequencingcomprises one or more high-throughput sequencing methods selected fromthe group consisting of Massively Parallel Signature Sequencing (MPSS),polony sequencing, 454 pyrosequencing, Illumina sequencing, SOUL)sequencing, ion semiconductor sequencing. DNA nanoball sequencing,heliscope single molecule sequencing, single molecule real time (SMRT)sequencing, RNAP sequencing, Nanopore DNA sequencing, sequencing byhybridization, or microfluidic Sanger sequencing.
 11. (canceled)
 12. Themethod of claim 1, wherein the at least one genetic sample is collectedfrom blood, saliva, urine, serum, tears, skin, tissue, or hair from theone or more subjects.
 13. The method of claim 1, wherein the assayingthe at least one genetic sample of the one or more subjects comprisespurifying nucleic acids from the at least one genetic sample.
 14. Themethod of claim 1, wherein the assaying the at least one genetic sampleof the one or more subjects comprises amplifying at least one nucleotidesequence in the at least one genetic sample.
 15. The method of claim 1,wherein the assaying the at least one genetic sample for at least onegenetic variation comprises a microarray analysis of the at least onegenetic sample.
 16. The method of claim 15, wherein the microarrayanalysis comprises a CGH array analysis.
 17. (canceled)
 18. The methodof claim 1, further comprising determining whether the one or moresubjects has a Pervasive Developmental Disorders (PDD) or a PervasiveDevelopmental Disorder-Not Otherwise Specified (PDD-NOS), or an alteredsusceptibility to a PDD or PDD-NOS.
 19. The method of claim 1, whereinthe one or more subjects were previously diagnosed or are suspected ashaving the PDD or PDD-NOS based on an evaluation by a psychologist, aneurologist, a psychiatrist, a speech therapist, or other professionalswho screen subjects for a PDD or a PDD-NOS.
 20. The method of claim 18,wherein the determining comprises an evaluation of the one or moresubject's communication, socialization, cognitive abilities, bodymovements, or a combination thereof.
 21. (canceled)
 22. (canceled) 23.The method of claim 1, wherein the screening the one or more subjectsfurther comprises selecting one or more therapies based on the presenceor absence of the one or more genetic variations.
 24. The method ofclaim 1, wherein the assaying at least one genetic sample obtained fromeach of the one or more subjects comprises analyzing the whole genome orwhole exome from the one or more subjects.
 25. The method of claim 1,wherein the nucleic acid information has already been obtained for thewhole genome or whole exome from the one or more individuals and thenucleic acid information is obtained from in silico analysis. 26.(canceled)
 27. (canceled)
 28. The method of claim 2, wherein the one ormore subjects has at least one symptom of a PDD or at least one symptomof a PDD-NOS. 29-83. (canceled)
 84. A method of screening for atherapeutic agent for treatment of a PDD or a PDD-NOS, comprisingidentifying an agent that disrupts, modulates, or comprises one or moregenomic sequences of SEQ ID NOs 77 to 209 or one or more expressionproducts thereof, wherein the one or more expression products thereofare selected from the group consisting of RNA transcripts andpolypeptides.
 85. The method of claim 84, wherein the therapeutic agentcomprises a small molecule, polypeptide, polynucleotide, or acombination thereof.
 86. The method of claim 84, wherein the therapeuticagent comprises a gene therapy agent, an exogenous polynucleotidecomprising a gene, an agent that treats a subject in need of genetherapy, an agent that treat a subject with a deficiency in apolypeptide, or a combination thereof.
 87. (canceled)
 88. (canceled) 89.The method of claim 84, wherein disrupting or modulating the one or moregenomic sequences of SEQ ID NOs 77 to 209 or expression productsthereof, comprises an increase or decrease in expression of the one ormore expression products. 90-106. (canceled)
 107. A kit for screeningfor a PDD or PDD-NOS in one or more subjects, the kit comprisingreagents for assaying a genetic sample from the one or more subjects forthe presence of at least one genetic variation encoded by SEQ ID NOs1-76, at least one genetic variation in a polynucleotide sequenceencoded by SEQ ID NOs 77 to 209, at least one genetic variation in anexpression product encoded by SEQ ID NOs 77 to 209, or a combinationthereof. 108-122. (canceled)
 123. An isolated polynucleotide sequence orfragment thereof, comprising at least 60% identity to any one of SEQ IDNOs 1 to 76, or a compliment thereof, wherein the isolatedpolynucleotide sequence, or fragment thereof, is hybridized to asynthetic oligonucleotide.
 124. The isolated polynucleotide sequence orfragment thereof, of claim 123, comprising at least 70% identity to anyone of SEQ ID NOs 1 to 76, or a compliment thereof.
 125. The isolatedpolynucleotide sequence or fragment thereof, of claim 123, comprising atleast 80% identity to any one of SEQ ID NOs 1 to 76, or a complimentthereof.
 126. The isolated polynucleotide sequence or fragment thereof,of claim 123, comprising at least 90% identity to any one of SEQ ID NOs1 to 76 or a compliment thereof.
 127. The isolated polynucleotidesequence or fragment thereof, of claim 123, comprising at least 95%identity to any one of SEQ NOs NOs 1 to 76, or a compliment thereof.128-133. (canceled)
 134. The isolated polynucleotide sequence, orfragment thereof, of claim 123, wherein the polynucleotide sequencecomprises a genetic variation not present in the human genome March 2006(NCBI36/hg18) assembly.
 135. A cDNA encoded by an RNA sequencetranscribed from any one of SEQ ID NOs 77 to
 209. 136. The cDNA of claim135, wherein the cDNA comprises a genetic variation not present in thehuman genome March 2036 (NCBI36/hg18) assembly. 137-142. (canceled) 143.A panel of biomarkers for detection of a PDD or as PDD-NOS comprisingfragments of two or more polynucleotide sequences selected from SEQ IDNOs 77 to
 209. 144. (canceled)
 145. The panel of claim 143, wherein thepanel comprises fragments of at least 5, 10, 25, 50, or 100polynucleotide sequences selected from SEQ ID NOs 77-209. 146.(canceled)
 147. (canceled)
 148. The panel of claim 143, wherein thefragments are arrayed on a flat substrate.
 149. (canceled)
 150. Thepanel of claim 143, wherein the fragments are attached to one or morebeads.
 151. The panel of claim 143, wherein the fragments are attachedto a solid support.
 152. A method for measuring expression levels ofpolynucleotide sequences from biomarkers for a POD or a POD-NOS in asubject, comprising: a) selecting a panel of biomarkers comprising twoor more genes contained in one or more polynucleotide sequences selectedfrom SEQ ID Nos 77 to 209: b) isolating cellular RNA from a sampleobtained from the subject; c) synthesizing cDNA from the cellular RNAfor each biomarker in the panel using suitable primers; d) optionallyamplifying the cDNA; and e) quantifying levels of the cDNA from thesample. 151-159. (canceled)
 160. A method for measuring expressionlevels of polypeptides comprising: a) selecting a panel of biomarkerscomprising at least two polypeptides encoded by an RNA sequencetranscribed from a genomic sequence of SEQ ID Nos 77 to 209; b)obtaining a biological sample; c) creating an antibody panel for eachbiomarker in the panel: d) using the antibody panel to bind thepolypeptides from the sample; and e) quantifying levels of thepolypeptides hound from the sample to the antibody panel. 161-211.(canceled)